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1. Summary
Spinal muscular atrophy (SMA) is an autosomal-recessive neurological heredopathia caused
by homozygous loss of the survival of motor neuron 1 (SMN1) gene. Although SMN protein is
ubiquitously expressed as core part of the nuclear spliceosomal machinery, SMN depletion
exerts its deleterious effects mainly in lower α-motoneurons of the spinal cord. The
subsequent motoneuronal death and disruption of neuromuscular connectivity evokes
de-nervation and atrophy of skeletal muscles in proximal limbs and trunk causing a high
morbidity in affected infants. In humans there is naturally a second SMN gene copy (SMN2)
present almost identical to SMN1. Notably, a C>T transition in exon 7 interrupts an important
exonic splicing enhancer site in SMN2 nucleotide sequence. Consequently, diminished
intron/exon border recognition frequently causes exon 7 skipping so that approximately 90%
of total transcripts are shortened (Δ7-SMN isoform). Still, about 10% full-length SMN
transcripts (FL-SMN) are produced per SMN2 gene copy ensuring a basal expression of fully
functional FL-SMN protein even in SMN1-deleted SMA patients, after all. Variable numbers of
SMN2 (2-6 copies) are present within the population and SMA patients due to high dynamics
in this genomic region. Hence, the number of SMN2 copies inversely correlates with SMA
severity. SMN2 was regarded as the sole genetic modifier in SMA until the discovery of actin
bundling protein plastin 3 (PLS3) (Oprea et al. 2008). In rare “discordant” families, some
individuals over-expressing PLS3 remain phenotypically asymptomatic despite sharing the
same genotype as SMA affected siblings. Thus, PLS3 obviously acts as protective modifier in
SMA. Findings in cell culture models as well as in zebrafish and mouse models proved
PLS3-induced rescue of SMA-mediated deficits in respect of axonal outgrowth and NMJ
maintenance. Yet, the ameliorating effects of PLS3 could not be directly investigated in
motoneurons of discordant family members.
The same problem occurred in examining the effects of SMA drugs such as histone deacetylase
(HDAC) inhibitor valproic acid (VPA) (Brichta et al. 2006; Swoboda et al. 2011). However, not
all SMA patients exhibited the desired SMN2 activation and elevation of blood FL-SMN levels
pointing to a different responsiveness to VPA administration (Brichta et al. 2006; Piepers et
al. 2011). The underlying molecular mechanisms remained elusive so far.
The general infeasibility to obtain living neuronal tissue inheres in any neurological illness in
humans. Therefore, introduction of induced pluripotent stem cell (iPSC) technology
(Takahashi et al. 2006) paved the way for the generation of individualised patient-derived
in vitro cell culture models. Via ectopic over-expression of pluripotency-related transcription
factors (OCT4, SOX2, KLF4, c-MYC) human somatic target cells are reprogrammed into a
pluripotent state displaying typical characteristics of naturally pluripotent embryonic stem
cells (ESCs) (Takahashi et al. 2007). Directed re-differentiation of these iPSCs towards spinal
motoneurons enables the generation of a patient-derived in vitro SMA model (Ebert et al.
2009). The goal of this doctoral thesis was to establish such a personalised iPSC-based in vitro
cell culture model of PSL3-discordant family members as well as individuals with different
responsiveness towards VPA.
Fibroblasts of VPA responder/non-responder SMA patients as well as two PLS3 discordant
SMA families (SMA III affected and their corresponding asymptomatic SMN1-deleted siblings)
were successfully reprogrammed by classical retroviral 4F transduction or by application of
state-of-the-art non-integrative Sendai virus. Subsequently, twelve iPSC lines were clonally
expanded and subjected to standardised validation procedures affirming bona fide
pluripotency in all iPSC lines, indeed. In addition, an optimised iPSC-derived embryoid body
(EB)-based motoneuron differentiation protocol was set up with which patient-derived iPSCs
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were differentiated into human motoneuron (MNs) cultures lacking sufficient MN numbers
for meaningful studies, however. Instead, generation of stable small molecule neural
precursor cell (smNPC) lines provided a valuable tool in SMA studies representing a
homogeneous cell population with high MN yield upon differentiation. Stringent examination
of four phenotypic groups (i.e. healthy controls, SMA I and PLS3 discordant SMA III and
asymptomatic siblings) in several different cell populations representing the iPSC-derived in
vitro MN development (i.e. fibroblasts, iPSCs, smNPCs and MN cultures) enabled monitoring
of cell-specific features during developmental course.
Subsequent MN differentiation of correctly patterned smNPCs resulted in considerable yield
of bona fideMN cultures stunningly displaying significant differences in MN survival rate with
SMA I exhibiting a massive MN decline while SMA III and asymptomatic showed an
intermediate MN number relative to control upon maturation. These findings perfectly
matched patients’ respective phenotypes.
Furthermore, SMN expression RNA and protein levels and concomitant gem numbers broadly
mirrored familiar SMN1/SMN2 copy number distribution amongst phenotype classes with
regard to principally known decreasing SMN expression in adult vs. foetal cells or in
proliferating cells vs. post-mitotic cells: SMA I cultures indicated lowest SMN expression rates
as well as fewest gem numbers in comparison to controls. In contrast, only a moderate
reduction in gem numbers and SMN expression levels was found in SMA III and asymptomatic
siblings relative to controls. In addition, PLS3 expression on RNA and protein levels depicted
strong over-expression in neural lineages of asymptomatic siblings highlighting the
importance of tissue-specific PLS3 over-expression for exertion of the protective effect in mild
SMA III.
Different neurite length was not observed among phenotype classes in early MN cultures.
PLS3/actin co-localisation occured in neuronal growth cones of MN cultures. Co-culturing
iPSC-derived motoneurons with human myotubes successfully established the initial
prerequisites for studying deficits in neuromuscular synapse formation, a key feature of SMA
pathology.
Application of iPSCs successfully presented VPA response in GABAergic neuronal cultures of
VPA (non)responders. Altered GABA release ultimately corroborated data disclosing
membrane fatty acid transporter C36 as causative element in VPA responsiveness (Garbes et
al. 2013).
For the first time, this study profoundly and reliably recapitulated SMN deficiency-conditioned
deficits in SMA diseased cell lines of different severity grades and healthy control at decisive
steps of MN differentiation directly in the target tissue. Moreover, PLS3 expression course
during MN development gave new insight into putative PLS3-mediated protection specifically
in MN cultures of asymptomatic asymptomatic siblings. Additionally, similar VPA
responsiveness as in fibroblasts and blood was verified in neuronal cultures
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2. Zusammenfassung
Spinale Muskelatrophie (SMA) ist eine verheerende autosomal-rezessive, neurodegenerative
Erkrankung. Das verantwortliche Gen survival of motor neuron 1 (SMN1) ist bei den
betroffenen Patienten homozygot deletiert. Obwohl das korrespondierende Protein SMN
ubiquitär als Kernbestandteil der Spliceosom-Maschinerie exprimiert wird, entfaltet der SMN-
Verlust seinen schädlichen Effekt selektiv in den unteren α-Motoneuronen der ventralen
Hörner des Rückenmarks. Der Untergang dieser Nervenpopulation und die folgende
Unterbrechung der neuromuskulären Signalübertragung  verursachen eine fortschreitende
Denervierung mit progressivem Muskelschwund in der proximalen Skelettmuskulatur.
Allerdings besitzen Menschen eine mit SMN1 fast identische Gen-Duplikation (SMN2).
Bemerkenswerterweise zerstört eine C>T Transition im Exon 7 einen wichtigen exonischen
Spleiß-Enhancer, woraufhin die verminderte Erkennung der Exon/Intron-Grenzen zu einem
verstärkten Ausschluss von Exon 7 im Transkript (Δ7-SMN Isoform) führt. Daher fehlen in
ungefähr 90% der SMN2-Transkripte Exon 7. Nichtsdestotrotz werden pro SMN2-Genkopie ca.
10-20% Volllänge-Transkript (FL-SMN) transkribiert, wodurch sogar in SMA-Patienten mit
homozygoter SMN1-Deletion eine Grundexpression von funktionstüchtigem SMN-Protein
gewährleistet wird. Die Lage von SMN2 in einer variablen Genomregion resultiert in einer
variierenden Anzahl von SMN2-Kopien (2-6) in der Bevölkerung und bei SMA-Patienten. Somit
korreliert die Anzahl der SMN2-Kopien umgekehrt mit dem Schweregrad der SMA-
Erkrankung. SMN2 war lange Zeit deshalb der einzig bekannte genetische Modifier für SMA,
bis in diesem Zusammenhang der protektive Effekt des actinbündelnden Proteins Plastin 3
(PLS3) entdeckt wurde (Oprea et al. 2008). In seltenen, sogenannten „diskordanten“ Familien
zeigten einige Personen, die PLS3 überexprimierten, phänotypisch keine SMA-Symptome trotz
desselben Genotyps wie ihre von SMA III betroffenen Verwandten. Studien in Tiermodellen
und Zellmodellen bestätigten den durch PLS3-Überexpression induzierten Schutzeffekt.
Allerdings konnte der Schutzeffekt von PLS3 nicht direkt in den Motoneuronen der
Betroffenen untersucht werden. Dieselbe Problematik trat bei Studien potentieller
Medikamente auf wie dem Histon-Deacetylase (HDAC) Hemmstoff Valproinsäure (VPS)
(Brichta et al. 2003; Swoboda et al. 2011). Allerdings wiesen nicht alle Probanden die
erwünschte stärkere SMN2 Transkription und einen höheren SMN Proteingehalt im Blut auf
(Brichta et al. 2006; Piepers et al. 2011). Augenscheinlich sprachen SMA-Patienten
unterschiedlich auf VPS-Behandlung an aufgrund unbekannter molekularen Ursachen.
Da es generell unmöglich bleibt, Menschen eine Biopsie lebender Neuronen zu entnehmen,
ist jedwede Studie über neurologische Erkrankungen durch diese Unzugänglichkeit des
eigentlichen Zielgewebes behindert. Die Einführung der iPSZ-Technologie (induziert
pluripotente Stammzellen) eröffnete dagegen die Möglichkeit, individuell
patientenspezifische Krankheitsmodelle in vitro zu erstellen (Takahashi et al. 2006). Mittels
ektopischer Überexpression von vier Pluripotenz aufrechterhaltenden Transkriptionsfaktoren
(OCT4, SOX2, KLF4, c-MYC) konnten humane somatische Zellen in einen pluripotenten Zustand
reprogrammiert werden (Takahashi et al. 2007), der dem Zustand natürlich pluripotenter
embryonaler Stammzellen (ESZs) glich. Eine gerichtete Re-Differenzierung dieser iPSZ zu
spinalen Motoneuronen ermöglichte die Etablierung eines vom Patienten abgeleiteten in vitro
SMA-Modells (Ebert et al. 2009). Das Ziel dieser Doktorarbeit lag in der Generierung eines
ebenjenen personalisierten, iPSZ-basierten in vitro Zellkulturmodells von PLS3-diskordanten
Familienmitgliedern sowie SMA-Patienten mit unterschiedlicher VPS-Reaktivität.
Fibroblasten von VPS-Responder/-Nichtresponder SMA-Patienten wie auch zwei
PLS3-diskordanten Familien (SMA III-Patienten sowie ihre asymptomatischen
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SMN1-deletierten Geschwister) wurden erfolgreich reprogrammiert mittels klassischer
retroviraler 4F-Transduktion oder durch Anwendung des nicht-integrativen Sendai-Virus. Die
erhaltenen zwölf iPSZ-Linien wurden klonal expandiert und einem standardisierten
Validierungsprozess unterzogen zum Beweis echter Pluripotenz, den tatsächlich alle
iPSZ-Linien erfüllten. Als weiteres Ergebnis dieser Arbeit wurde zusätzlich ein optimiertes,
iPSZ-basiertes motoneuronales Differenzierungsprotokoll eingeführt, mit dem sich die
Patienten-abgeleiteten iPSZ in Motoneuron (MN)-Kulturen differenzieren ließen, deren
geringer MN-Gehalt weiterführende Untersuchungen jedoch beeinträchtigte. Statt dessen
erbrachte die Generierung einer stabilen, homogenen neuralen Vorläuferzellpopulation
(small molecule neural precursor cell, smNPCs) eine genügende MN-Ausbeute nach
Differenzierung. Stringente Untersuchung von vier Phänotypklassen (d.h. gesunde Kontrollen,
SMA I sowie PLS3-diskordante SMA III und asymptomatische Geschwister) in verschiedenen
Zellpopulationen (Fibroblasten, iPSZ, smNPCs, MN-Kulturen) ermöglichten genauere Studien
zell-spezifischer, SMA-bedingter Veränderungen während der in vitro MN-Differenzierung.
Tatsächlich erbrachte die motoneuronale Differenzierung von smNPCs eine beträchtliche
Menge echter MN, deren Anzahl signifikant und massiv bei SMA I abfiel nach fortgeführter
Reifung, wohingegen die MN-Zahl der SMA III und asymptomatischen Geschwister einen
mittleren Wert annahm relativ zur Kontrolle. Diese Resultate deckten sich perfekt mit den
entsprechenden realen Phänotypen der Patienten.
Ferner spiegelten die SMN-Expression sowie die damit einhergehende Anzahl der Gems die
Anzahl der respektiven SMN1/SMN2-Genkopien unter den Phänotypklassen wider. Zudem
stimmten die vorliegenden Daten mit denen vorheriger Studien überein hinsichtlich
variierender SMN-Expression in adultem oder fötalen Gewebe oder verschiedenen
Zellpopulationen. SMA I-Kulturen wiesen die niedrigsten SMN-Expressionsraten und die
geringste Gem-Zahl auf im Vergleich zur Kontrolle. Dahingegen zeigten relativ zur Kontrolle
SMA III und asymptomatische Geschwister lediglich eine milde Reduktion in puncto
SMN-Menge und Gem-Zahl. Des weiteren förderte die Untersuchung der PLS3-Expression auf
RNA- und Proteinlevel eine beachtliche Überexpression in neuralen Entwicklungslinien der
asymptomatischen Geschwister zutage, was zusätzlich die offensichtliche Bedeutung einer
gewebsspezifischen PLS3-Überexpression für einen protektiven Effekt hervorhob.
Unterschiedliche Neuritenlängen innerhalb der Phänotypklassen sind in jungen MN-Kulturen
nicht gemessen worden. PLS3 und Actin ko-lokalisieren in Wachstumskegeln von Neuronen in
MN-Kulturen. Indem man von iPSZ abgeleitete Motoneurone zusammen mit humanen
Muskelzellen ko-kultivierte, wurden die Grundvoraussetzungen für eine erfolgreiche
Untersuchung von Defiziten in der neuromuskulären Synapsenbildung geschaffen – einem
Kernmerkmal der SMA-Pathologie.
Erfolgreich wurden iPSZ außerdem angewandt, um VPS-bedingte Veränderungen bei der
GABA-Ausschüttung Neuronenkulturen von VPS-Respondern/Nichtrespondern zu
verifizieren. Diese Daten untermauerten letztlich die verantwortliche Rolle des
membranständigen Fettsäuretransporters CD36 hinsichtlich der abweichenden VPS-Wirkung
bei SMA-Patienten (Garbes et al. 2013). Zum ersten Mal überhaupt rekapitulierte die
vorliegende Studie in profunder und verlässlicher Weise die durch SMN-Defizienz bedingten
Defizite bei SMA-Zelllinien mit verschiedenen Krankheitsschweregraden sowie bei gesunden
Kontrollen an entscheidenden Punkten der motoneuronalen Entwicklung direkt im
Zielgewebe. Ferner hob der PLS3-Expressionsverlauf während der MN-Differenzierung
schlüssig die Rolle des mutmaßlichen, PLS3-vermittelten Schutzes speziell in MN-Kulturen
asymptomatischer Geschwister hervor.
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3. Introduction
3.1 Spinal Muscular Atrophy (SMA)
3.1.1 Classification and clinical symptoms
In the 1890s, Viennese neurologist Guido Werdnig and autonomously German neurologist
Johann Hoffmann in Heidelberg firstly described the symptoms of an autosomal-recessively
inherited neurodegenerative disease termed spinal muscular atrophy (SMA). After cystic
fibrosis, SMA is the major monogenetic cause of infant mortality in the Western European
population (Lefebvre et al. 1995; Montes et al. 2009). Its incidence ranges from 1:6,000 to
1:10,000 live births with a carrier frequency of 1:35 in the Caucasian population (Pearn 1978;
Czeizel et al. 1989; Emery 1991; Lefebvre et al. 1995; Wirth et al. 1999). However, this carrier
frequency differs among ethnic groups in which Caucasians exhibit the highest and Hispanics
and African Americans the least carrier frequency (Hendrickson et al. 2009; Sugarman et al.
2012). The causative gene SMN1 was mapped by linkage analysis to a complex region of
chromosome 5q13 (Brzustowicz et al. 1990; Melki et al. 1990). The disorder is caused by the
selective degeneration of lower α-motoneurons situated in the anterior (ventral) horns of the
spinal cord. Loss of this specific motoneuronal subpopulation ultimately results in symmetrical
progressive de-nervation and subsequent atrophy of proximal skeletal and intercostal chest
musculature. In contrast, corticomotoneuronal function remains preserved (Farrar et al.
2012).
As common postnatal symptom, affected individuals suffer from gradual weakening of
voluntary muscles in limbs and trunk. Legs are more affected than arms and proximal muscles
more than distal ones (Markowitz et al. 2004). In a milder progression, distal muscles in hands
and feet are also impaired later. Since leg muscles are damaged first, usually patients become
wheelchair-bound or face strong difficulties concerning gait and locomotive system.
Depending on severity and ongoing progression, further symptoms appear e.g. paralysis and
joint contractures. Despite profound motor deficits in SMA patients, the sensory nervous
system as well as cognitive abilities remain intact usually (Crawford 2002; D'Angelo et al. 2006)
although hints exist that in severely affected mouse models brain development in
hippocampal regions is disturbed (Wishart et al. 2010). Albeit diaphragmatic strength is
maintained in SMA patients, atrophy in intercostal chest musculature eventually leads to
respiratory failure, secondary infections and death. In severely affected SMA patients, first
symptoms such as abnormally decreasing foetal movements (MacLeod et al. 1999) and
concomitant motoneuronal degeneration occur already in utero (Markowitz et al. 2004).
According to genotype and disease severity, SMA is classified into four subgroups whose
characteristics are outlined in the following (Munsat et al. 1992):
Type I SMA (Werdnig-Hoffmann Disease, MIM #253300):
The acute infantile form SMA I is the most severe type and renders the highest morbidity. It
accounts for approx. 50% of all SMA cases (Werdnig 1891; Pearn 1978; Markowitz et al. 2004).
SMA I neonates exhibit profound truncal and limb hypotonia (“floppy babies”) often around
birth, yet within the first six months at the latest. The generalised muscle debilitation makes
these infants unable to sit or walk independently giving an overall poor prognosis. Death
occurs within the first two years due to respiratory insufficiency with seven months as average
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survival rate (Rudnik-Schöneborn et al. 2009). Just 6% of SMA I patients survive longer than
two years (Cobben et al. 2008; Rudnik-Schöneborn et al. 2009).
Type II SMA (MIM #253550):
In the chronic intermediate form SMA II, the disease onset commences between six months
and 18 years. Most patients are diagnosed between six to 18 months. Patients are able to sit,
however, their ambulatory capabilities are massively impaired because they cannot stand or
walk without aid. The long-term survival varies broadly depending on involvement of
intercostal chest musculature and possible detrimental effects due to the development of
kyphoscoliosis (Talbot 1999). Normally, SMA II patients survive beyond two years of age with
98.5% still living at five years and 68.5% at 25 years (Zerres et al. 1997).
Type III SMA (Kugelberg-Welander Disease, MIM #253400):
The chronic juvenile form SMA III manifests after the first 18 months (Kugelberg et al. 1956)
and is mostly diagnosed before the age of adolescence (between two to twelve years) by
Gowers’ sign for instance. SMA III yields rather modest symptoms for patients are capable of
sitting, walking and climbing stairs, but wasting musculature hampers mobility with rising age.
SMA III patients do not show a reduced lifespan. SMA III is further subgrouped into type IIIa
with onset before the age of three years and type IIIb with onset after the third year (Zerres
et al. 1997).
Type IV SMA (MIM #271150):
The adult form SMA IV exhibits the mildest disease phenotype. The age of manifestation lies
in the 30s (Pearn 1978; Zerres et al. 1995) and is marked by only minor restrictions concerning
gait and general mobility. SMA IV patients possess a normal life expectancy.
3.1.2 SMA genetics – SMN1 & SMN2 as disease causing genes
In 1990, linkage analysis revealed the SMA determining gene survival of motor neuron 1
(SMN1) in a complex region on human chromosome 5q11.2-q13.3 (Brzustowicz et al. 1990;
Melki et al. 1990). This genomic region features a large inverted duplication with at least five
genes present in telomeric and centromeric copies making humans the only species to possess
two SMN genes (SMN1 & SMN2) (Fig. 1). After intense investigation, a homozygous mutation
of telomeric SMN1 was identified as the cause of SMA (Lefebvre et al. 1995). The SMN1 gene
spans a 28 kb genomic region and consists of nine exons (1, 2a, 2b, 3, 4, 5, 6, 7 and 8) of which
exons 1-7 are translated. The coding sequence of SMN1 is 882 bp long and produces an
approx. 1.7 kb transcript (containing 5' and 3' UTR) which is ubiquitously expressed, especially
highly in spinal cord and brain. The mRNA encodes for a protein of 294 amino acids with a
molecular weight of 38 kDa (FL-SMN). In addition, SMN1 is highly conserved among all
eukaryotic organisms underlining its essential function (Miguel-Aliaga et al. 1999; Paushkin et
al. 2000).
Fig. 1: Scheme of 500 kb genomic region in chromosome 5q containing SMN1 and its centromeric duplication
SMN2.
Introduction 7
Yet, an almost identical SMN1 copy termed SMN2 is located in the centromeric region. This
duplication differs from the original SMN1 nucleotide sequence only at five sites. However, all
base pair exchanges do not affect the amino acid (aa) sequence. In total, four point mutations
are located in untranslated regions (UTR) in exon 8 (nt 27869 G>A), intron 6 (nt 27092 G>A)
and two others in intron 7 (nt 27289 A>G and nt 27404 A>G). In the coding region, there is a
C to T transition (c.840C>T, codon C280T) at position +6 in exon 7 (Lefebvre et al. 1995; Bürglen
et al. 1996) (Fig. 2).
Nevertheless, this minor mutation in exon 7 tremendously interferes with the unique splicing
pattern of SMN genes. SMN1 produces exclusively full length transcript (FL-SMN) containing
all exons and giving rise to proper SMN protein as seen in individuals who possess only two
SMN1 copies. On the other hand, control probands carrying both SMN1 and additional SMN2
copies generated a specific mRNA population lacking exon 7 (Δ7-SMN2) (Lefebvre et al. 1995).
Exon 7 contains a weak splicing enhancer site at its 3' end. This exonic splicing enhancer (ESE)
acts as a cis-regulatory element and facilitates binding of auxiliary trans-acting splicing
proteins such as Tra2, hnRNPs and SF2/ASF which recruit further serine-rich (SR)-like splicing
factors excising only intron 6 and intron 7 (Lorson et al. 1999; Cartegni et al. 2002). However,
the nucleotide exchange c.C280T in exon 7 destroys the ESE thereby inflicting damage to the
whole splicing process. Since the splicing boundaries of exon 7 are poorly recognised, the
entire exon 7 is frequently skipped from pre-mRNA resulting in 90% Δ7-SMN2 and only 10%
FL-SMN2 transcript (Lorson et al. 1999; Cartegni et al. 2002). Another hypothesis suggests that
this C to T transition in exon 7 generates a novel exonic splicing silencer (ESS) which favours
exon 7 exclusion by recruitment of splicing factor hnRNP A1 (Kashima et al. 2003). As exon 7
contains the original stop codon, an alternative stop codon in exon 8 terminates translation
of Δ7-SMN2 transcript, thus solely producing a truncated protein. Δ7-SMN2 protein is unstable
and possesses a reduced oligomerisation ability (Lorson et al. 1998) resulting in rapid
degradation (Burnett et al. 2009).
Fig. 2: Schematic illustration of nucleotide and splicing differences in SMN1 and SMN2 genes. Note the five
differences in nucleotide sequence with C>T transition in exon 7 as the most influential one leading to frequent
exon 7 skipping. Thus, SMN2 generates almost exclusively Δ7-SMN2 transcript (90%) (from (Wirth et al. 2006a)).
Nearly all SMA patients show a homozygous deletion of SMN1 gene or a conversion of SMN1
into SMN2 (Feldkötter et al. 2002; Mailman et al. 2002). However, some patients exhibit subtle
intragenic missense mutations in SMN1 (Alias et al. 2009; Vezain et al. 2011) or de novo
rearrangements in the genomic region (Wirth et al. 1997). DNA based testing methods verify
reliably and quickly clinical diagnosis of SMA in newborns beside overt motor impairments.
The two most common techniques to detect loss in SMN1 gene are (i) a PCR-based approach
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with following test restriction enzyme digestion (Scheffer et al. 2001) or (ii) Multiplex Ligation-
dependent Probe Amplification (MLPA) (Scarciolla et al. 2006; Zapletalova et al. 2007).
Standard genetic sequencing procedure is alternatively usable in the rare case of subtle
intragenic deleterious mutations within the SMN1 gene (Alias et al. 2009; Vezain et al. 2011).
In general, SMA I patients retain 1-2 SMN2 copies (patients with solely one SMN2 are
sometimes denoted congenital SMA type 0), SMA II and SMA IIIa patients possess 3 SMN2
copies, SMA IIIb patients carry 4 SMN2 copies and SMA IV patients keep 4-6 SMN2 copies
(Feldkötter et al. 2002; Wirth et al. 2006b). Yet, there are exceptions with patients whose
genotype does not match the phenotype diagnosed. For instance, Prior and colleagues
reported that a SNP (c.859G>C substitution) in SMN2 leads to a mild clinical progression in
unrelated SMA patients even though they carry only 1-2 SMN2 copies (Prior et al. 2009). So in
conclusion, various factors may alter the outcome of SMA such as modifying genes, external
factors, intragenic SMN2 mutations and incomplete SMN2 copies with partially deleted or
duplicated SMN2 copies (Feldkötter et al. 2002; Oprea et al. 2008; Chen et al. 2011; Wirth et
al. 2013). Total loss of any SMN copy is embryonic lethal in humans and rodents (Burghes
1997; Schrank et al. 1997), yet 5-15% of the population possess no SMN2 copies while they
retain two SMN1 copies (Feldkötter et al. 2002; Markowitz et al. 2012).
SMN2 copy number is variable within the human population because SMN2 resides in a
chromosomal region being susceptible for genomic rearrangements. In spite of a complete
loss of SMN1-derived FL-SMN protein in SMA patients, every SMN2 gene still delivers approx.
10% FL-SMN protein. Therefore, the SMA phenotype i.e. the disease severity inversely
correlates with the SMN2 copy number (Burghes 1997; Brahe 2000; Feldkötter et al. 2002;
Wirth et al. 2006b).
3.1.3 SMN protein – Occurrence and function
SMN protein is an evolutionary highly conserved 294 aa housekeeping protein of 38 kDa in
size encoded by 8 exons (Lefebvre et al. 1995). It is present at high levels in the central nervous
system (CNS) and especially in spinal cord during embryogenesis and neonatal development
emphasising the importance of a critical time window of developmental vulnerability in which
SMN depletion causes its most detrimental effects (Burlet et al. 1998; Gabanella et al. 2007).
SMN is ubiquitously expressed and found in both nucleus and cytoplasm of all cell types (Liu
et al. 1996; Fallini et al. 2012), yet abundantly in spinal and brain stem motoneurons (Battaglia
et al. 1997). An axonal SMN isoform has been delineated (Setola et al. 2007) but its disease-
causing effect is regarded as unlikely (Burghes 2008). While SMN is diffusely distributed in the
cytoplasm, in the nucleus SMN is present in distinct punctual nuclear sub-structures called
“Gemini of Coiled bodies” (abbreviated “gems”) which are located in close proximity to Cajal
bodies (Liu et al. 1996). Vertebrate gems are stable multiprotein complexes comprising
oligomerised SMN, UNRIP and diverse gemin proteins (GEMIN2-GEMIN8) (Meister et al. 2000;
Meister et al. 2001; Gubitz et al. 2004; Carissimi et al. 2006). Cajal bodies are associated with
the biogenesis of small nuclear ribonucleoprotein particles (snRNPs) (Carvalho et al. 1999;
Jády et al. 2003). As part of the spliceosome, snRNPs conduct catalytic removal of introns from
pre-mRNAs (Pellizzoni 2007). Most eukaryotic introns are excised by the major
(U2-dependent) spliceosome whereas a small proportion of introns (~1%) are processed by
the minor (U12-dependent) spliceosome (Patel et al. 2003; Lotti et al. 2012).
SMN protein contains different functional domains like a N-terminal RNA-binding domain in
exons 2b/3, a Tudor-domain for interaction with Sm proteins in exon 3 and a poly-proline
stretch in exons 4/5 mediating cytoskeletal interaction via profiling. As a characteristic of RNP
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components, SMN protein possesses a C-terminal tyrosine-glycine (YG-)-box in exon 6
involved in self-oligomerisation (Lorson et al. 1998; Bertrandy et al. 1999; Selenko et al. 2001;
Bowerman et al. 2007).
Turn-over of FL-SMN protein is regulated by proteasomal degradation (T0.5 ~4.5 h). Δ7-SMN2
is a truncated protein of only 282 aa in size; however, degradation of Δ7-SMN2 is unlikely only
due to lack of exon 7, reduced self-association ability and enhanced susceptibility to
ubiquitinylation. Instead, low amounts of Δ7-SMN2 in patients are probably caused by its
missing binding partner i.e. FL-SMN1 (Burnett et al. 2009). Despite poor oligomerisation ability
in vitro, Δ7-SMN2 is able to inefficiently incorporate into heterotypic complexes with FL-SMN
(Le et al. 2005). Without protection to proteasomal cleavage, however, Δ7-SMN2 amount
drops rapidly (Burnett et al. 2009).
Recent studies demonstrated that SMN fulfils plenty of different functions in cellular
processes. Its participation in the generation of small nuclear ribonucleoprotein particles
(snRNPs) is well characterised. SMN oligomerises and forms a multiprotein complex with
UNRIP and gemins (Lorson et al. 1998; Pellizzoni et al. 1999; Meister et al. 2001; Gubitz et al.
2004). This SMN complex mediates efficient and specific binding of a heptameric ring (Sm
core) of Sm proteins (SmB/B’, SmD1, SmD2, SmD3, SmE, SmF and SmG) onto a conserved
sequence of newly exported uridine-rich snRNAs (U small nuclear RNAs, e.g. U1, U2, U4/U6,
U5, U11 or U12) in an ATP-dependent manner in the cytoplasm (Liu et al. 1997; Pellizzoni et
al. 1999; Raker et al. 1999; Meister et al. 2001; Pellizzoni 2007). As part of the spliceosomal
machinery, this Sm core is required for snRNP stability and function (Fig. 3).
Fig. 3: SMN-mediated snRNP biogenesis. SMN complex consisting of SMN and gemin proteins conducts Sm ring
formation and delivers the methylated Sm ring onto UsnRNA which is further modified. The resulting UsnRNP is
imported into the nucleus and acts as part of the spliceosomal machinery (taken from (Briese et al. 2005)).
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Moreover, the multimeric SMN complex interacts with various other proteins e.g. FUSE-
binding protein; profilin II; WRAP53 and coilin for nuclear localisation nearby Cajal bodies;
fragile-X mental retardation protein (FMRP); hnRNPs; Sm-like proteins; fibrillarin and GAR1 as
components of small nucleolar RNPs (snoRNPs) (Pellizzoni et al. 1999; Williams et al. 2000;
Pellizzoni et al. 2001; Rossoll et al. 2002; Sharma et al. 2005; Eggert et al. 2006; Piazzon et al.
2008; Mahmoudi et al. 2010).
In addition, SMN plays a more specific role in neurons since SMN protein can shuttle from
nucleus and inner cytoplasm to the outer cellular periphery during CNS ontogenesis (Giavazzi
et al. 2006). Furthermore, another study unveiled the bidirectional cytoskeleton-dependent
transport of SMN granules along microtubules for long-range transportation and via actin
filaments for short-range trafficking (Zhang et al. 2003).  Thus, an additional function of SMN
in neurons has been postulated possibly connecting SMN, motoneurons and the
pathomechanism of SMA.
3.1.4 Pathomechanism in SMA
Disease onset often happens rather sudden with rapid decline in motor function followed by
a long slow plateau period of deterioration (Sumner 2007). Considering strong SMN
expression in embryonic and postnatal development with only residual expression during
adulthood points at an important developmental time window in which SMN is absolutely
essential (Burlet et al. 1998; Gabanella et al. 2007; Sleigh et al. 2011). Adenovirus-mediated
SMN delivery (Foust et al. 2010) or compound-induced SMN elevation (Narver et al. 2008) in
severe SMA mouse models rescue lethality at early but not later time points. These results are
backed by the normal viability of SMA mice with doxycycline inducible SMN expression when
SMN expression is triggered at both embryonic and early postnatal stages (Le et al. 2012). The
importance of timely correct SMN expression during embryogenesis is thereby substantiated
(Butchbach et al. 2007; Hammond et al. 2010).
The fact that SMN is an omnipresent protein provokes the puzzling question about elucidating
the pathomechanism of SMA: Why does general impairment of snRNP biogenesis by SMN
depletion cause fatal loss of just one specific neuronal subpopulation, i.e. lower
α-motoneurons?
SMA and snRNP biogenesis
If failure of snRNP biogenesis is the major cause of motoneuronal death, dysfunctional splicing
should cover a wide range of pre-mRNAs as well as alter the stoichiometry of snRNAs. Indeed,
there are numerous aberrant transcripts which are not normally seen in tissues at
physiological levels (Zhang et al. 2008). Cell lines from SMA patients do show reduced snRNP
levels (Wan et al. 2005; Gabanella et al. 2007; Zhang et al. 2008) whose elevation rescues SMA
phenotype in mice and zebrafish (Winkler et al. 2005; Workman et al. 2009). Even a negative
feed-back loop is proposed in which SMN depletion and hampered snRNP synthesis attenuate
exon 7 inclusion in SMN2 mRNA especially in motoneurons (Ruggiu et al. 2012). Additonally,
U1A protein, a component of the U1 snRNP assembled by the SMN complex, specifically
inhibits 3' processing of the SMN pre-mRNA and might negatively influence SMN expression
in SMA (Workman et al. 2013). Moreover, Lotti and colleagues recently demonstrated a tissue-
specific decline in snRNP biogenesis, particularly affecting minor U12 splicing machinery (Lotti
et al. 2012). Expression profiles showed that gene targets containing those U12 introns are
frequently dysregulated in SMN deficient cells. Ostentatiously, some of these genes fulfil
Introduction 11
essential functions in neurogenesis such as Stasimon. Similarly, pre-synaptic adhesion
molecule Neurexin2a is down-regulated in smn-depleted zebrafish and SMA mice (See et al.
2013). mRNA of arginine methyltransferase CARM1 is also misdirected upon SMN depletion
(Sanchez et al. 2012).
However, other data conjecture no direct congruence between splicing
abnormalities/relevant RNA processing and SMA pathology because snRNP assembly activity
in spinal cord extracts from severe SMA mice and milder Δ7-SMN2 mice is notably
indistinguishable (Gabanella et al. 2007; Sleigh et al. 2011). Neither do motoneurons possess
a specifically higher constitutive requirement for snRNP assembly (Sleeman 2013). In this
context, alterations in RNA splicing appear rather as secondary effect in later stage of disease
than as causative elicitor for SMA (Briese et al. 2005; Bäumer et al. 2009; Rossoll et al. 2009).
Hence, difficulties remain to envision how a general cellular defect such as snRNP assembly
could account for the motoneuron pathology underlying SMA (Shababi et al. 2013).
SMA and motoneuron maintenance
The aforementioned function of SMN in axonal RNA-trafficking sheds a more conclusive light
on its potential role in SMA pathogenesis. SMN localises in RNA granules transporting β-actin
mRNA along the axon (Glinka et al. 2010). Obviously, SMN facilitates recognition of
mRNA-binding proteins (mRBPs) such as Hu antigen D (HuD) and insulin-like growth factor
mRNA-binding protein 1 (IMP1) with their targets including the mRNAs of β-actin, the
microtubule associated protein tau (MAPT) and growth-associated protein 43 (GAP-43)
(Hubers et al. 2010; Akten et al. 2011; Fallini et al. 2013; Yoo et al. 2013). Thereby, the
assembly of mRNA-containing hnRNPs and their axonal transport is enhanced (Fallini et al.
2011). For example, SMN interaction partner hnRNP R binds 3' UTR of β-actin mRNA
whereupon hnRNP R co-localises with murine Smn only in motor axons, but not in nuclear
gems (Rossoll et al. 2002; Rossoll et al. 2003). Decrease and axonal mislocalisation of IMP1, a
major protein regulating β-actinmRNA localisation and translation, exerts pathogenic effects
in SMA (Fallini et al. 2013).
SMN associates with polyribosomal mRNPs and can repress translation in an in vitro luciferase
assay (Sanchez et al. 2012). Growth cones do contain polyribosomal structures after several
days in in vitro culture advocating vectored ribosome transport and protein synthesis ability
(Twiss et al. 2009; Jablonka et al. 2013). Indeed, such local protein synthesis is crucial for
axonal maintenance (Holt et al. 2009) supported by the observation that SMN deficient
neurons exhibit defects in axonal outgrowth and path-finding (van Bergeijk et al. 2007;
McWhorter et al. 2008; Oprea et al. 2008). Furthermore, related processes like axon
elongation, growth cone size, β-actin dynamics and spontaneous excitability in primary
motoneurons from lumbar spinal cord isolates of severe SMA mice are evidently impaired
(Rossoll et al. 2003; Jablonka et al. 2007). In other words, these findings suggest that SMN
might have a distinct motoneuron (MN)-specific role in maintaining motoneuronal
functionality. The axonal pool of SMN and associated proteins like gemins hardly contributes
to snRNP biogenesis (Cauchi 2010; Fallini et al. 2012) pointing to an additional function.
Notably, those axonal RNA granules also differ from canonical SMN complex constitution for
they lack Sm proteins (Zhang et al. 2006; Todd et al. 2010). Therefore, SMN seems to be
involved in mRNP transport and maintenance of proper local translation in motor growth
cones instead.
This essential function is even more highlighted when specific motoneuronal substructures
like neuromuscular junctions (NMJs) are examined. SMN could be located at NMJs (Fan et al.
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2002). Decrease in SMN elicits here cytoskeletal disorganisation, synaptic vesicle clustering
and reduction of the readily releasable pool (RRP) retaining NMJs at an immature state and
lagging overall neurotransmitter release (Torres-Benito et al. 2011; Ackermann et al. 2013).
Moreover, two essential mRNAs for NMJ maintenance, i.e. β-actin and candidate plasticity-
related gene 15 (cpg15)/neuritin are significantly reduced in SMA motoneurons (Akten et al.
2011). In particular, the localisation and regional translation of β-actinmRNA in growth cones
and axons are crucial for response to axonal guidance cues, maintenance and regeneration
(Donnelly et al. 2013). Recent data suggest an enhanced demand for SMN during early
post-natal days of murine NMJ maturastion while adult NMJs become refractory towards SMN
depletion (Kariya et al. 2014). Most probably, SMA displays a foetal developmental maturation
error at NMJs and a consecutive postnatal retrograde dying-back degeneration of
α-motoneurons (Fidzianska et al. 2002; Ito et al. 2011). This circumstance is explained in 3.3.5
in detail.
The view is gaining momentum that effects of SMN demise do not exclusively derogate
motoneurons (Hamilton et al. 2013). Instead, SMA encompasses lesions in further non-
motoneuronal tissues and organs like heart (cardiac muscle), bones, lung, liver, intestine,
pancreas, brain (telencephalon, hippocampus) and muscle (Finsterer et al. 1999; Felderhoff-
Mueser et al. 2002; Ito et al. 2004; Rudnik-Schöneborn et al. 2008; Wishart et al. 2010;
Mutsaers et al. 2011; Bowerman et al. 2012b; Schreml et al. 2013; Shababi et al. 2013). So, a
threshold hypothesis delineates the pathogenesis in SMA the best: In SMA patients, there is a
differential susceptibility of cell types and tissues to SMN reduction with motoneurons to be
the most sensitive cell population at the very end of a vulnerability-resistance spectrum (Fig. 4)
(Sleigh et al. 2011).
Fig. 4: Threshold hypothesis schematises the susceptibility of different tissues concerning SMN protein depletion
with motoneurons as most vulnerable cells at the outermost end of the spectrum whereas other tissues tolerate
lesser SMN levels (taken from (Sleigh et al. 2011).
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3.1.5 Possible therapies in SMA
The outcome of many studies implies that mere increase of SMN exclusively in motoneurons
does not rescue severe SMA mice. With a motoneuron-specific inducible Hb9-Cre allele,
Gogliotti et al.managed to restore SMN in motoneurons autonomously. However, the overall
effect in survival was just very moderate (Gogliotti et al. 2012). Similarly, when SMN was
depleted specifically in motoneurons, only modest SMA symptoms occurred instead of the
expected severe SMA phenotype (Park et al. 2010). Neuronal-specific SMN expression
improved survival and weight gain in SMA mice whereas muscle-specific SMN expression had
only little positive effect (Gavrilina et al. 2008). Significant extension of murine life span was
achieved by an inducible SMN rescue allele which clarified the positive effect of temporal SMN
expression, meaning early in all tissues (Lutz et al. 2011). This obvious requirement of SMN
restoration in a spatiotemporal manner, i.e. at pre-symptomatic stage in all tissues,
exacerbates any possible therapeutic treatment in SMA.
Nonetheless, several therapeutic approaches exist on genetic, transcriptional, translational
and cellular levels. Different chemical compounds and other therapies have been examined in
respect to these contact points of SMA phenotype; however, until now no absolute cure is
available yet (Sumner 2006; Wirth et al. 2006a; Lorson et al. 2012).
Gene replacement strategies gave good results. Delivery of FL-SMN cDNA by self-
complementary adeno-associated virus 9 (scAAV9) provided substantial improvement in
severe SMA mice (Foust et al. 2010; Dominguez et al. 2011; Glascock et al. 2012; Shababi et
al. 2013).
A direct transcriptional activation of FL-SMN expression is achieved by administration of
hydroxyurea or histone deacetylase inhibitors (HDACi) such as short-chain fatty acids valproic
acid (VPA) and sodium butyrate, the benazamide M344, suberoylanilide hydroxamic acid
(SAHA), Trichostatin A (TSA) or JNJ-26481585 (Grzeschik et al. 2005; Riessland et al. 2006; Avila
et al. 2007; Wirth et al. 2007; Riessland et al. 2010; Schreml et al. 2013). Restoration of correct
splicing pattern of SMN2 pre-mRNA is successfully established by quinazolines, the
chemotherapeutic anthracycline antibiotic aclarubicin or the phosphatase inhibitor sodium
vanadate (Andreassi et al. 2001; Zhang et al. 2001; Jarecki et al. 2005; Wirth et al. 2007).
Another utterly promising approach is the use of short antisense oligonucleotides (ASOs)
which block the intronic splicing silencer ISS-N1 adjacent to exon 7, thereby facilitating the
inclusion of exon 7 in SMN2 transcripts and rescuing SMA phenotype in mice (Singh et al. 2009;
Hua et al. 2011; MacKenzie 2012; Osman et al. 2012; Porensky et al. 2012). Recently, splicing
modifiers were introduced which elevated SMN levels, MN numbers and survival rate and
prevented motor dysfunction in SMA fibroblasts, iPSC-derived MNs and mice (Naryshkin et al.
2014).
On translational level, the antibiotic aminoglycosides are able to suppress the accurate
identification of translation termination codons in eukaryotic cells. Oppressed recognition of
the native stop codon in exon 8 of SMN2 transcripts leads to a longer C-terminus and stabilised
SMN2 protein. Thus, wild-type SMN localisation and quantity is restored (Wolstencroft et al.
2005) and lessens severity in SMA mouse models (Mattis et al. 2009; Mattis et al. 2012).
Similar SMN protein stabilisation is exerted by the cyclooxygenase inhibitor indoprofen (Lunn
et al. 2004). Protease inhibitors like MG132 block ubiquitin-mediated proteasomal SMN
degradation (Chang et al. 2004). Inhibition of proteasome by bortezomib elevates SMN
amounts in SMA mice and improves their motor function (Kwon et al. 2011).
Cellular replacement of diseased motoneurons is the ultimate goal in curing SMA. Yet, any
stem cell therapy needs to overcome demanding hurdles including cell survival, generation of
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functional motor units and sufficient axonal projection for long distances. Availability of
primary motoneurons is restricted to isolation from fresh human or rodent foetal tissue
touching ethical concerns as well as risking repulsion of xenograft transplants due to host
immune response (Gowing et al. 2011). Generation of patient-derived motoneurons via direct
reprogramming circumvents these problems indeed. However, transplantation of mature
motoneurons and primed neural stem cells (NSCs) into SMA mice rather leads to engraftment
of NSCs and development of supporting CNS cells than to insertion of exogenous
motoneurons. Thus, the progressive loss of endogenous motoneurons is probably slowed
down by secretion of neurotrophic factors from transplanted cells (Corti et al. 2008; Corti et
al. 2010; Corti et al. 2012).
3.1.6 SMA models
Animal models are a suitable tool to elucidate the pathomechanism of diseases such as SMA.
On account of high conservation of SMN genes between species throughout evolution, several
transgenic animal models have been engineered to explore the consequences of SMN
deficiency in different cell types, above all in neurons and muscle.
Thus, detrimental effects of SMN ablation have been modelled in nematode (Caenorhabditis
elegans) (Briese et al. 2009), fruit-fly (Drosophila melanogaster) (Chan et al. 2003; Chang et al.
2008), zebrafish (Danio rerio) (McWhorter et al. 2008), cat (Felis catus) (He et al. 2005) and
swine (Sus scrofa) (Lorson et al. 2011). The most important SMA animal models are house
mice (Mus musculus) owing to an 82% homology in Smn aa sequence compared to human
FL-SMN1. Murine gene orthologue Smn is only present as a single copy (DiDonato et al. 1997)
so that homozygous Smn deletion inevitably leads to embryonic death by prevention of
uterine nidation (Schrank et al. 1997). Introduction of human SMN2 gene in different copy
number into murine null Smn–/– background and subsequent cross-breeding resulted in mouse
strains reflecting the whole bandwidth of human SMA phenotype with severe, intermediate
or mild disease progression (Hsieh-Li et al. 2000; Monani et al. 2000; Le et al. 2005; Bowerman
et al. 2009).
Nevertheless, every animal model is only capable of displaying a human disorder by
approximation and hence incompletely. In particular, living human neurons cannot be
obtained by biopsy obstructing the possibility to examine any neurodegenerative disease
pathology in a patient-specific context. The emergence of direct reprogramming technology
however circumvents the inaccessibility of neuronal target tissues in neurodegenerative
diseases, thus enabling generation of a patient-derived in vitro model (see 3.2.4). Therefore,
the set-up of such in vitro models is recently gaining more and more importance concerning
drug screening studies and in-depth analyses of the actual pathomechanisms on molecular
level.
3.2 Pluripotency and reprogramming
3.2.1 Pluripotency – An early starting point in development
Per definition in developmental biology, pluripotency describes the capability of unlimited
differentiation into cell types of all three germ layers, i.e. into all >200 functional cell types of
the human embryonic and adult organism (Thomson et al. 1998; Smith et al. 2009), however,
excluding extraembryonic tissues (e.g. placentary trophectoderm). This ability of total
organismal development – termed totipotency – is solely restricted to the fertilised ovum
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(zygote) and the subsequent four blastomeres in mammals (Van de Velde et al. 2008; Smith
et al. 2009).
Pluripotency is naturally found in embryonic stem cells (ESCs), embryonic germ cells (EGCs)
and epiblast stem cells (EpiSCs) (Amabile et al. 2009). ESCs reside in the inner cell mass (ICM)
of the blastocyst. The first explant of ESCs succeeded in 1981 in mice (Evans et al. 1981) and a
decade later in humans in 1998 (Thomson et al. 1998). Moreover, there are reprogramming
techniques artificially increasing potency and conferring “stemness” (the undifferentiated
state): First, somatic cell nuclear transfer (SCNT) denotes the introduction of a donor nucleus
of a fully differentiated somatic cell into an enucleated, mature, metaphase II-arrested oocyte
(cytoplast). Oocyte-specific cytoplasmatic factors erase the donor epigenetic pattern, thus
converting the somatic identity into a SC-like state. This “reproductive cloning” was firstly
conducted in African clawed frog (Xenopus laevis) in the 1960s (Gurdon 1962), later also in
mammals creating sheep “Dolly” in 1997 (Wilmut et al. 1997). In 2013, an optimised protocol
for SCNT in humans was published (Tachibana et al. 2013). Second, cellular fusion of an ESC
with a somatic recipient cell delivers tetraploid hybrids in which the developmental potential
is reset to a pluripotent state (Tada et al. 2001; Cowan et al. 2005). These hybrids share many
features with the ancestral ESC indicating a domination of the pluripotent state in these fusion
products (Jaenisch et al. 2008). Third, a direct in vitro transdifferentiation back to pluripotency
is manageable with spermatogonia. By prolonging culture conditions, pluripotent ES-like cells
can be isolated from such cultures (Kanatsu-Shinohara et al. 2004; Golestaneh et al. 2009).
Finally, in direct reprogramming, introduction and ectopic expression of defined pluripotency
transcription factors (TFs) revert the somatic state to a pluripotent one (induced pluripotent
SCs) (see 3.2.3).
3.2.2 Stem cells (SCs) – Occurrence and properties
Stem cells (SCs) are characterised by both the ability of undifferentiated proliferation
(self-renewal) and the differential potency to develop into various functional cell types.
During normal ontogenesis, cells transit in a unidirectional way from totipotent zygotic SCs to
pluripotent embryonic SCs until it narrows down to terminally differentiated somatic cells
(Jaenisch et al. 2008). While their grade of potency gradually diminishes, cells become
developmentally more restricted, thereby adopting distinct epigenetic modifications. Yet, this
process is not irreversible as unambiguously proven by the aforementioned reprogramming
methods to remodel the somatic epigenome and thus “rejuvenate” the entire cell.
Additionally, adult SC populations are left in the organism: Multipotent SCs give rise to
multiple cell types of one specific lineage (e.g. haematopoietic SCs for blood cells of myeloid
and lymphoid lineage), whereas unipotent SCs are only capable of generating one specific cell
type, e.g. spermatogonial SCs for sperm (Jaenisch et al. 2008).
In the adult human, NSCs solely populate two neurogenic brain regions: the subventricular
zone (SVZ) of the lateral ventricle and the dentate gyrus of the hippocampus (Eriksson et al.
1998; Gage 2002; Hsu et al. 2007). In addition, adult NSCs in the neuroepithelium of the
olfactory bulb exhibit crucial reparative potential of the sensory nervous system, yet these
neuroblasts descend from the SVZ (Curtis et al. 2007; Leung et al. 2007).
3.2.3 Induced pluripotent stem cells (iPSCs) – Back to the roots
At Kyoto University in 2006, Yamanaka and Takahashi succeeded in the Nobel prize-awarded
discovery of directly reprogramming somatic cells to an ES-like state (Takahashi et al. 2006).
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This marked a revolutionary milestone in comprehension of cellular plasticity and
developmental biology.
Out of 24 candidate genes related to ESC-pluripotency, the authors found that the
combinatory over-expression of just four transcription factors (Oct4, Sox2, c-Myc & Klf4)
sufficed to reprogram murine embryonic fibroblast (MEFs) and adult fibroblasts which thus
acquired a pluripotent ESC-like identity. These cells are coined “induced pluripotent stem
cells” (iPSCs) (Takahashi et al. 2006). Since then, immense endeavours have been undertaken
to generate iPSCs from different sources and species and to fully characterise the process of
reprogramming.
Human iPSCs were successfully generated from foetal and adult fibroblasts in 2007 (Takahashi
et al. 2007; Yu et al. 2007). Moreover, generation of iPSCs was accomplished in further species
such as cow (Bos taurus), dog (Canis lupus familiaris), horse (Equus caballus), rat (Rattus
norvegicus), sheep (Ovis aries) and Tibetan miniature pig (Sus scrofa) (Esteban et al. 2009; Liao
et al. 2009; Bao et al. 2011; Han et al. 2011; Luo et al. 2011; Nagy et al. 2011).
First successful attempts in direct reprogramming were carried out with dermal fibroblasts
(Takahashi et al. 2006; Takahashi et al. 2007; Yu et al. 2007; Park et al. 2008b). Beyond
fibroblast as frugal, easily accessible donor cell population, various other cell types were
reprogrammed meanwhile, inter alia adipose SCs, B-lymphocytes, gastric cells, germ line SCs,
hepatocytes, keratinocytes, melanocytes, NSCs, pancreatic β-cells and umbilical chord blood
cells (Aasen et al. 2008; Aoi et al. 2008; Hanna et al. 2008; Kim et al. 2008; Stadtfeld et al.
2008; Ko et al. 2009; Sun et al. 2009; Utikal et al. 2009).
The initial reprogramming experiments were performed by retroviral-mediated transduction
of the four transcription factors (4F) Oct4, Sox2, c-Myc and Klf4 (Takahashi et al. 2006), ever
since named “Yamanaka factors” (Sommer et al. 2010). Oct4 is the crucial factor in that row
with an expression exclusively restricted to pluripotent SCs, while the other factors are also
present in other tissues.  The human equivalents to the Yamanaka factors (OCT4, SOX2, KLF4
& c-MYC) unproblematically fulfilled their function in reprogramming human fibroblasts
(Takahashi et al. 2007). In an additional study briefly published afterwards, Yu and colleagues
announced LIN28 and NANOG as surrogates for c-MYC and KLF4, respectively, in 4F
reprogramming (Yu et al. 2007).
iPSCs arguably depict a developmental stage equivalent to that of ESCs, however, nuanced
comparison in early studies disclosed distinct disparities concerning global gene expression,
epigenetics and miRNAome (Takahashi et al. 2006; Yu et al. 2007; Wilson et al. 2009). Thus, a
broader consensus manifests concerning the equivalence of iPSCs and ESCs to date: Both
populations are rather overlapping than identical or distinct. Their functional equality is more
theoretical because in practice, both ESCs and iPSCs possess genetic and epigenetic
differences mirroring their different history (Robinton et al. 2012). The most illustrative
systematic comparison of transcriptional profile, epigenetic pattern and developmental
potential in twelve human iPSC and 20 ESC lines solidified the common view that
transcriptional and epigenetic variation is common within iPSC lines, among ESC lines and
between iPSC and ESC populations (Bock et al. 2011).
3.2.4 Medical application of iPSCs – Going where no one has gone before
Introduction of iPSC technology marked a breakthrough in generating a unique platform for
patient-specific disease models in vitro, drug-screening and putative cell-replacement
strategies. Within the last years, several different human disorders have been displayed by
iPSC technology such as Alzheimer’s Disease, Down’s Syndrome, Fanconi Anaemia,
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Friedreich’s Ataxia, Huntington’s Disease, Hutchinson-Gilford Progeria Syndrome, Machado-
Joseph Disease, Marfan Syndrome, Parkinson’s Disease or β-Thalassaemia (Park et al. 2008a;
Raya et al. 2009; Soldner et al. 2009; Ku et al. 2010; Quarto et al. 2010; Koch et al. 2011; Zhang
et al. 2011; HD iPSC Consortium 2012; Israel et al. 2012; Ito et al. 2012; Wang et al. 2012).
However, the patient’s phenotype is not always successfully mimicked as it happened in
Fragile X-Syndrome (Urbach et al. 2010).
Concerning generation of diseased motoneurons by iPSC technology, different groups
pioneered in modelling SMA (Ebert et al. 2009) or familial and sporadic ALS (Dimos et al. 2008;
Burkhardt et al. 2013).
Beside general understanding of human ontogenesis, the prospective goal of human SC
research lies in elucidating the chances of application in medical context, i.e. replacement of
diseased cell/organs (regenerative medicine). In comparison to other pluripotent SCs, iPSCs
bear several advantages: First, no human embryo is destroyed in generating iPSCs, thus
bypassing strong ethical and religious objections towards SC research in society. Second, iPSC
technology enables to obtain “customised” ESC-like surrogate cells in respect of the relevant
disorder. When genetic correction is possible in vitro like in the rescue of a humanised sickle
cell anaemia mouse model (Hanna et al. 2007), healthy patient-specific cells could be applied,
thereby circumnavigating potential host immune rejection response upon transplantation.
Third, iPSC generation became in the meantime a robust method with reliable efficiency
compared to alternative reprogramming strategies: SCNT is extremely ineffective on account
of faulty reprogramming resulting in death of most animal clones soon after implantation or
birth of clones with serious anomalies (Hochedlinger et al. 2003). Like ESCs, SCNT in humans
fiercely touches ethical concerns since receiving enough unfertilised human oocytes is a
tedious, straining procedure impeding applicability. Inherent disadvantages in cellular fusion
are inefficiency and polyploidy in fusion products.
Nevertheless, any medical application is hampered by the incalculable risk of tumour
formation which transplantation of pluripotent SCs bears. Even when iPSCs are generated in
the absence of the oncogenic gene c-Myc or integrative approaches, the peril of tumorigenesis
is immanent (Nakagawa et al. 2008; Okita et al. 2008; Kim et al. 2009a).
In conclusion, despite apparent current shortcomings in tissue repair direct reprogramming
bears profound advantages in establishing disease-specific in vitromodels, in particular when
naturally inaccessible cell types are affected such as neurons or cardiomyocytes. In order to
obtain the desired cell type, mimicking the natural developmental processes of
embryogenesis is essential when differentiating iPSCs with reasonable efficiency and
specificity.
3.3 Neuromuscular development and generation of motoneurons
3.3.1 Vertebrate neurogenesis
One cornerstone of vertebrate embryogenesis is the generation of the three germ layers
endoderm, mesoderm and ectoderm (triploblasty). Vast knowledge has been gained by
developmental studies with African clawed frog (Xenopus laevis) in which this process
commences at the late blastula stage when most of the embryonic tissue is not determined
yet. However, some pluripotent blastomeres specialise in a dorsal vegetal mesoderm region
(Nieuwkoop Centre) and induce formation of a further inductive region in close vicinity to the
dorsal lip of the blastopore. This primary “organiser” (Spemann’s organizer) dorsalises the
surrounding tissue during early gastrulation, thus defining the dorso-ventral (DV) axis and
18 Introduction
simultaneously initialising gastrulation – a process in which the three germ layers are
specified, the body axes are determined and wide cellular rearrangements herald
organogenesis (Spemann et al. 1924; Nieuwkoop 1952; Harland et al. 1997; Carlson 1999;
Weinstein et al. 1999; Smukler et al. 2006).
The primary organiser secretes BMP inhibitors such as chordin and noggin as well as TGFβ
inhibitors like follistatin into the overlying ectodermal cells. Depleted from BMPs and TGFβ,
de-repression of gene transcription enhances promoter accessibility of pro-neural genes. So,
an intrinsic neural program is spurred enabling the ectodermal cells to adopt a neural fate
(Weinstein et al. 1999; Muñoz-Sanjuán et al. 2001). In amniotes like chick, mice and humans,
a similar inductive system (node) is active (Levine et al. 2007).
The rostro-caudal (RC) axis is marked by the specification of dorsal mesodermal cells forming
a flexible rod-shaped structure (notochord) when the node regresses towards the posterior
end of the primitive streak (Wilson et al. 2005). Concomitantly, the overlying dorsal
ectodermal layer thickens (neural plate) designating the start of neurulation and the
surrounding paraxial mesoderm segments into somites (somitogenesis) (Fig. 5) (Carlson 1999;
Copp et al. 2003). By the end of the third gestational week, human neurulation begins with
formation of a neural plate in the epiblast, a distinct ICM layer of a human blastocyst.
Subsequently, the neural plate invaginates, thereby forming the neural groove and
simultaneously elevating the surrounding tissue wall to neural folds. After all, the neural folds
converge to the neural tube covered by non-neural epidermal ectoderm (Smith et al. 1997;
Copp et al. 2003). Neurulation makes ectodermal cells competent to respond to morphogenic
patterning from non-organiser mesoderm, hence specifying the RC axis between anterior and
posterior pole of the embryo (Carlson 1999; Copp et al. 2003).
Fig. 5: Successive steps of neurulation and spinal cord development. Neurally primed cells form neural plate
which are flanked by epidermal ectoderm (ECT) (A). Invagination of neural plate forms neural groove while the
nethermost cells are primed to floor plate (F) by subjacent notochord (N) and somatic mesoderm begins to
develop (S) (B). Once neural folds close to neural tube, roof plate cells (R) are determined. Neural cells are
allocated along the dorso-ventral axis (D-V). Neural crest cells transiently delaminate from dorsal neural tube (C)
(adapted from (Jessell 2000)).
3.3.2 Neural tube patterning and generation of motoneurons (MNs)
One of the most fundamental concepts of embryology is the establishment of morphogenetic
fields in the developing embryo. A biochemical coordinate system of diffusible factors (termed
“morphogens”) defines different developmental zones in a spatiotemporal manner, thereby
allocating every cell in developing tissues positional information (Jaeger et al. 2006). Wolpert’s
French Flag model schematises this concept in which a row of cells are exposed to an idealised
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morphogen concentration gradient. Positional information is conveyed relative to field
boundaries which coincide with the distance between source and sink of a morphogen in
respect to temporal context (Wolpert 1969; Jaeger et al. 2006).
The node regressing head-to-tail along the primitive streak and pre-somitic mesoderm lying
ahead secrete FGFs, in particular FGF8, thus establishing a proliferative caudal zone (Wilson
et al. 2005). Behind it, the neural plate cambers and the resultant neural groove closes to the
neural tube. There, the roof plate and dorsal ectoderm secrete BMPs and Wnt members
defining dorsal progenitor (pd) domains pd1-pd6 plus pdIL (Fig. 6) (Helms et al. 2003). The
ventral neural tube is specified by Sonic Hedgehog (SHH) protein secreted by the floor plate
and notochord (Marti et al. 1995; Ericson et al. 1996). Retinoic acid (RA) is a soluble lipophilic
molecule produced by the oxidation of its corresponding alcohol (retinol = vitamin A). RA
exerts pleiotropic functions during embryogenesis including cellular proliferation,
differentiation, apoptosis, tissue patterning and maintenance of bilateral symmetry via
nuclear receptor binding (Duester 2008). The segmented paraxial mesoderm stretching on
both sides of the neural tube (somites) secretes RA during neurulation, thus caudalising the
neighbouring neuroepithelial tissue and allocating positional information along the RC axis
(Sockanathan et al. 1998). Taken together, four major signalling systems (SHH, FGFs, BMPs
and RA) determine position as well as time of progenitor domain generation in the neural tube
in reference to both RC and DV body axes.
Within the nascent spinal cord, neuron subpopulations are topologically assigned according
to their origin and function (Briscoe et al. 2001). Dorsal neurons mostly relay cutaneous
sensory input whereas ventral neurons exert motor functions by the majority, thus reflecting
ancient tetrapod locomotion. SHH signalling defines generic motoneuronal identity in
motoneuronal progenitor domain (pMN). Later, mesodermal retinoid signals aid to specify
identity and position (Jessell 2000). In neural tube, SHH either represses expression of
transcription factors (TFs) (Class I, e.g. Pax6, Irx3) or induces synthesis of TFs (Class II, e.g.
Nkx6.1, Nkx2.2) (Briscoe et al. 2001). Therefore, incremental concentration relative to the SHH
source determines five different progenitor cell domains in the ventral neural tube (p0, p1,
p2, pMN and p3) characterised by a unique TF combination (Fig. 6) (Wilson et al. 2005). On
the other hand, RA promotes class I TF expression (Diez del Corral et al. 2003). As a common
feature, an individual subset of basic helix-loop-helix (bHLH) and homeo-domain box (Hox) TFs
is expressed conferring each domain a very specific TF profile. Typically, TFs in one progenitor
domain cross-repress expression of complementary factors in abutting domains, hence
avoiding hybrid identities (Briscoe et al. 2001; Lee et al. 2001). Nearly all domains give rise to
interneurons, just pMN domain generates motoneurons early and later oligodendrocytes (Lee
et al. 2001; Soula et al. 2001).
Within the emerging motor column of the developing neural tube, maturating MNs diversify
further into motor pools, each innervating individual muscles. Organisation is evident in the
alignment of motor neurons with common target projections into longitudinally oriented
columns (Landmesser 1978; Jessell 2000). Post-mitotic MNs become divided into the medial
and hypaxial motor columns (MMC and HMC) which innervate the back (epaxial) and trunk
(hypaxial) musculature, respectively (Fig. 7). The third lateral motor column (LMC) is
subdivided into a medial and lateral portion innervating the ventral part (LMCm) and the
dorsal part (LMCl) of limbs, respectively (Sockanathan et al. 1998; Wilson et al. 2005). So along
the RC axis, LMC is only found at brachial and lumbar levels of the spinal cord at putative limb
buds (Lee et al. 2001). Motor column diversification is predominately regulated by RA
expression in MNs at brachial and lumbar levels of the spinal cord (Sockanathan et al. 1998;
Wilson et al. 2005; Ricard et al. 2013).
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Lower motoneurons are among the largest cells in the human body. Their thin and extremely
long axons connect the CNS with the periphery and function as relays for central signals by
transducing electric stimuli to target skeletal muscles. Lower motoneurons themselves are
wired to different afferent neurons including upper motor neurons, glutamatergic
interneurons and sensory neurons. As each myelinated motor axon reaches its target, it
divides into 20–100 unmyelinated terminal fibres, each of which innervates a single muscle
fibre (Fallini et al. 2012).
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Fig. 7: Transverse section of a chick embryo at limb levels depicting the position of motor columns, their TF profile
and the respective axonal projections into the target muscle fields (N, notochord; F, floor plate; MMC, medial
motor column; LMC(m), medial portion of lateral motor column; LMC(l), lateral portion of lateral motor column)
(taken from (Jessell 2000)).
3.3.3 Mammalian motor circuit – exerting force
The motor circuit of voluntary movements relies on a two-staged system (Fig. 8): First, axons
of large pyramidal neurons (upper motoneurons) originating in layer V of the cerebral motor
cortex extend through the medullary pyramids, where most fibres decussate in the caudal
medulla before descending as lateral corticospinal tracts within the spinal cord (Carpenter
1991; Blackstone 2012). The second part
consists of lower motoneurons whose axons
connect to skeletal muscle fibres throughout
the body via highly specialised terminal
structures (NMJs). Even though some upper
motoneurons directly contact their lower
counterparts, in the vast majority interneurons
are interconnecting both types of motoneurons
(Carpenter 1991).
There are three sub-classifications of lower
motoneurons (Manuel et al. 2011): (i)
α-motoneurons (α-MNs) reside in the spinal
cord with their axons projecting outside CNS via
the ventral horns. They transmit nerve impulses
via NMJs to ordinary extrafusal muscle fibres,
thereby eliciting voluntary movements by
contraction. In vertebrates, the release of
neurotransmitter acetylcholine (ACh) mediates
signal transduction. (ii) The smallest subgroup
comprises β-MNs which innervate intrafusal &
extrafusal muscle fibres. (iii) γ-MNs innervate
intrafusal muscle fibres and refine their
sensitivity. So, motoneurons are a
Fig. 8: Schematic illustration of human motor circuit.
Upper MNs descend to the spinal cord where lower
MNs extend axonal connections to skeletal muscles
(from (Damjanov 2000)).
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heterogeneous group of CNS neurons responsible for motricity (locomotive system) (Manuel
et al. 2011).
3.3.4 Neuromuscular junctions (NMJs) – an extraordinary cell-cell contact
Motor axons end in a specially designed synaptic structure establishing connectivity between
the pre-synaptic motor nerve site and the post-synaptic muscle site, denoted neuromuscular
junction (NMJ) (Fig. 9). The NMJ is wholly capped by supportive terminal Schwann cells (TSCs)
and kranocytes (Court et al. 2008) whose absence severely impedes NMJ functionality (Lin et
al. 2000).
Fig. 9: Schematic depiction of a neuromuscular junction. Incoming action potential (1) causes opening of
voltage-gated Ca2+ ion channels (2) and subsequent influx. Ca2+-mediated synaptic vesicle fusion with the
synaptic membrane leads to emptying of neurotransmitter molecules (i.e. ACh) into the synaptic cleft (3).
Punctual high AChR occupation (4) on the post-synaptic site efficiently pursues signal transduction by induction
of Na+ influx (5) conducting local sarcolemma de-polarisation (end-plate potential) (6) which triggers large-scale
muscular action potentials (7) and subsequently muscle contraction (taken from ©2013
neuroanatomyblog.tumblr.com).
Once a pre-natal motor axon approaches its target muscle, a number of events take place
during synaptogenesis: (i) Prolonging motor axons secrete the proteoglycan agrin which binds
to the transmembrane receptor muscle-specific kinase (MuSK) and its co-factor Lrp4.
Thereupon, cytoskeletal re-distribution takes place by Rho GTPase induced signalling. At last,
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rapsyn, a cytoplasmatic linker, mediates plaque-like clustering of acetylcholine receptors
(AChR) anchored to the cytoskeleton on the myotube surface (Sanes et al. 2001; Wu et al.
2010). (ii) The post-synaptic sarcolemma folds to a lamella-like structure (motoric end-plate)
massively equipped with AChRs (Sanes et al. 2001). (iii) Moreover, the de-myelinated motor
axon tip bulges into a button-like swelling (“bouton”) above the sarcolemmal invaginations,
spacing the synaptic cleft (Sanes et al. 2001). (iv) Growing motor axons terminally branch and
innervate several muscle fibres. Thus, one AChR cluster of a single muscle fibre might be
transiently covered by numerous MN terminals of different MNs at birth (polyneuronal
innervation) (Slater 2009).
Elimination of such redundant neuronal connections in the immature nervous system, termed
axonal pruning, is a common feature of neurogenesis ensuring proper formation of neural
functionality (Low et al. 2006). Therefore, in a postnatal selection process, motor axons
compete for maintenance of their synapses leading to physiological weakening and retraction
of most motor axons. Eventually, all exuberant but one pre-synaptic MN connections are
removed so that only one single MN terminal innervates one endplate (Lichtman et al. 2000;
Luo et al. 2005).
Further regular postnatal NMJ maturation comprises rearrangement of immature oval AChR
plaque shape to a perforated, pretzel-like structure since AChRs agglomerate at the crests of
junctional sarcolemmal folds (Wu et al. 2010). The area of AChR clusters moderately enlarges.
Likewise, the composition of AChRs changes: AChR are heteropentamers composed of α-, β-
and δ-subunits plus embryonic γ-isotype subunits which are substituted by adult ε-isoforms
(Sakmann et al. 1978; Sine 2012). In adult muscle, the density of AChRs reaches >10,000 per
μm² (Sanes et al. 2001). In summary, functional NMJ connections are established at birth,
however, the mature adult configuration is adopted post-natally (Ruegg 2001). Stable
neurotransmitter release and augmented receptor number and density yield an efficacious
mature NMJ in the end (Sanes et al. 2001).
3.3.5 Effects of SMN depletion in the motoneuronal circuit
Summarising recent studies, hints accumulate that SMN protein function in motoneurons may
go beyond snRNP biogenesis. Instead, necessary levels of SMN are essential for motor axon
development and NMJ maintenance (Fallini et al. 2012).
In SMA patients, the greatest loss of muscular strength occurs at disease onset indicating an
initial loss of lower motoneurons followed by a low deterioration (Sumner 2007). A SMA
mouse model failed to exhibit any significant abnormalities in motor axon formation
(McGovern et al. 2008), thus corroborating evidence that SMA is rather a disease of
maintenance of MNs and NMJs. SMN loss in SMA patients and SMA mouse models is
accompanied by pronounced synaptic defects and de-nervation: (i) Reduced stimulatory input
onto motoneurons because of decrease in glutamatergic synapses of proprioceptive sensory
neurons (Mentis et al. 2011); (ii) phosphorylated neurofilament aggregation in motoneuronal
NMJs (Cifuentes-Diaz et al. 2002; Ling et al. 2010; Ling et al. 2011; Bowerman et al. 2012a);
(iii) disturbed Ca2+ homeostasis (Ruiz et al. 2010); (iv) irregularities in synaptic architecture
concerning pre-synaptic vesicle distribution and recycling as well as lower neurotransmitter
release (Kariya et al. 2008; Kong et al. 2009); (v) atypical motor endplate appearance on pre-
synaptic motoneuronal side indicated by poor arborisation, shortened axon length and
reduced growth cone size (Murray et al. 2008; Ling et al. 2011; Torres-Benito et al. 2011;
Bowerman et al. 2012a); (vi) delayed AChR clustering and NMJ maturation on post-synaptic
muscle side (Arnold et al. 2004; Kariya et al. 2008; Martínez-Hernández et al. 2013). In SMA,
24 Introduction
NMJs detain embryonic AChR subunits and keep the immature plaque form (Kariya et al. 2008;
Kong et al. 2009; Bowerman et al. 2012a).
So, loss of motoneuron cells is caused by a dying-back axonopathy because MN-axon
degeneration occurs before actual MN-cell death (Cifuentes-Diaz et al. 2002; Fallini et al.
2012). Considering a normal embryonic development, SMN seems more important for foetal
NMJ maturation and NMJ maintenance in postnatal/adult stages (Fallini et al. 2012).
Disturbed ubiquitin homeostasis is additionally causal for MN death elicited by disrupted
splicing of ubiquitin-like modifier activating enzyme 1 (Uba1) mRNA and lost interaction
between UBA1 and SMN in several SMA model systems (Wishart et al. 2014). Axonal
microRNA (miRNA) expression and distribution are dysregulated in SMN-deficient neurons
(Kye et al. 2014). Moreover, autophagy dysregulation was recently connected to SMA
pathology in mouse models (Custer et al. 2014; Garcera et al. 2013).
To which extent actin bundling protein PLS3 might positively influence the maintenance of
SMA-diseased NMJs is still a matter of debate. Particularly with regard to the inability of a
PLS3 over-expressing mouse model to appropriately phenocopying the SMA ameliorating
effect of this SMA modifier (Ackermann et al. 2013), the significance of a human
patient-derived PLS3 discordant cell model is highlighted.
3.4 Plastin 3 (PLS3) as disease modifier in SMA discordant families
3.4.1 The effects of modifiers in disease phenotype – no 1:1 translation from
gene to malady
Genetic disorders oftentimes exhibit a broad spectrum of phenotypic characteristics owing to
environmental as well as intrinsic genetic factors (“modifiers”). Monogenetic diseases like
SMA provide the unique framework to examine the possible impact of those modifiers since
they possess a uniform aetiology with a single causal gene, detailed clinical phenotype in
affected individuals and familial cumulation (Cutting 2010). The type of genetic mutation often
defines outcome and severity of a single-gene disorder. For instance, the kind of deletion in
the dystrophin gene determines whether a nonsense/frame-shift mutation or an in-frame
mutation occurs leading either to severe Duchenne Muscular Dystrophy or to milder Becker
Muscular Dystrophy (Abmayr et al. 2006; Kanagawa et al. 2006). However, when patients with
exactly the same genotype display a phenotypic variability, these observations point to the
existence of modifiers.
For many years, SMN2 was the sole known SMA-modifying gene displaying a strong inverse
correlation between its copy number and SMA phenotype (Feldkötter et al. 2002). Beside
SMN2 copy number, SMA severity and progression is decisively influenced by different disease
modifying factors: Barring an ameliorating SNP (c.859G>C substitution) in SMN2 (Prior et al.
2009), over-expression of zinc finger protein 1 (ZPR1) in mice led to increase in SMN levels and
gem formation as well as stimulation of neuritogenesis and rescue of axonal growth deficits
(Ahmad et al. 2012). In contrast, stathmin, a ubiquitous microtubule-destabilising
phosphoprotein enhancing the microtubule catastrophe rate, is aberrantly augmented in SMA
mice. Stathmin reduction improved motor abilities and NMJ formation in SMA mice, but failed
to prolong total viability. Ergo, microtubule depolymerisation apparently favours detrimental
effects in SMA linking microtubule stability to disease severity (Wen et al. 2010; Wen et al.
2012).
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3.4.2 PLS3 acts as protective modifier in SMA – but how?
In rare families, siblings showing the identical genotype, i.e. 3-4 SMN2 copies and homozygous
absence of SMN1, exhibit variable SMA phenotypes. Scrutinising this observation in so-called
“discordant families” suggests the influence of unknown modifying factors in SMA penetrance
(Helmken et al. 2000). In six such discordant families, some individuals with no SMN1 copy
and 3-4 SMN2 copies suffer from SMA III whereas other relatives are totally asymptomatic
despite sharing the same SMN1/SMN2 genotype. Remarkably, the number of affected male
SMA patients significantly outweighed the number of female patients alluding to a gender-
specific effect. In this context, the actin filament bundling protein plastin 3 (PLS3) was
eventually discovered by differential gene expression (micro-array) analysis as first SMA
modifier beside SMN2 copy number (Oprea et al. 2008).
Further qRT-PCR and protein analysis affirmed PLS3/PLS3 to be highly up-regulated in Epstein-
Barr-virus (EBV)-transformed lymphoblastoid (LB) cell lines of asymptomatic individuals
compared to their affected siblings. As expected, PLS3 protein is strongly expressed in solid
tissues like foetal and adult human brain, muscle and spinal cord. Interestingly, a high PLS3
expression was also found in blood of asymptomatic individuals being unusual for this PLS3
isotype (see 3.4.3). In only 5% of healthy control probands PLS3 expression could be detected
in native blood samples, at all. Yet, PLS3 over-expression in blood of asymptomatic individuals
rules out that EBV-mediated cell immortalisation led to the finding in this study (Oprea et al.
2008).
Previous PLS3 over-expression studies in fibroblast-like cell lines in vitro demonstrated cell
rounding, accumulation in the apical periphery and in microvilli of polarised epithelial cells,
PLS3 withdrawal from adhesion foci and simultaneously a massive actin filament
rearrangement to a polygonal meshwork (Arpin et al. 1994). To dissect the functional
mechanism behind the protective effect of PLS3 as well as the connection between SMN and
PLS3, different approaches have been undertaken in the original study by Oprea et al.:
On cellular level, healthy primary murine motoneurons exhibit a co-localisation of
endogenous Smn, actin and Pls3 which accumulate in F-actin-rich growth cones. As soon as
rat PC12 cells are differentiated into motoneurons, a similar distribution of Smn and Pls3 is
visible with agglomeration at neurites/growth cones and diffuse cytoplasmatic disposition.
PLS3 over-expression in HEK293 cells shifts G-/F-actin ratio in favour of filamentous actin
whereas a PLS3 knock-down results in the opposite effect and elevation of G-actin. LB cells of
asymptomatic siblings with high PLS3 expression reveal augmented F-actin levels.
Knock-down of Pls3 in rat PC12 cell-derived motoneurons evoked a dramatic shortage in
neurite length, whereas an over-expression of PLS3 caused markedly elongated neurite
growth. Besides, PLS3 over-expression with concomitant Smn knock-down rescued neurite
outgrowth in PC12 cell-derived motoneurons. No increase in SMN levels was detectable due
to PLS3 over-expression. Co-immunoprecipitation experiments insinuate an indirect
PLS3/SMN interaction. Summing up, these in vitro findings lead to the conclusion that PLS3 is
likely to exert its positive effect by stabilising actin filaments at crucial hotspots of structural
motoneuronal homeostasis e.g. axonal growth cones. Actin cytoskeleton dynamics, namely
G-/F-actin ratio, is a key player in axogenesis and path-finding (Dent et al. 2003).
Additionally, this hypothesis is strikingly circumstantiated by in vivo findings: PLS3
over-expression is able to fully rescue axonal growth defects including precocious branching
and truncations in smn depleted zebrafish embryos (Oprea et al. 2008; Hao le et al. 2012).
Moreover, in smn–/– zebrafish mutants Pls3 protein levels are significantly mitigated, while
pls3mRNA levels remain unchanged suggesting that SMN affects PLS3 protein synthesis (Hao
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le et al. 2012). Ackermann et al. recently provided a conditional PLS3 over-expressing mouse
model SMAPLS3 bred into the severe Taiwanese SMA background (Smn–/–; SMN2+/–; PLS3+/– in
pure C57Bl/6N background). In detail, the authors found an increased F-actin amount in pre-
synapses, restoration of synaptic vesicle and active zone content, re-assembly of the readily
releasable pool, increased endplate and muscle fibre size and improved neurotransmission,
summarised a general amelioration in MN-synapse architecture, activity and neuromuscular
connectivity (Ackermann et al. 2013). Furthermore, MN somata in SMAPLS3 mice are bigger
and receive more afferent proprioceptive inputs as compared to SMA mice. Yet, ubiquitous
over-expression moderately improved survival and motor function only in mildly affected SMA
mice with mixed background (50%C57Bl/6N/50%FVB/N), not in severe SMAPLS3mice reflecting
the human state in which only putative SMA III patients (≥3 SMN2 copies) benefit from PLS3
abundance. Over-expression of human PLS3 caused a significant delay in axon pruning until
postnatal day 8 (P8) counteracting the poor synaptic connectivity seen in SMA mice. Axonal
pruning is a major process of NMJ maturation in which exuberant axonal branches are
removed and endplates finally become innervated by a single axon (Redfern 1970; Luo et al.
2005) (see 3.3.4). In addition, PLS3 orthologues fimbrin (Fim) and plst-1 in D. melanogaster
and C. elegans, respectively, act as protective modifiers in SMA models of these invertebrates,
verifying the human data from the previous study and implying the relevance of PLS3 as a
cross-species modifier of SMA (Dimitriadi et al. 2010).
The nexus between PLS3, SMN and further microfilament components is illustratively
investigated by Bowerman and colleagues (Bowerman et al. 2009). In MNs of their
intermediate SMA mouse model (Smn2B/–) they detected a cell-autonomous increase in
profilin IIa levels, an actin monomer-binding protein and direct interaction partner of SMN,
which was accompanied by a decrease of Pls3 levels.
Yet, only PLS3 expression rescued axonal growth deficits in smnmorphant zebrafish whereas
other proteins modifying actin filaments (e.g. cofilin, profilin or α-actinin) failed. Deletion of
conserved PLS3 structural domains revealed that mutations in Ca2+-binding residues in the EF
hand motifs totally impaired the ameliorative impact of PLS3. Astonishingly, despite the loss
of their actin-binding domains, PLS3 mutants still exerted a moderate protective effect in
motor axons of smn morphants implying an actin-independent action of PLS3 (Lyon et al.
2013).
Further insight to the human state provided following study: Bernal et al. assessed PLS3
expression in LB cell lines of non-consanguineous discordant families (Bernal et al. 2011). PLS3
levels are 8-9 fold increased in asymptomatic siblings when compared to affected siblings.
However, PLS3 levels in fibroblasts of discordant siblings exceed those of blood and LB cells
~12-200-fold, questioning the validity of the observed subtle differences of PLS3 expression in
LB cells of asymptomatic individuals. If these results mirror the PLS3 expression state in the
spinal cord remains to be elucidated in depth. Unlike the study from Oprea et al., PLS3
expression levels are different when comparing LB cell lines to native blood of the same
patient. Thus, the authors do not exclude that other internal factors or the EBV-mediated
transformation process causes these slight changes in PLS3 expression (Bernal et al. 2011).
The gender-related aspect of PLS3 expression was examined in a cohort of SMA patients of
both sexes with different severity and age. Pre-pubertal male and female patients possess the
highest PLS3 expression. Yet, a stringent correlation between SMA type, SMN2 copy number,
gross motor function and PLS3 expression is only visible in mildly affected post-pubertal
women making hormonal influences probable. Thus, PLS3 seems unsuitable as general
biomarker for SMA in most clinical trials (Stratigopoulos et al. 2010).
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3.4.3 PLS3 – Occurrence and function
The human plastin 3 (PLS3) gene (also called T-plastin) is located on Xq23 spanning a
chromosomal region of ~90 kb (Lin et al. 1988). It consists of 16 exons and generates three
mRNA transcript variants (1, 2 and 3) which are expressed in epithelial and mesenchymal cells
of solid tissue (Delanote et al. 2005). Apart from PLS3, there exist two gene paralogues in
humans: I-plastin (PLS1) and L-plastin (PLS2) which are expressed in small intestine/kidney and
haematopoietic cell lineages, respectively (Lin et al. 1993; Lin et al. 1994).
Human plastins (earlier called fimbrins) derive from one ancestral gene. In general, plastin
genes are highly conserved in eukaryotic evolution (Lin et al. 1993; Delanote et al. 2005). The
three plastin protein isoforms share 70% aa homology.
PLS3 is 630 aa long cytoskeleton-associated protein with a size of roughly 70 kDa. Its nuclear
export signal (NES) ensures a strict cytoplasmatic localisation. Like its tissue-specific relatives,
PLS3 cross-links F-actin filaments into rigid, tight bundles with the same polarity. Thus, PLS3 is
involved in dynamics and re-organisation of any highly ordered microfilament structure,
amongst others microvilli, lamellipodia, membrane ruffles, focal adhesions, sometimes stress
fibres and invasion of intracellular prokaryotic pathogens like Rickettsia parkeri or
Shigella flexneri (Delanote et al. 2005; Serio et al. 2010).
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4. Aim of the study
One of the most frequent monogenetic cause of infant death worldwide is spinal muscular
atrophy (SMA), a devastating autosomal-recessive neurodegenerative disorder. SMA is
characterised by selective loss of lower α-motoneurons (MNs) in the spinal cord eliciting
de-nervation and progressive wasting of proximal skeletal musculature in limbs and trunk. The
responsible gene survival of motor neuron 1 (SMN1) is homozygously deleted. An almost
identical copy of SMN1, i.e. SMN2, contains a C>T transition in exon 7 which destroys an exonic
splicing enhancer site, thus negatively interfering with mRNA splicing because of undue
skipping of exon 7. Consequently, ~90% of SMN2 transcripts are devoid of exon 7 (Δ7-SMN),
leading to a truncated and instable SMN protein. Nevertheless, about 10% correct full-length
SMN transcripts (FL-SMN) are generated. Therefore, SMA severity is inversely correlated to
the total number of SMN2 copies which is variable in human population (2-6 on average).
Beside SMN2 copy numbers, up-regulation of actin bundling protein plastin 3 (PLS3) is linked
to protective effects in SMN1-deleted asymptomatic individuals of SMA discordant families.
Moreover, the SMA drug valproic acid (VPA) induced SMN elevation only in approx. ⅓ of SMA
patients due to individual VPA responsiveness. Yet, studies on neurological disorders like SMA
are hampered by the inaccessibility to patients’ neurons. The emergence of direct
reprogramming of patient-derived cells overcomes this obstacle by generating induced
pluripotent stem cells (iPSCs) and subsequent motoneuronal differentiation.
The major aim of this study was to obtain such a SMA patient-derived iPSC-based in vitro cell
culture model. Firstly, fibroblasts of six members of PLS3-discordant families as well as one
VPA responder/non-responder each were either reprogrammed by classical retroviral
transduction or by a non-integrative approach with Sendai virus. Secondly, one to two clones
per subsequent iPSC line were subjected to thorough standard validation procedure in order
to verify bona fide pluripotency. Thirdly, appropriate protocols for directed in vitro
re-differentiation of iPSCs into spinal motoneurons were set up. Thus, the in vitro SMA disease
model enabled further elucidation of the SMA pathomechanism directly in the target tissue,
i.e. α-motoneurons.
In four phenotypic groups (i.e. healthy controls, SMA I and PLS3 discordant SMA III and
asymptomatic siblings), SMA disease-related features (e.g. gem number, neurite length, MN
survival, growth cone architecture and SMN expression on RNA and protein levels) were
scrutinised during developmental course in order to recapitulate SMA pathology proven in
mouse models and established in vitro cell systems. Furthermore, previous findings in animal
models and non-neuronal patients’ cell lines like fibroblasts and immortalised lymphoblastoid
cells substantiated the ameliorative impact of PLS3 in SMA phenotype. Thus, this study
addressed the key question to which extent protective effects of PLS3 over-expression would
display in this model representing a mild discordant SMA cell system for the first time.
Moreover, the importance of neuromuscular junctions (NMJ), specialised motor synapses at
skeletal muscles, is gaining momentum concerning SMA pathology. Therefore, a co-culture
model of iPSC-derived motoneurons with human myotubes was introduced enabling further
studies of the mutual MN-muscle interaction in that putative hotspot of SMA pathology.
Finally, (moto)neuronal differentiation of VPA responders/non-responders was supposed to
verify previous results from patients’ fibroblasts and blood after VPA application and
furthermore to elucidate molecular mechanisms underlying variable VPA responsiveness in
SMA patients.
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5. Materials
5.1 Technical equipment
Table 1: Technical equipment
Appliance Name Manufacturer Registered Office
Autoclave DX-150 Systec Wettenberg,
Germany
Balance LA310S
BL610
Satorius
Satorius
Göttingen, Germany
Göttingen, Germany
Block heater Thermomixer compact Eppendorf Hamburg, Germany
Cell culture centrifuge Megafuge 1.0R Kendro Hanau, Germany
Centrifuge tubes Ultra Cone Polyallomer Seton Petaluma, USA
Counting chamber Fuchs-Rosenthal Laboroptik Bad Homburg,
Germany
Digital camera Canon Power Shot G5 Canon Krefeld, Germany
FACS FACS® Canto II BD Biosciences San Jose, USA
Fluorescence camera Axiocam MRm Carl Zeiss Jena, Germany
Fluorescence lamp HXP 120c Carl Zeiss Jena, Germany
Fluorescence microscope Axio Imager.M2 Carl Zeiss Jena, Germany
Freezer -20 °C/-80 °C HERAfreeze Heraeus Hanau, Germany
Freezing container “Mr. Frosty” 5100 Cryo 1°C Nalgene Roskilde, Denmark
Gel documentation Geldoc2000/ChemiDoc XRS Bio-Rad Munich, Germany
Gel electrophoresis
chambers
Agagel
SGE-020-02
Biometra
CBS-Scientific
Göttingen, Germany
San Diego, USA
Horizontal hood HERAguard Heraeus Hanau, Germany
Incubator HERAcell 150 Heraeus Hanau, Germany
Inverse light microscope Axiovert 40C Carl Zeiss Jena, Germany
Liquid nitrogen store MVE 611 German cryo Jüchen, Germany
Magnetic stirrer SB162 Stuart Scientific Staffordshire, UK
Micropipette 2.5 μl, 10 μl, 20 μl,
100 μl, 1,000 μl
Eppendorf Hamburg, Germany
Microplate reader TECAN Safire² Tecan Männedorf,
Switzerland
pH-meter Microprocessor pH meter Hanna-
instruments
Woonsocket, USA
Pipette-boy Accu-Jet II Brand Wertheim, Germany
Power supply for agarose
electrophoresis
Standard Power Pack P25 Biometra Göttingen, Germany
Real time thermocycler Light cycler® 1.5
iCycler
Roche
Bio-Rad
Penzberg, Germany
Munich, Germany
Refrigerator 4 °C KGEE36A Bosch Gerlingen, Germany
Spectrophotometer Nanodrop® ND-1,000
BioPhotometer
Peqlab
Eppendorf
Erlangen, Germany
Hamburg, Germany
Sterile laminar flow hood HERAsafe Kendro Hanau, Germany
Table centrifuge Centrifuge 5415D Eppendorf Hamburg, Germany
Thermocycler T3000 Biometra Göttingen, Germany
Ultracentrifuge Sorvall® Discovery 90SE Hitachi Wiesbaden, Germany
Vacuum pump Vacuubrand Brand Wertheim, Germany
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Vortexer Vortex Genie 2 Scientific
Industries
Bohemia, USA
Water bath W22 Medingen-GKS Dresden, Germany
5.2 Chemicals and consumables
If available, chemicals used in this study are purchased as purity grade “pro analysis”. For RNA
isolation and analysis, only RNase-free chemicals are employed.
Table 2: Chemicals
Chemical Manufacturer Registered Office
Accutase PAA Cölbe, Germany
Advanced DMEM Life Technologies Darmstadt, Germany
Advanced DMEM/F-12 Life Technologies Darmstadt, Germany
Alfazyme PAA Cölbe, Germany
Ascorbic acid Sigma-Aldrich Hamburg, Germany
B27® supplement Life Technologies Darmstadt, Germany
B27® supplement minus vitamin A (B27-RA) Life Technologies Darmstadt, Germany
β-mercaptoethanol Life Technologies Darmstadt, Germany
BDNF(rhBDNF) R&D Systems Wiesbaden, Germany
BSA Fraction V Carl Roth Karlsruhe, Germany
cAMP Sigma-Aldrich Hamburg, Germany
CHIR99021 Stemgent Bergisch Gladbach,
Germany
CNTF (rhCNTF) R&D Systems Wiesbaden, Germany
Collagenase type IV Life Technologies Darmstadt, Germany
DAPT Sigma-Aldrich Hamburg, Germany
DAPI Sigma-Aldrich Hamburg, Germany
db-cAMP Enzo Life Sciences Lörrach, Germany
D-Glucose Carl-Roth Karlsruhe, Germany
DMEM/F-12 (1:1) Life Technologies Darmstadt, Germany
Dispase Life Technologies Darmstadt, Germany
DMEM high Glucose Life Technologies Darmstadt, Germany
DMSO Sigma-Aldrich Hamburg, Germany
DNase I (for molecular biology) Promega Mannheim, Germany
Dorsomorphin Sigma-Aldrich Hamburg, Germany
EGF R&D Systems Wiesbaden, Germany
Ethanol (for molecular biology) Merck Darmstadt, Germany
FCS Life Technologies Darmstadt, Germany
FGF2 (= bFGF) R&D Systems Wiesbaden, Germany
FGF2 (= bFGF) Life Technologies Darmstadt, Germany
Fibronectin Sigma-Aldrich Hamburg, Germany
Fluorescein calibration dye Bio-Rad Laboratories Munich, Germany
Forskolin Enzo Lörrach, Germany
FuGENE® HD transfection reagent Roche Penzberg, Germany
GDNF (rhGDNF) R&D Systems Wiesbaden, Germany
Gelatine Life Technologies Darmstadt, Germany
Gentamicin Life Technologies Darmstadt, Germany
GlutaMAX™ Supplement Life Technologies Darmstadt, Germany
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ddH2O (Ampuwa® sterile water) Fresenius Kabi Bad Homburg, Germany
HBSS buffer Life Technologies Darmstadt, Germany
Heparin Sigma-Aldrich Hamburg, Germany
Horse serum Life Technologies Darmstadt, Germany
IGF-1 (rhIGF-1) R&D Systems Wiesbaden, Germany
iScript reverse transcriptase Bio-Rad Laboratories Munich, Germany
Knockout DMEM Life Technologies Darmstadt, Germany
Knockout Serum Replacement Life Technologies Darmstadt, Germany
L-Ascorbic-Acid-2-Phosphat (LAAP) Sigma-Aldrich Hamburg, Germany
Laminin Sigma-Aldrich Hamburg, Germany
LDN193189 Axon MedChem Groningen, Netherlands
Magnesium chloride Life Technologies Darmstadt, Germany
Matrigel™ BD Biosciences Heidelberg, Germany
Mowiol 4-88 Merck Darmstadt, Germany
mTeSR™1 STEMCELL Technologies Cologne, Germany
N2 Supplement PAA Cölbe, Germany
Neurobasal® medium Life Technologies Darmstadt, Germany
Non-essential amino acids (NEAA) Life Technologies Darmstadt, Germany
Opti-MEM® Life Technologies Darmstadt, Germany
PAGE Ruler Plus protein ladder Fermentas Pittsburgh, USA
Paraformaldehyde (PFA) Sigma-Aldrich Hamburg, Germany
PBS Life Technologies Darmstadt, Germany
PeqGOLD dNPT set PEQLAB Biotechnologie Erlangen, Germany
Penicillin/Streptomycin Life Technologies Darmstadt, Germany
Picric acid Sigma-Aldrich Hamburg, Germany
Poly-L-ornithine Sigma-Aldrich Hamburg, Germany
Purmorphamine Merck Darmstadt, Germany
Retinoic acid (RA) Sigma-Aldrich Hamburg, Germany
RIPA buffer Sigma-Aldrich Hamburg, Germany
SAG Calbiochem Läufelfingen, Germany
SB431542 Sigma-Aldrich Hamburg, Germany
Sendai virus vector (SeV) DNAVEC Tsukuba, Japan
SkGM + supplement PromoCell Heidelberg, Germany
Sodium pyruvate Life Technologies Darmstadt, Germany
SYBR-green I nucleic acid gel stain (10,000 ×) Sigma-Aldrich Hamburg, Germany
Taq DNA polymerase recombinant Life Technologies Darmstadt, Germany
Triton-X100 Sigma-Aldrich Hamburg, Germany
Trypan blue Life Technologies Darmstadt, Germany
Trypsin EDTA Life Technologies Darmstadt, Germany
Y-27632 (ROCK Inhibitor) Merck Darmstadt, Germany
Table 3: Consumables
Consumable Manufacturer Registered Office
Adhesive PCR films Peqlab Erlangen, Germany
Cellsive cell strainer (40 μm) BD Biosciences Heidelberg, Germany
Cell scraper Corning Kaiserslautern, Germany
Chamberslide (4-well glass) Millipore Schwalbach, Germany
Cotton swabs Hartmann Neuhausen, Schwitzerland
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Coverglass (24×60 mm)
(Ø 30 mm)
Paul Marienfeld
Glaswarenfabrik Karl
Hecht
Lauda-Königshofen, Germany
Sondenheim, Germany
Coverslips Labomedic Bonn, Germany
Cryovials (1 ml, 1.8 ml) Nunc Wiesbaden, Germany
Cuvettes Brand Wertheim, Germany
Glass pipettes Hirschmann Laborgeräte Eberstadt, Germany
Hyperfilm ECL Amersham Glattbrugg, Switzerland
KimWipes Kimberly-Clark Koblenz, Germany
OP-mask Hartmann Neuhausen, Switzerland
Parafilm Bemis Meckenheim, Germany
Pasteur pipettes Brand Wertheim, Germany
PCR plate (96 well) PEQLAB Biotechnologie Erlangen, Germany
PCR stripe tubes (0.2 ml) PEQLAB Biotechnologie Erlangen, Germany
Pipette tips Axygen (FischerScientific)
Greiner Bio One
Schwerte, Germany
Solingen, Germany
Reaction tubes (0.5 ml, 1.5 ml, 2 ml) Sarstedt Nümbrecht, Germany
Serological pipettes Corning Kaiserslautern, Germany
Single-use gloves Ansell Munich, Germany
Syringe filter (0.2 μm) PALL Corporation Dreieich, Germany
Syringes (1 ml, 5 ml, 10 ml)
(50 ml)
BD Biosciences
Braun
Heidelberg, Germany
Melsungen, Germany
Syringe needles BD Biosciences Heidelberg, Germany
Tissue culture dishes BD Biosciences
Nunc
Corning
Heidelberg, Germany
Wiesbaden, Germany
Kaiserslautern, Germany
Tissue culture flasks (T75, T175) Greiner Bio One Solingen, Germany
Tubes (15 ml, 50 ml) BD Biosciences Heidelberg, Germany
48-well-plate (transparent, flat
bottom
Corning Kaiserslautern, Germany
96-well-plate (black, flat bottom) Greiner Bio One Solingen, Germany
5.3 Kits
Table 4: Kits
Kit Manufacturer Registered Office
Alkaline Phosphatase Substrate Kit III SK-5300 Vector Laboratories Burlingame, USA
DNeasy Blood & Tissue Kit Qiagen Hilden, Germany
Fast Start DNA Master SYBR® Green I Roche Penzberg, Germany
GoTaq Flexi DNA polymerase Kit Promega Mannheim, Germany
iScript Reverse Transcription Kit Bio-Rad Munich, Germany
Plasmid Maxi Kit Qiagen Hilden, Germany
Quant-iT™ RiboGreen® RNA Assay Kit Life Technologies Darmstadt, Germany
QuantiTec Reverse Transkriptase Kit Qiagen Hilden, Germany
RNeasy Blood & Tissue Kit Qiagen Hilden, Germany
SuperSignal® West Pico Chemiluminescent
Substrate
Pierce Bonn, Germany
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5.4 Software
Table 5: Software programs
Name Application Version Producer
Axiovision Fluorescence microscopy 4.8 Carl Zeiss, Germany
iCycler analysis
software
qRT-PCR analysis V.3.1 Bio-Rad, Germany
iControl software Plate reader 1.6 Tecan, Switzerland
EndNote Bibliography 9.0.1 Thomson, USA
GraphPad Prism® Graph design 6 La Jolla, USA
LightCycler Software qRT-PCR analysis 3.5 Roche, Switzerland
Microsoft® Office 2007 Figure and text processing 2007 Microsoft, USA
Openlab Fluorescence microscopy 4.0.1 PerkinElmer, USA
Photoshop Image processing CS4 Adobe, Ireland
Quantity One Electrophoresis gel
documentation
4.6.3 Bio-Rad, Germany
XFluor4Safire² software Plate reader 1.2 Tecan, Switzerland
ZEN Fluorescence microscopy 2011 Carl Zeiss, Germany
5.5 Primers
All primers used in this thesis are designed by Johannes Jungverdorben or Dr. Bastian
Ackermann. Primers are individually designed for specific DNA targets and purchased from
Metabion or Life Technologies in lyophilised form. Upon arrival, lyophilised primers are diluted
to 100 pmol/μl stock solutions using sterile ddH2O. Working solutions are produced by diluting
stock solutions to a final concentration of 10 pmol/μl (FL-SMN, PLS3).
Table 6: Sequences of RT-PCR primers
Transcript Forward sequence (5'-3') ff Reverse sequence (5'-3') rev Tanneal
18S rRNA TTCCTTGGACCGGCGCAAG GCCGCATCGCCGGTCGG 60 °C
c-MYC endo TTCGGGTAGTGGAAAACCAC CCTCCTCGTCGCAGTAGAAA 60 °C
c-MYC total AAGACTCCAGCGCCTTCTCT TCTTGTTCCTCCTCAGAGTCG 60 °C
FL-SMN CCACCACCCCACTTACTATCA GCTCTATGCCAGCATTCCTCCT 60 °C
GAPDH TGACAACTTTGGTATCGTGGA CCAGTAGAGGCAGGGATGAT 60 °C
NP GAAAGAAATTTCACCGCTAGCGCGG
CCGCATGCTAACACGGCGCAATG
CATTGCGCCGTGTTAGCATGCGGCC
GCGCTAGCGGTGAAATTTCTTTC
60 °C
KLF4 endo GACCAGGCACTACCGTAAACA CTGGCAGTGTGGGTCATATC 60 °C
KLF4 total CCCAATTACCCATCCTTCCT ACGATCGTCTTCCCCTCTTT 60 °C
LEFTYA AATGTGTCATTGTTTACTTGTCCTGTC CAGGTCTTAGGTCCAGAGTGGTG 60 °C
LEFTYB GTCCATCACCCATCCTAAGCAC GCCAGCATTTCCTACTAGAGCTCA 60 °C
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT 60 °C
NODAL GGCGAGTGTCCTAATCCTGTTG GGTAACGTTTCAGCAGACTCTGG 60 °C
OCT4 endo GACAGGGGGAGGGGAGGAGCTAG GTTCCCTCCAACCAGTTGCCCCAAAC 60 °C
OCT4 total GTGGAGGAAGCTGACAACAA ATTCTCCAGGTTGCCTCTCA 60 °C
PLS3 GAACGTTGAGTGAAGCTGGA TTGCCACTCTTCACAAGGTC 60 °C
REX1 GCACACTAGGCAAACCCACC CATTTGTTTCAGCTCAGCGATG 60 °C
SOX2 endo GTATCAGGAGTTGTCAAGGCAGAG TCCTAGTCTTAAAGAGGCAGCAAAC 60 °C
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SOX2 total GCCGAGTGGAAACTTTTCTCG GCAGCGTGTACTTATCCTTCTT 60 °C
TERT GCGTTTGGTGGATCATTTCT ACCACTGTCTTCCGCAAGTT 60 °C
Oligo-dT primers for qRT-PCR are purchased from Fermentas (Pittsburgh, USA).
5.6 Plasmids and bacterial strains
5.6.1 Plasmids
Table 7: Plasmids
Name Description Reference
pMXs-hOCT4 Expression vector; MCS, Ψ, MMLV LTRs, Ampr (Takahashi et al. 2007)
pMXs-hSOX2 Expression vector; MCS, Ψ, MMLV LTRs, Ampr (Takahashi et al. 2007)
pMXs-hKLF4 Expression vector; MCS, Ψ, MMLV LTRs, Ampr (Takahashi et al. 2007)
pMXs-hc-MYC Expression vector; MCS, Ψ, MMLV LTRs, Ampr (Takahashi et al. 2007)
All plasmids (17217, 17218, 17219 and 17220) are purchased from Addgene (Cambridge, USA).
Corresponding vector maps are listed in 10.3, Fig. 62.
5.6.2 Bacterial strains
Table 8: Bacterial strains
Strain Description Reference
E. coli DH5α F—, Φ80lacZΔM15 Δ(lacZYA-argF) U169, recA1,
endA1, hsdR17 (rK—-, mK+) supE44, λ—, thi-1, gyrA,
relA1
(Hanahan 1983)
5.7 Buffers and solutions
5.7.1 Media for bacterial work
All bacterial media are autoclaved before use (121 °C, 1 bar pressure, 20 min).
LB medium SOC medium
10 g trypton 10 g trypton
5 g yeast extract 5 g yeast extract
5 g NaCl 0.3 g NaCl
Add up to 500 ml with ddH2O 0.09 g KCl
pH 7.4-7.5 is adjusted by NaOH 1.02 g MgCl2 × 6 H2O
1.23 g MgSO4 × 7 H2O
Add up to 500 ml with ddH2O
After autoclaving 20 mM D-glucose is
added
LB-agar is fabricated by adding 15 g agar per litre LB medium.
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5.7.2 Antibiotics
Table 9: Antibiotics
Antibiotic Stock concentration Dissolved in
Ampicillin 100 mg/ml ddH2O
Doxycycline 1 mg/ml ddH2O
G418 50 mg/ml ddH2O
Puromycin 10 mg/ml ddH2O
5.7.3 Solutions for DNA and RNA work
TAE 50 × qRT-PCR super mix
242 g Tris Base 1,511.5 µl ddH2O
57.1 ml Acetic acid 2,000 µl 5 × GoTaq Flexi Buffer
100 ml 0.5 M EDTA (ph = 8.0) (colourless)
Add up to 1 l with ddH2O and store at RT 1,000 µl MgCl2 (25 mM)
80 µl dNTPs (100 mM)
PCR super mix 400 µl DMSO
1,520 µl ddH2O 7.5 µl SYBR Green (1,000 ×)
2,000 µl 5 × GoTaq Flexi Buffer 1 µl Fluorescine (100 µM)
1,000 µl MgCl2 (25 mM)
80 µl dNTPs (100 mM) TE-4
400 µl DMSO 1 ml Tris (1 M, pH 8.0)
20 µl EDTA (0.5 M, pH 8.0)
DNA loading buffer 10 × Add up to 100 ml with ddH2O
2.5 ml SDS (20%)
10 ml EDTA (0.5 M, pH 7.2-8.5)
27.7 ml Glycerol (87%)
0.05 g Bromophenol blue
Add up to 50 ml with ddH2O
The super mixes are aliquoted and stored at -20 °C. 20 µl of each dNTP
(dATP/dCTP/dGTP/dTTP) are taken which results in 0.4 mM final concentration. Primers are
reconstituted in ddH2O to 100 µM final concentration. Primer mix is generated by combining
each forward primer with the corresponding reverse primer and diluting in ddH2O to 3.3 µM
final concentration.
5.7.4 Solutions for work with proteins
Laemmli buffer 2 × Lower buffer (1.5 M, pH 8.8)
0.757 g Tris Base 91 g Tris
20 ml Glycerine Add up to 500 ml with ddH2O and store at RT
6 g SDS
10 mg Bromophenol blue Upper buffer (1 M, pH 6.7)
Add up to 90 ml with ddH2O and store
dark at RT
60.57 g Tris
Add up to 500 ml with ddH2O and store at RT
1/10 β-mercaptoethanol is freshly added
prior to use.
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Running buffer 10 × Transfer buffer 1 ×
30.29 g Tris Base 4.84 g Tris Base
144.13 g Glycine 22.52 g Glycine
10 g SDS 400 ml Methanol
Add up to 1 l with ddH2O and store at RT Add up to 2 l with ddH2O and store at RT
10 × running buffer is diluted 1:10 with ddH2O.
Lower gel solution 10%
Upper gel solution 3% 2 ml Acrylamid stock solution
330 µl Acrylamid stock solution 30% (29:1)
30% (29:1) 1.3 ml Lower buffer pH 8.8
250 µl Upper buffer pH 6.7 1.7 ml ddH2O
1.4 ml ddH2O 50 µl SDS 10%
20 µl SDS 10% 50 µl APS 10% aqueous solution
20 µl APS 10% aqueous solution 2 µl TEMED
2 µl TEMED
Bradford solution
TBS/Tween 10 × 100 mg Coomassie Brilliant Blue
8 g NaCl G250
2.42 g Tris 100 ml H3PO4
5 ml Tween 20 50 ml Ethanol
Add up to 1 l with ddH2O and store at RT Add up to 1 l with ddH2O and store at RT
10 × TBS/Tween is diluted 1:10 with ddH2O.
5.8 Cell culture
5.8.1 Cell culture media
All media mixtures are stored at 4°C and used within two to four weeks. If necessary,
Pen/Strep is added at a final concentration of 1%.
All sera utilised are heat-inactivated (30 min, 56 °C).
MEF medium Final concentration
DMEM (high glucose) 88%
FCS 10%
Sodium pyruvate (100 ×) 1%
NEAA (100 ×) 1%
iPSC medium Final concentration
Knockout-DMEM 78%
Knockout Serum-Replacement 20%
NEAA (100 ×) 1%
GlutaMAX™ (100 ×) 1%
β-mercaptoethanol (50 mM) 0.1 mM
bFGF (10 µg/ml) 6 ng/ml
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N2 medium Final concentration
DMEM/F12 98%
N2 Supplement 1%
D-Glucose stock (160 mg/ml) 1%
EB medium EB1 Final concentration
DMEM/F12 77%
Knockout Serum-Replacement 20%
NEAA (100 ×) 1%
Sodium pyruvate (100 ×) 1%
GlutaMAX™ (100 ×) 1%
β-mercaptoethanol (50 mM) 0.1 mM
freshly added:
SB-431542 Inhibitor (50 mM) 5 µM
Dorsomorphin (5 mM) 1 µM
3 germ layer medium EB2 Final concentration
Knockout-DMEM 78%
Knockout Serum-Replacement 20%
NEAA (100 ×) 1%
GlutaMAX™ (100 ×) 1%
Neurosphere medium NSP1 Final concentration
N2 medium 97%
Pen/Strep (100 ×) 1%
freshly added:
B27-RA (50 ×) 2%
Pur (10 mM) 1 µM
Heparin (1 mg/ml) 1 µg/ml
RA (1 mM) 0.75 µM
MN maturation medium MN1 Final concentration
N2 medium 98.5%
GlutaMAX™ (100 ×) 0.5%
NEAA (100 ×) 1%
freshly added:
BDNF (10 µg/ml) 10 ng/ml
GDNF (10 µg/ml) 10 ng/ml
IGF1 (10 µg/ml) 10 ng/ml
CNTF (10 µg/ml) 10 ng/ml
Heparin (1 mg/ml) 1 µg/ml
RA (1 µM) 300 nM
Pur (10 mM) 0.5 µM
AA (200 mM) 200 µM
db-cAMP (200 mM) 5 µM
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lt-NES®SC medium NSC1 Final concentration
N2 medium 100%
freshly added:
B27-RA (50 ×) 0.1%
bFGF (10 µg/ml) 10 ng/ml
EGF (10 µg/ml) 10 ng/ml
CHIR99021 (10 mM) 1 µM
Original smNPC generation
medium smEB1
Final concentration
Knockout-DMEM 77%
Knockout Serum-Replacement 20%
NEAA (100 ×) 1%
GlutaMAX™ (100 ×) 1%
Pen/Strep 1%
β-mercaptoethanol (50 mM) 1 mM
freshly added:
Pur (10 mM) 0.5 µM
CHIR99021 (10 mM) 3 µM
Original smNPC medium
smNPC1
Final concentration
DMEM/F12 49%
Neurobasal® medium 49%
B27-RA (50 ×) 1%
GlutaMAX™ (100 ×) 0.5%
N2 Supplement 0.5%
freshly added:
LAAP (221 mM) 150 µM
Pur (10 mM) 0.5 µM
CHIR99021 (10 mM) 3 µM
smNPC medium NPC1 Final concentration
Advanced DMEM/F12 48%
Neurobasal® medium 48%
B27-RA (50 ×) 2%
GlutaMAX™ (100 ×) 1%
N2 Supplement 1%
BSA (5 mg/ml) 5 µg/ml
freshly added:
LAAP (221 mM) 150 µM
Pur (10 mM) 1 µM
CHIR99021 (10 mM) 3 µM
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Myocyte medium MYO1 Final concentration
SkMGM 88,5%
FCS 10%
GlutaMAX™ (100 ×) 1,5%
Gentamicin (50 mg/ml) 30 µg/ml
Skeletal muscle growth medium SkMGM = 100 ml SkMG basal medium +
5 ml SkMG supplement.
smNPC medium NPC2 Final concentration
Advanced DMEM/F12 48%
Neurobasal® medium 48%
B27-RA (50 ×) 2%
GlutaMAX™ (100 ×) 1%
N2 Supplement 1%
BSA (5 mg/ml) 5 µg/ml
freshly added:
LAAP (221 mM) 150 µM
SAG (1 mM) 1 µM
Pur (10 mM) 1 µM
RA (1 mM) 1 µM
smNPC medium NPC3 Final concentration
Neurobasal® medium 95%
B27-RA (50 ×) 2%
GlutaMAX™ (100 ×) 1%
N2 Supplement 1%
NEEA 1%
freshly added:
BDNF (10 µg/ml) 10 ng/ml
GDNF (10 µg/ml) 10 ng/ml
IGF1 (10 µg/ml) 10 ng/ml
LAAP (221 mM) 0.2 mM
db-cAMP (100 mM) 500 µM
Schwann cell medium SC1 Final concentration
DMEM  (high glucose) 96%
FCS 2%
Sodium pyruvate (100 ×) 1%
NEAA (100 ×) 1%
Forskolin (10 mM) 2 µM
Myotube medium MYO2 Final concentration
DMEM (high glucose) 94%
Horse serum 5%
Sodium pyruvate (100 ×) 1%
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Table 10: Standard freezing media
Cell type DMSO Additive(s)
Fibroblasts 10% 90% FCS
Schwann cells 10% 90% FCS
Myocytes 10% 20% FCS + 70% DMEM
lt-NES®SCs 10% 25% N2 medium + 65% KO-SR
smNPCs 10% 25% N2 medium + 65% KO-SR
Human iPSCs 10% 90% KO-SR
5.8.2 Cell culture solutions
Table 11: Stock solutions in cell culture
Stock solution Concentration Dissolved in
Ascorbic acid 200 mM ddH2O
B27® (-RA) 50 × /
BDNF 10 µg/ml ddH2O + 0.1% BSA
BSA Fraction V 7.5% ddH2O, sterile filtered
cAMP 1 mg/ml (= 3 mM) ddH2O
CHIR99021 10 mM DMSO
Chloroquine 25 mM ddH2O
CNTF 10 µg/ml ddH2O + 0.1% BSA
DAPT 10 mM DMSO
db-cAMP 100 mM ddH2O
D-Glucose 160 mg/ml DMEM/F12, sterile filtered
Dorsomorphin 5 mM DMSO
EGF 10 µg/ml ddH2O + 0.1% BSA + 10 mM
glacial acetic acid
FGF2 (= bFGF) 10 µg/ml ddH2O + 0.1% BSA
Fibronectin 1 mg/ml ddH2O
Forskolin 10 mM DMSO
GDNF 10 µg/ml ddH2O + 0.1% BSA
Heparin 1 mg/ml PBS
IGF-1 10 µg/ml ddH2O + 0.1% BSA
LAAP 64 mg/ml (= 221 mM) ddH2O
Laminin 1 mg/ml ddH2O
LDN193189 200 mM DMSO
Picric acid 1.3% saturated supernatant
Polybrene 4 mg/ml ddH2O
Infection medium Final concentration
Advanced DMEM 93%
FCS 5%
GlutaMAX™ (100 ×) 1%
Pen/Strep (100 ×) 1%
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Poly-L-ornithine 15 µg/ml ddH2O
Purmorphamine 10 mM DMSO/Ethanol 1:1
Retinoic acid 1 mM DMSO/Ethanol 1:100
SAG 1 mM ddH2O
SB431542 50 mM DMSO
Y-27632 10 mM ddH2O
Table 12: Working solutions in cell culture
Working solution Concentration Dissolved in
Collagenase Type IV 1 mg/ml Knockout-DMEM, sterile filtered
Dispase 0.15 mg/ml N2 medium, sterile filtered
DNase 1 mg/ml ddH2O, sterile filtered
Gelatine 0.1% ddH2O, autoclaved
Matrigel™ / DMEM/F12
Poly-L-ornithine 15 µg/ml ddH2O, sterile filtered
Trypsin/EDTA 1 × PBS
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5.9 Immunocytochemistry
5.9.1 Antibodies
Table 14: Primary antibodies
gt = goat, ms = mouse, rb = rabbit
Primary antibody Species & isotype Dilution Manufacturer Registered office
AFP rb, IgG 1:100 Dako Hamburg, Germany
AP2 ms, IgG 1:250 DSHB Iowa City, USA
β-actin ms, IgG 1:60,000 Sigma Deisenhofen, Germany
ChAT gt, IgG 1:100 Chemicon Schwalbach, Germany
DACH1 rb, IgG 1:100 Proteintech Herford, Germany
GAD65/67 rb, IgG 1:1,000 Chemicon Schwalbach, Germany
GFAP rb, IgG 1:1,000 Dako Hamburg, Germany
HB9 ms, IgG 1:250 DSHB Iowa City, USA
HN ms, IgG 1:1,000 DNAVEC Tsukuba, Japan
HOXB4 rat, IgG 1:250 DSHB Iowa City, USA
ISL1 ms, IgG 1:250 DSHB Iowa City, USA
MAPT ms, IgG 1:500 Millipore Schwalbach, Germany
Nestin ms, IgG 1:100 Chemicon Schwalbach, Germany
Nestin rb, IgG 1:200 Millipore Schwalbach, Germany
NF ms, IgG 1:250 DSHB Iowa City, USA
NF rb, IgG 1:1,000 Millipore Schwalbach, Germany
NKX2.2 ms, IgG 1:250 DSHB Iowa City, USA
NKX6.1 ms, IgG 1:250 DSHB Iowa City, USA
OLIG2 rb, IgG 1:500 Millipore Schwalbach, Germany
PAX6 rb, IgG 1:300 Covance Münster, Germany
PLS3 rb, IgG 1:50 Eurogentec Cologne, Germany
PLZF ms, IgG 1:25 Calbiochem Läufelfingen, Germany
SMA ms, IgG 1:100 Dako Hamburg, Germany
SMI-32 ms, IgG 1:1,000 Covance Münster, Germany
SMN ms, IgG 1:100 immunoGlobe Himmelstadt, Germany
SOX1 rb, IgG 1:100 Millipore Schwalbach, Germany
SOX2 ms, IgG 1:500 R&D Systems Wiesbaden, Germany
SSEA-3 rat, IgM 1:250 Millipore Schwalbach, Germany
SSEA-4 ms, IgG 1:200 DSHB Iowa City, USA
SV2 ms, IgG 1:100 DSHB Iowa City, USA
TH rb, IgG 1:500 Millipore Schwalbach, Germany
TRA-1-60 ms, IgM 1:500 Millipore Schwalbach, Germany
TRA-1-81 ms, IgM 1:500 Millipore Schwalbach, Germany
TUJ1 (β III-tubulin) ms/rb, IgG 1:1,000 Covance Münster, Germany
v-Glut1 rb, IgG 1:1,000 Synaptic
Systems
Göttingen, Germany
ZO-1 rb, IgG 1:100 Life
Technologies
Darmstadt, Germany
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Table 15: Secondary antibodies
Secondary antibody
(conjugate)
Species &
isotype
Dilution Manufacturer Registered office
Actin-Phalloidin
(Alexa 555)
Death cap
(Amanita
phalloides)
1:40 Life Technologies Darmstadt, Germany
anti-gt IgG (Alexa 488) donkey, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-gt IgG (Alexa 555) donkey, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-ms IgG (Alexa 488) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-ms IgG (Alexa 555) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-ms IgG (Alexa 647) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-ms IgG (HRP) goat, IgG 1:1,000 Dianova Hamburg, Germany
anti-ms IgM (Alexa 555) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-rat IgG/IgM (Cy3) goat, IgG 1:250 Jackson/Dianova Hamburg, Germany
anti-rb IgG (Alexa 350) donkey, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-rb IgG (Alexa 488) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-rb IgG (Alexa 555) goat, IgG 1:1,000 Life Technologies Darmstadt, Germany
anti-rb IgG (HRP) goat, IgG 1:1,000 Pierce Bonn, Germany
BTX (Alexa 555) Taiwanese
banded krait
(Bungarus
multicinctus)
1:500 Life Technologies Darmstadt, Germany
5.9.2 Solutions for immunocytochemistry
Solution Concentration Dissolved in
DAPI 0.1  µg/ml PBS
Mowiol 4-88 0.415 g/ml ddH2O + 1 g/ml Glycerol  +
2 volumes of Tris-HCl (pH=8.5)
PFA 4% PBS
Triton-X-100 10% PBS
Blocking solution: HBSS (+Ca2+/Mg2+) + 10% FCS + 0.1% Triton-X-100 (if necessary)
Antibody solution: HBSS (+Ca2+/Mg2+) + 5% FCS + 0.1% Triton-X-100 (if necessary)
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6. Methods
6.1 Cell culture methods
6.1.1 Cell culture coatings
Coating TC dishes with different matrices provides cells with specific substrata for growth and
adherence and is conducted by standard protocols as follows (Lindl 2002).
Gelatine coating
TC dishes/plates are incubated with an accordingly sufficient volume of gelatine working
solution at 37 °C for at least 30 min. The gelatine solution is immediately aspirated before
usage.
Matrigel™ (MG) coating
Overnight, 1 ml aliquots of Matrigel™ are thawed on ice. The other day, this Matrigel™ stock
is dissolved in 29 ml ice-cold DMEM/F-12 medium according to manufacturer’s data sheet.
Always using pre-cooled equipment, this working solution is sufficiently spread onto TC
dishes/plates. Those are sealed with Parafilm and stored for 24 h at 4 °C. The Matrigel™
solution is removed directly before plating any cells.
Poly-L-ornithine (PO) coating
TC dishes/plates are incubated with an accordingly sufficient volume of PO working solution
at 37 °C for at least 1 h. The PO working solution is aspirated and dishes washed with PBS
twice. Optionally, additional matrix protein coating may be performed.
Fibronectin (Fn) coating
The Fn working solution is freshly produced by diluting Fn stock in PBS (2-10 µg/ml final
concentration). PO-coated TC dishes/plates are incubated with an accordingly sufficient
volume of Fn working solution at 4 °C for 24 h to obtain PO/Fn coating. Plates are wrapped in
Parafilm during storage.
Laminin (Ln) coating
The Ln working solution is freshly produced by mixing Ln stock with PBS (2-10 µg/ml final
concentration). PO-coated TC dishes/plates are incubated with an accordingly sufficient
volume of Ln working solution at 4 °C for 24 h to obtain PO/Ln coating. Plates are wrapped in
Parafilm during storage.
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6.2 General cell culture methods
6.2.1 Cultivation of human fibroblasts
Human fibroblast cell lines are grown in T75 cell culture flasks in MEF medium with medium
change every two to three days. When fibroblasts are 70-75% confluent cells are split starting
with a singular rinsing with PBS. Then, cells are incubated with trypsin/EDTA working solution
for several minutes at 37 °C. As soon as cells start detaching, the trypsinisation reaction is
stopped by adding fresh MEF medium at the ratio 1:1. Cells are collected and centrifuged
(1,200 rpm, 3 min, 4 °C). The pellet is resuspended in fresh MEF medium. In a specific split
ratio, cells are distributed on new culture dishes/flasks in respect to the desired time period
until cells should have reached 70% confluence again (Lindl 2002).
6.2.2 Cultivation of human myocytes
Human myocyte line hMC is a kind gift of Prof. Hanns Lochmüller (University of Newcastle,
UK). Myocytes are grown in T75 cell culture flasks in MYO1 medium which is changed every
day according to collaborator’s instructions. Myocytes must not become ever confluent to
avoid loss of myogenic potential. Therefore, cells are split by standard trypsinisation when
myocytes are 70-75% confluent at the latest.
6.2.3 Cultivation of murine Schwann cells (SCs)
Murine Schwann cell line iMS32 is a kind gift of Rebecca Conrad/Dr. Michael Karus (University
of Bochum, Germany). iMS32 is a spontaneously immortalised Schwann cell line isolated from
long-term cultures of adult murine DRG and peripheral neurons and is cultivated accordingly
(Sango et al. 2006): Schwann cells are grown on 10 cm cell culture dishes (PO-coated) in MEF
medium with medium change every other day. Splitting occurs by standard trypsinisation
when SCs reach confluence of approx. 80% (see 6.2.1).
For the generation of Schwann-cell conditioned medium (SC-CM), Schwann cells are grown on
10 cm cell culture dishes until they reach total confluence. Subsequently, cells are fed with
10-15 ml SC1 medium (Kwiatkowski et al. 1998). For one week, medium is harvested each day,
pooled and sterile filtered (0.2 µm).
6.2.4 Cultivation of human iPSCs
Human iPSC lines are grown in 6-well cell culture plates (MG-coated) in mTeSR™1 medium
with daily medium change. iPSCs are split by the following standard singularisation protocol
when cells are 70-75% confluent (StemcellTechnologies Version 3.0.0): Each well is rinsed
once with PBS. Then, 0.5 ml of warm (RT) alfazyme is added and cells are incubated at 37 °C
for 5-7 min. When cells begin to loosen, the alfazyme is diluted by addition of 2-3 ml
pre-warmed (37 °C) DMEM/F-12 medium. Detached iPSCs are washed off with this medium
at once. After centrifugation (800 rpm, 3 min, 4 °C) the cell pellet is resuspended only once
with a 5 ml serological pipette in mTeSR™1 medium supplemented with 10 µM ROCK inhibitor
Y-27632 to promote single cell survival and transferred to new 6-well-plates in the same
medium. This way, human iPSCs are regularly split at a ratio of 1:6-1:14.
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6.2.5 Freezing & thawing
For long-term cryopreservation, cells are detached according to the respective splitting
protocol. However, after the centrifugation step the pellet is resuspended in ice-cold freezing
medium (see 5.8.1, Tab. 10) instead of cultivation medium (Lindl 2002). Immediately, the
cellular suspension is filled in pre-cooled cryovials and transferred into freezing boxes for one
day at -80 °C. For long-term storage, cryovials are kept in liquid N2.
For thawing cells, fast warming up is required in a 37 °C water bath. Before the icy cell mass is
totally molten, cells are quickly transferred into a 15 ml tube filled with 5 ml pre-warmed
(37 °C) medium. After centrifugation (800-1,200 rpm, 3 min, 4 °C), the pellet is resuspended
in the correspondent maintenance medium and cells are seeded on new cell culture
dishes/flasks at the desired ratio.
To spare sensitive single iPSCs, only low rotation values are used. Furthermore, any iPSC
medium is supplemented with 10 µM ROCK inhibitor Y-27632 during the thawing process to
enhance single cell survival (Watanabe et al. 2007).
6.2.6 Cell counting
From a single cell suspension, a 1:10 or 1:100 dilution is made according to the original cell
density (Lindl 2002). 20 µl of this dilution is thoroughly mixed with 20 µl trypan blue solution.
A counting chamber is prepared with half of the mixture. Cells in at least three smaller squares
in one whole square are counted whereas dead cells marked by bluish colour are ignored. The
sum is averaged and the result describes the mean cell numbers x ×104/ml volume.
6.3 Induction of pluripotency
6.3.1 Preparation of feeder-plated TC dishes
Frozen cryovials with irradiated murine embryonic fibroblasts (MEFs) are thawed in a 37 °C
water bath (Lindl 2002). Quickly, cells are transferred in a 15 ml tube filled with pre-warmed
(37 °C) MEF medium. After centrifugation (1,200 rpm, 3 min, 4 °C), the pellet is resuspended
in warm MEF medium and cells are sowed on gelatine-coated TC dishes at a density 3×104 to
4×104 cells per cm².
6.3.2 Generation of 4F retroviruses
In order to introduce the reprogramming factors into target cells, suitable retroviruses have
to be generated. Here, the human HEK293-derived retroviral packaging cell line 293-GPG was
employed yielding high virus titres (Ory et al. 1996). 293-GPG already contains the retroviral
gag-pol cluster for capsid formation and reverse transcription. The G-protein of vesicular
stomatitis virus (VSV) as envelope protein conveys a broad tropism for efficient host infection.
Modified from Koch et al., 2011, 293-GPG cells are sown on gelatine-coated 10 cm TC dishes
at a density 9.5×106 per dish in MEF medium supplemented with antibiotics (2 µg/ml
puromycin, 300 µg/ml G418, 1 µg/ml doxycycline). The next day, transfection is performed by
mixing 500 µl Opti-MEM + 9.5 µl retro-DNA plasmid containing one single reprogramming
factor (2 mg/ml) + 47.5 µl FuGENE® HD transfection reagent. During 15 min incubation,
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transfection reagent and plasmids form complexes. In the meantime, medium is changed on
293-GPG cells with Opti-MEM supplemented with 25 µM chloroquine. This quinoline derivate
prevents lysosomal acidification. Hence, retro-DNA plasmid containing endosomes escape
lysosomal degradation and release a higher amount of plasmids increasing infecitivity
(Fredericksen et al. 2002). The transfection mix is gently distributed dropwise in every TC dish.
Seven to eight hours later, MEF medium is added to every TC dish. The next morning, the
medium is wholly changed with plain MEF medium.
After three days, retrovirus containing medium is harvested separately for each
reprogramming factor for the first time and cells are fed with fresh MEF medium. Further
harvests are conducted on the following two mornings. The supernatant containing the
retrovirus is sterile filtered (0.45 µm cellulose acetate filter) and stored at 4 °C. First and
second harvests are pooled. Eventually, the retrovirus harvests of every factor fraction are
concentrated by ultracentrifugation (4 °C, 50,000 g, 90 min). The supernatant is thoroughly
removed and the retrovirus pellet is carefully resuspended in 50 µl reflux. The four factor
fractions are coalesced in a specific ratio (OCT4:SOX2:KLF4:c-MYC=1.5:1:1:0.5).
To rid the ultraconcentrate from cytotoxic precipitations, this retroviral ultraconcentrate is
spun again (4 °C, 15,000 g, 10 min) and the remaining supernatant is cautiously gathered.
6.3.3 Infection of target fibroblasts with 4F retroviruses
Following protocol is adapted from (Koch et al. 2011). At least two hours before infection,
5×104 fibroblasts are plated in a 12-well plate in MEF medium supplemented with 10 ng/ml
bFGF to enhance proliferation and thus nuclear invasion of retroviral transgenes later.
The 4F ultraconcentrate is filled up with cold MEF medium to 350 µl final volume and
supplemented with 4 µg/ml polybrene. This cationic polymer neutralises cellular surface
charge and fosters uptake of retroviral particles by counteracting putative repellent effects of
surface epitopes like sialic acid (Davis et al. 2002). At last, the target fibroblasts are infected
(day 0) by aspirating the old medium and adding the retroviral ultraconcentrate mixture ON.
The next morning, retroviral medium is removed and plain MEF medium allows fibroblast to
recover. In the afternoon, infection is repeated with freshly prepared retroviral
ultraconcentrate (day 1). From day 2 onwards, infected fibroblasts are maintained in MEF
medium. On day 6, 4F fibroblasts are transferred onto MEF feeder coated TC dishes and
cultivated in iPSC medium for the next weeks until first iPSC colonies appear.
6.3.4 Infection of target fibroblasts via SeV spinfection
Following protocol is modified from (Aasen et al. 2008). One day before infection, 10×104
target fibroblasts are seeded on uncoated 24-well-plates in MEF medium. The following day,
¼ of original commercially purchased Sendai virus (SeV) vector stock (see manufacturer’s
instructions) is diluted in infection medium while MEF medium is aspirated. Per well, 500 µl
of diluted SeV vector solution are added. Fibroblasts are spun in a centrifuge for 45 min at
32 °C with 1,500 g (spinfection). Cells are incubated further with viral infection medium
overnight. The next five days, daily medium change is performed with pure infection medium
(without virus).
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6.3.5 Induction of pluripotency
Protocol is adapted from (Koch et al. 2011). At day 5 post-infection, SeV infected fibroblasts
are trypsinised and split onto two 10 cm feeder-plated TC dishes (10×104 and 15×104 cells,
respectively) in 10 ml iPSC medium. Excessive cells can be frozen.
During the following weeks, medium is changed every other day until the first hints of
reprogrammed cells emerge, normally between day 21 and day 28. If necessary, up to ¼ of
the original amount of feeder cells are seeded onto the 10 cm dishes replenishing dying feeder
cells.
6.3.6 Generation of clonal iPSC lines
As soon as new iPSC colonies emerging on primary 10 cm TC dishes reach a certain size, they
can be manually picked to obtain single clonal iPSC lines. At the horizontal hood, one
appropriate iPSC colony with proper stem cell morphology is quartered by a syringe cannula.
Afterwards, the surrounding feeder layer is carefully scratched off. With a 100 µl pipette tip,
iPSC colony fragments are collected and broken down further by pipetting up and down in a
96-well-plate several times. At last, these iPSC colony fragments are transferred into a
4-well-plate (MG-coated) filled with mTeSR™1 medium supplemented with 10 µM ROCK
inhibitor Y-27632.
If a new clonal iPSC line grows properly in a stable manner without spontaneous
differentiation, it will be split on 6-well-plates (MG-coated) and expanded according to
standard maintenance protocol.
Particularly young iPSC lines tend to spontaneously differentiate partly at early passages
sometimes. To purify these lines, differentiated parts of iPSC colonies are scratched off by a
10 µl pipette tip under a microscope at the horizontal hood during regular maintenance
culture. Alternatively, incubation time with alfazyme is reduced to just 2-3 min. Detached
iPSCs are washed off very gently only once with DMEM/F-12.
6.4 Directed motoneuronal differentiation in vitro
Subsequent protocol steps are adapted from (Hu et al. 2009).
6.4.1 Embryoid bodies (EB) formation
Three to five wells of a 6-well-plate (70-80% confluence) iPSCs are detached by collagenase
(1 mg/ml) treatment for 60-70 min. Instead of densely packed colonies, iPSCs form delicate
and fragile layers under feeder-free maintenance conditions. So, colonies are only very
carefully washed off using a 10 ml serological pipette and pre-warmed (37 °C) DMEM/F-12.
Cells are spun down (800 rpm, 30 sec, 4 °C) and the pellet is carefully resuspended in 2 ml EB1
medium supplemented with 10 µM ROCK inhibitor Y-27632. Cellular fragments are
transferred to a 10 cm-Petri dish into total 10 ml EB1 medium + 10 µM Y-27632. Every other
day, medium is totally changed by collecting the EBs in a 15 ml tube, letting them slump and
congregate at the tube bottom for approx. 5 min. The supernatant is carefully aspirated and
EBs are gently resuspended in fresh EB1 medium with subsequent re-transfer onto the Petri
dish.
50 Methods
6.4.2 Neural rosette formation
On day 6, EBs are equally plated onto four to six 6 cm TC dishes (PO/Fn-coated) per cell line in
2.5 ml N2 medium + 10 ng/ml bFGF + 2 µg/ml Fn + 5 µM SB431542 + 1 µM dorsomorphin. The
next day, only supplements are added (10 ng/ml bFGF + 0.75 µM RA) in 200 µl N2 medium per
dish. Subsequently, daily medium change is carried out with 2-3 ml N2 medium + 10 ng/ml
bFGF + 0.75 µM RA.
6.4.3 Neurosphere formation
On day 13, neural rosettes are enzymatically isolated from surrounding differentiating,
non-rosette cells (e.g. neural crest cells). Neural rosettes are rinsed once with HBSS.
Treatment with dispase working solution for 2-3 min selectively detaches neural rosettes. By
tapping the dish and carefully washing with N2 medium, neural rosettes can be collected and
centrifuged (800 rpm, 30 sec, 4 °C). After removing the supernatant, pelleted rosettes are
gently resuspended and transferred in NSP1 medium to a 10 cm Petri dish to promote
neurosphere formation. Even though the dish surface is non-adherent, the next day some
neurospheres settled as well as differentiating cells in particular. To keep these spheres also
into suspension, the Petri dish is moderately tapped without detaching differentiated
aggregates. Any floating neurosphere is collected in a 15 ml tube and allowed to sediment for
5 min. In order to minimise stickiness of neurospheres due to cellular debris, 1:100 DNase
might be added optionally. Then, the supernatant is aspirated slowly and pelleted
neurospheres are transferred to a new Petri dish in 10 ml NSP1. Every other day, medium is
fully changed according to the aforementioned suspension culture techniques.
On day 19, neurospheres are mechanically broken into smaller fragments. After having
pelleted neurospheres in a 15 ml tube, spheres are vigorously pipetted two to three times
with a 1,000 µl pipette tip in 1 ml NSP1 + DNase (1:100). Moreover, further titruation occurs
by pipetting twice with a glass Pasteur pipette. The entire cell suspension is transferred to a
new Petri dish in 10 ml NSP1. Often, neurospherical fragments attach owing to this previous
splitting step. Therefore, Petri dishes are moderately tapped to loosen neurospheres on the
following day. Floating spheres are transferred to a new Petri dish in 12 ml NSP1. After this
cleaning step, ⅔ of the medium are replaced the other day. Since then, a full medium
exchange is performed every second day.
6.4.4 Plating neurospheres and final MN maturation
On day 27, neurospheres are sown for the final maturation step. Mature, fully pMN-domain
patterned neurospheres are collected and pelleted in a 15 ml tube. The supernatant is
removed and spheres washed once with PBS. Afterwards, structural integrity of those spheres
is loosened by incubation in 500 µl accutase + 30 µM ROCK inhibitor Y-27632 (5 min, 37 °C).
To dilute accutase and to minimise its enzymatic activity thereby, 1.5 ml N2 medium + DNase
(1:50) is added. Manual titruation is performed by moderately pipetting two to three times
with a 1,000 µl pipette tip and once with glass Pasteur pipette. This cellular suspension is
briefly centrifuged (800 rpm, 4 °C) and the supernatant containing any debris is removed.
Hence, spherical fragments are gently resuspended in MN1 medium + 10 µM ROCK inhibitor
Y-27632 and adequately distributed to MG-coated 3.5 cm TC dishes (for RNA/protein
extraction) or chamberslides (MG- or PO/Fn/Ln-coated; for immunocytochemical stainings).
Medium change is conducted at least every other day with an appropriate volume of MN1
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medium (500 µl-1 ml with chamberslides; 2-4 ml with 3.5 cm dishes). In addition, it is
recommendable to equilibrate MN1 medium beforehand by aseptically putting the medium
in any TC dish in the cell culture incubator for 1 h (37 °C, 5% CO2) as it is regularly done in this
study.
6.5 Preparation of teratoma assay
Teratoma assay is adapted from (Takahashi et al. 2007). From one well of a 6-well-plate
(80-90% confluence) iPSCs are detached by collagenase (1 mg/ml) treatment for 60-70 min.
Cells are carefully washed off with pre-warmed (37 °C) DMEM/F-12 medium according to the
EB formation procedure and centrifuged (800 rpm, 3 min, 4 °C). The supernatant is removed;
the pellet is gently resuspended in 500 µl PBS to keep cells as bigger clumps and stored on ice.
Cell clumps are injected in 10 µl liquor into the right testis capsule of six- to eight-weeks-old
male SCID/Beige mice by Anke Leinhaas in the Haus für Experimentelle Therapie (HET),
University of Bonn.
Between six to eight weeks after transplantation, the mice are sacrificed. Any tumour is
surgically removed and fixed in a 4% PFA solution for at least one week. Afterwards, teratomas
are dehydrated, embedded in paraffin and cut into sections of 7 μm thickness by Kristina
Hupperich or Andrea Hoffmann. Standard eosin/haematoxylin staining is performed by 30 min
incubation in xylol for de-paraffinisation. Then, sections are incubated in ethanol baths of
decrementing concentrations (100%, 96%, 70%, 50% for 3 min each) and quickly rinsed in PBS.
After 1 h incubation in H2O, the sections are stained in haematoxylin for 6 min and washed in
H2O for 15 min afterwards. To remove redundant dye, the sections are briefly washed in H2O
and subsequently stained with eosin for 1 min. Thereafter, sections are purged in H2O several
times (6-7 ×), dehydrated in incrementing ethanol concentrations. Finally, tissue sections are
air dried, embedded in Entellan® and histologically analysed.
6.6 Undirected differentiation of iPSCs into three germ layers
Protocol is adapted from (Itskovitz-Eldor et al. 2000). To induce spontaneous differentiation
in human iPSCs, three to four wells of a 6-well-plate (70-80% confluence) iPSCs are detached
by collagenase (1 mg/ml) treatment for 60-70 min. According to EB formation procedure,
colonies are softly washed off and centrifuged. The pellet is carefully resuspended in 2 ml EB2
medium and cell clumps are transferred to a 10 cm-Petri dish into total 10 ml EB2 medium.
Every two days medium is wholly changed. After six days, EBs are equally sown out in total
2 ml medium onto 3.5 cm cell culture dishes (gelatine-coated in MEF medium; PO/Fn-coated
in EB2 medium) to promote either meso- and endodermal or neuroectodermal outgrowth,
respectively. Cells are cultivated for further ten days with full medium change every other day
and are then immunocytochemically analysed.
6.7 Generation and cultivation of smNPCs
Generating an appropriate neural precursor subpopulation massively shortens the time
period of motoneuronal differentiation compared to the EB-based run-through protocol.
Reinhardt et al. introduced human iPSC-derived, small molecule induced neural precursor cells
(smNPCs) last year (Reinhardt et al. 2013).
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Adapted from the published protocol, iPSC colonies are detached by collagenase treatment
and transferred to a non-adherent Petri dish in smEB1 medium + 10 µM ROCK inhibitor
Y-27632 + 0.5 µM LDN193189 + 10 µM SB431542. After two days, medium is changed omitting
Y-27632. On day 4, dual SMAD-signalling inhibition is stopped by withdrawing LDN193189 and
SB431542. Finally, EB-like spheres are collected and mildly chopped by titruation. Spheric
fragments are plated on MG-coated dishes in smNPC1 medium + 10 µM ROCK inhibitor
Y-27632. Soon, progenitor cells commence proliferating adherently.
Moreover, the original generation protocol was modified by Beatrice Weykopf and
Dr. Michael Peitz to a fully adherent protocol for which iPSCs are grown in mTeSR™1 medium
to approx. 70% confluence. Medium is switched to NPC1 plus 10 µM SB-431542 Inhibitor and
1 µM dorsomorphin, respectively for the following four days. Then, cells are detached by
alfazyme treatment (5-7 min, 37 °C), washed off with NPC1 medium and spun down
(1,000 rpm, 3 min, 4 °C). Finally, cells are split in a 1:8-1:10 ratio onto new MG-coated plates
in NPC1 medium plus 10 µM ROCK inhibitor Y-27632. Both generation protocols are carried
out with all cell lines in parallel.
After five passages, smNPCs are regularly growing stably. Then, medium is switched to NPC1
containing a higher portion of B27-RA and N2 Supplement thus allowing administration of a
higher Pur concentration (1 µM). Expansion of smNPCs is conducted by further propagating
cells up to 70% confluence. Regular splitting is carried out as described above in a ratio of 1:8-
1:12 in NPC1 medium. NPC1 medium is changed every other day.
In order to pre-pattern smNPCs towards a ventral-caudal fate, 1 µM RA and 1 µM SAG are
added to NPC1 medium with daily medium change.
6.8 Motoneuronal differentiation on smNPCs
Based on the original protocol by Reinhardt et al., 2013, a modified MN differentiation
protocol was developed with Dr. Michael Peitz and Johannes Jungverdorben. To differentiate
smNPCs into MNs, smNPCs are seeded onto 6-well plates (PO/Ln-coated) in NPC1 medium.
Once cells reach 70% confluence, medium is changed to NPC2 medium initiating
motoneuronal patterning for the next seven days. On day 7, cells are singularised by alfazyme
treatment (5-7 min, 37 °C). Bigger cell clumps are retained by a cell strainer (40 µm). 150,000
single cells per well of a chamberslide (PO/Ln/Fn-coated) are plated in NPC3 medium plus
10 µM ROCK inhibitor Y-27632 for final maturation during the following weeks. At least two
million cells are sown on 3.5 cm-dishes (PO/Ln/Fn-coated) for harvesting RNA or protein.
Medium is changed the next day. To thrust progenitor cells into motoneuronal differentiation,
10 µM notch-signalling inhibitor DAPT is added from d8-d12. Moreover, 0.5 mM Pur and
50 nM RA are subjoined to NPC3 medium from d8-d15 to ensure proper maturation of
potentially present pMN-patterned progenitor cells. NPC3 medium is changed every other
day. Motoneurons are maturated until day 27 for three weeks in total.
6.8.1 Plating MN-primed smNPCs for growth cone assay
For precise measurement of axonal length or of growth cone architecture, special seeding
technique is applied to avoid a tangled neuronal network in mature MN cultures which might
impair further analyses adapted by Beatrice Weykopf from Tomishima et al. (Tomishima
2012). For this purpose, 75,000 MN-primed smNPCs are seeded to previously prepared
chamberslides (PO/Fn/Ln-coated) of which the coating solution was aspirated beforehand.
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The coating of those chamberslides is allowed to become touch dry under a sterile laminar
flow hood for 10-15 min before usage.
In a single drop, the cells are set amidst in each chamberslide well, very cautiously put into
the incubator and let sit for 10 min at least. Without any mechanic disturbance, the cells
adhere to the coating matrix so that the wells can be flooded by 500 µl NPC3 medium + 10 µM
ROCK inhibitor Y-27632 afterwards. Like regular MN cultures, medium is changed every other
day. Punctiform plating enables coronal outgrowth of neurites and axons to the periphery.
6.9 Motoneuron-myotube co-culture in vitro
Based on previous protocols (Guo et al. 2011; Stockmann et al. 2011), the present co-culture
technique was developed. Similar to the seeding procedure on day 27 (see 6.4.4), MN
neurospheres are plated on 3.5 cm cell culture dishes (PO/Ln) and cultivated for the next nine
days in MN maturation medium.
In parallel to this motoneuronal pre-maturation, human myocytes are seeded on 3.5 cm cell
culture dishes (MG-coated) and grown until they reach nearly 90% confluence. Since that time,
MYO1 medium is replaced by MYO2 medium to induce myocyte differentiation with
subsequent syncytial myotube formation during the following four to six days under
low-serum conditions.
On day 36, plated neurospheres are transferred en bloc atop differentiated myotubes.
Therefore, medium is aspirated and neurospheres are incubated in 1.5 ml pre-warmed (37 °C)
HBSS (–Ca2+/Mg2+) for 10 min. By gentle tapping, neurospheres detach and can be collected.
1 ml N2 medium + B27-RA (1:100) + DNase (1:100) is added. To separate the sticky
neurospheres, cells are gently pipetted two to three times with a 5 ml serological pipette.
Spheres are allowed to accumulate for several minutes before equally distributing those
spheres on 3.5 cm cell culture dishes with myotubes whose medium was replaced in the
meantime with Schwann-cell conditioned medium (see 6.2.3). Co-cultures are ideally
cultivated for up to seven weeks or longer with medium change every two to three days.
6.10 Microbiological methods
6.10.1 Isolation of retro-DNA plasmids
Sufficient retro-DNA plasmids were kindly provided by Viola Poppe. To produce retro-DNA
plasmids, 5 ng of each plasmid (pMXs-hOCT4, pMXs-hSOX2, pMXs-hKLF4, pMXs-hc-Myc) is
added to 100 µl bacterial solution of heat-shock competent E. coli DH5α (in LB medium + 10%
polyethylene glycol 400 + 5% DMSO + 50 mM MgCl2 pH 6,5) and rested on ice for 20 min.
Hereafter, the plasmids are incorporated via heat induction (42 °C, 40 sec). Immediately,
bacteria are placed back on ice. After 2 min, they are dissolved in 900 µl SOC medium (RT) and
shook for 1 h at 37 °C. Thereafter, transformed bacteria are centrifuged (RT, 10,000 rpm,
5 min). The supernatant is carefully removed and the pellet is resuspended in 100 µl reflux.
Bacterial suspension is spread on LB-agar plates plus 100 µg/ml ampicillin and incubated ON
at 37 °C.
The next morning, emerging bacterial colonies were positively selected for incorporated
retro-DNA plasmids by Ampr. One distinct colony is picked and used for inoculation of 300 ml
LB medium plus 100 µg/ml ampicillin. After one night shaking at 37 °C, bacterial suspension is
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collected and spun down (4 °C, 4,500 g, 15 min). Retro-DNA plasmids are isolated by Plasmid
Maxi Preparation Kit (Qiagen) according to manufacturer’s instructions.
6.11 Molecular-biological methods
6.11.1 Polymerase chain reaction (PCR)
To amplify definite DNA fragments, PCR is a very productive and exact method due to its
primer-mediated high specificity (Mullis et al. 1986). For this purpose, the DNA sequence has
to be known in order to generate oligonucleotide primers flanking the DNA region of interest.
A typical PCR approach is prepared on ice and composes of the following:
Primer mix (3.3 µM) 1 µl
PCR super mix (2 x) 12.5 µl
ddH2O 10.375 µl
Template (cDNA/gDNA) 1 µl
GoTaq-Polymerase (5 U/µl) 0.125 µl
25 µl
First, the DNA template turns into single stranded DNA owing to heating up the mixture to
95 °C (denaturation). Second, subsequently cooling the mixture to a definite temperature –
usually 2-5 °C below Tm of the primers – enables the oligonucleotide primers to anneal
specifically to the DNA template (annealing). Third, the temperature is risen again to the value
of optimal working activity for the heat-stable Taq-polymerase which uses the final primer
base as starting point for the synthesis of the complementary DNA strand (elongation). By
cyclic repetition, the amount of target DNA is amplified exponentially.
For the house-keeping gene GAPDH, PCR program is as follows:
Initial denaturation 95 °C 5 min
Denaturation 95 °C 30 sec
Annealing 60 °C 30 sec 30 cycles
Elongation (1 min/kb) 72 °C 1 min
Final elongation) 72 °C 5 min
For all other trancripts, cycle number is elevated to 35.
6.11.2 Agarose gel electrophoresis
The functional principle of agarose gel electrophoresis is the size-dependent separation of
DNA fragments by migration through a polymeric agarose matrix in an electric field. Since the
deoxyribose-phosphate backbone of DNA is negatively charged, DNA always migrates towards
the positive pole (cathode) in an electric field.
To check for the amplification success of PCRs or the expression rate of specific mRNA
transcripts in a semi-quantitative Reverse Transription (RT)-PCR, samples are analysed via
agarose gel electrophoresis. 1.2% agarose gels supplemented with 0.1 µl ethidiumbromide
per ml gel are run in TAE buffer.
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Loading dye is already included in PCR samples. 15 µl of each PCR sample is applied to every
gel slot. Gel electrophoresis runs for 30-40 min at 100 V. Documentation and analysis are done
at the BioRad ChemiDoc XRS with program Quantity One.
6.11.3 Isolation of DNA
Genomic DNA (gDNA) of iPSCs is isolated from one well of a 6-well-plate (65-75% confluence)
by DNeasy Blood & Tissue Kit (Qiagen) according to manufacturer’s instructions. Elution is
done with first 50 µl TE-4 and second 80 µl TE-4 and 5 min incubation time each. Samples are
stored at -20 °C.
The concentration of nucleic acids is determined by spectrophotometric measurement. 1 µl
of each sample is measured at “Nanodrop” spectrophotometer with solvent as blank sample.
Particular attention has to be paid whether the wave length ratios for protein contamination
(260/280: ≥ 1.8) and organic reagents contamination (260/230: ≥ 2.0) fulfil purity criteria.
6.11.4 SNP-array
The maintenance of genomic integrity during the reprogramming process is verified by
SNP-array analysis. From every iPSC clone gDNA is isolated and 50 µl (60 ng/ml) are processed
for whole genome amplification. The amplified DNA is fragmented and hybridised to
sequence-specific oligomers bound to beads on an Affymetrix® Genome-Wide Human SNP
Array 6.0 for HGK13 and HGK16 by Prof. Peter Nürnberg at Cologne Centre of Genomics (CCG).
All other iPSC lines are processed by an Illumina® Human610-Quad chip or a
HumanCytoSNP-12 chip in the Institute of Human Genetics, University of Bonn. Data analysis
is conducted with Illumina® BeadStudio.
6.11.5 Isolation of RNA
Whole RNA is isolated by RNeasy Blood & Tissue Kit (Qiagen) according to manufacturer’s
instructions. Cells are washed once with HBSS and any liquor is removed thoroughly. Lysis
buffer is supplemented with β-mercaptoethanol (1:100 = 120 mM) to reduce sample-intrinsic
RNase activity.
Digestion of contaminating gDNA is performed directly on extraction columns by DNase I
treatment. Total RNA is eluted first by 50 µl ddH2O and 5 min incubation time. Second elution
occurs with first eluate plus 20 µl ddH2O extra. Samples are stored at -80 °C and always thawed
on ice due to higher degradation sensitivity of RNA. Sufficient concentration is verified by
spectrophotometric determination (see 6.11.3) and for higher precision by using the
Quant-iT™ RiboGreen® RNA Assay Kit according to the manufacturer’s instructions. The
fluorescent dye solely emits light if bound to RNA. Therefore, the fluorescence intensity
directly correlates to the sample’s RNA concentration. The assay is always conducted as
triplicates in black 96-well-plates and analysed with the TECAN Safire2 microplate reader.
6.11.6 Synthesis of cDNA
RNA has to undergo reverse transcription into a single cDNA strand, because RNA is not
capable of serving directly as template for a quantitative real-time (qRT)-PCR. 2 µg of total
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RNA are subjected to reverse transcription with Bio-Rad iScript™ kit according to
manufacturer’s manual. The cDNA is diluted (1:5) with ddH2O and used for RT-PCR applications.
Alternatively, whole RNA is re-transcribed to cDNA by QuantiTec Reverse Transkriptase Kit
according to manufacturer’s instructions. In addition, to ensure exclusive mRNA transcription,
oligo-dT primers binding to the mRNA-specific poly-A tail are utilised. For the individual
samples 300 ng of total RNA are transcribed in a volume of 20 μl. From the defined standard
600 ng of total RNA are transcribed in a volume of 20 μl. cDNAs are diluted in a ratio of 1:5 in
TE-4, after all.
6.11.7 Quantitative real-time PCR (qRT-PCR)
Real-time RT-PCR is carried out in order to quantitatively determine the amount of mRNA
transcripts. A typical qRT-PCR approach is prepared on ice and is composed of the reagents as
mentioned for a PCR with cDNA as template (see 6.11.1).
The qRT-PCR is performed and analysed in the iCycler with the following parameters:
Initial denaturation 95 °C 5 min
Denaturation 95 °C 1 min
Annealing 60 °C 1 min 40 cycles
Elongation (1 min/kb) 72 °C 40 sec
Final elongation 72 °C 5 min
Melting curve from 65 °C to 99 °C in 0.1 °C/sec increment
All experiments are done as triplicates. Expression levels are normalised to GAPDH expression
level.
Alternatively, qRT-PCR and its subsequent analysis are performed at the LightCycler with
FastStart DNA Master SYBR® Green. First, a standard has to be defined by mixing 16 μl with
24 μl of TE-4 properly. Then, the standard solution is diluted eight times in a ratio of 1:2 to
obtain nine dilutions, at last. 3 μl of the diluted sample as well as the standard samples are
needed in a standard qRT-PCR on a LightCycler 1.5 instrument using Fast Start DNA Master
SYBR® Green I with the following reaction approach:
Primer ff (10 pmol/µl) 1 µl
Primer rev (10 pmol/µl) 1 µl
Fast start DNA Master mix 0.83 µl
ddH2O 2.7 µl
MgCl2 1.2 µl
Template (cDNA) 1 µl
Polymerase 0.27 µl
8 µl
All annealing temperatures used in qRT-PCRs are in accordance with the values of 5.5, Tab. 6.
Experiments are conducted in triplicates all the time. Second derivative maximum method of
the LightCycler software is operated for analyses. Expression levels are normalised to total
RNA expression level.
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6.12 Protein-biochemical methods
6.12.1 Isolation of protein
To isolate total protein, cells are washed once with HBSS and any liquor is removed
thoroughly. On ice, 120 µl RIPA buffer are applied and incubated for 15 min. Then, cells are
scratched off using a cell scraper, transferred to a 1.5 ml reaction tube and several times
mechanically titruated by vigorous pipetting and vortexing. After further 15 min incubation on
ice, cells are centrifuged (12,000 rpm, 15 min, 4 °C) to pellet insoluble cellular debris.
Supernatant is carefully collected and frozen (-80 °C).
Sufficient concentration is verified by colorimetric determination according to Bradford
(Bradford 1976). Bradford dye is able to bind to proteins whereupon their absorption
maximum is shifted from 470 to 595 nm.  498 µl Bradford solution is mixed with 2 µl protein
lysate and incubated for 10-15 min at RT. 50 µl of each sample are transferred to cuvettes and
protein concentration is determined at the BioPhotometer with pure Bradford solution as
blank. The final protein concentration is calculated by means of comparison to a BSA standard
curve and divided by 2.
6.12.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
The protein content of cells can be investigated by SDS-PAGE. Proteins migrate with varying
speed in an electric field through a meshwork of polymeric acrylamide threads. The SDS
excessively sets a negative charge to proteins which cloaks the intrinsic charge and enables a
separation depending on size and weight (Laemmli 1970).
Protein-biochemical experiments were supportively conducted by Kristina Hupperich and
Irmgard Hölker. In general, 7.5-10 µg protein are prepared for a SDS-PAGE sample. The
corresponding volume of protein sample is added to 5 µl 2 × Laemmli buffer. The mixture is
denaturated (5 min, 95 °C) to unfold proteins, briefly chilled on ice and shortly centrifuged.
The total sample volume is filled into the gel slots.
After having assembled the glass panels (0.5 mm thickness) to the chamber scaffold, the
acrylamide gel is ready to be cast. Firstly, the so called lower “separation gel” solution (10%)
is prepared. When the solution is filled into the casting chamber, some water is added on top
to generate an even rim line. As soon as this lower gel has hardened, the water layer is
removed and the upper “stacking gel” solution (3%) is prepared and cast on top of the lower
gel. Directly, the slot comb is put into the still liquid upper gel solution. Upper and lower gels
differ in pore size and pH. The upper gel contains only little PAA leading to bigger pores and
enabling the proteins to move easily between a dipolar front of glycine and Cl– -ions until all
SDS-protein molecules accumulate at the borderline of the two gels. As soon as the molecule
front enters the lower gel, glycine disperses owing to the increased pH. Thereupon, the
SDS-protein molecules are free to migrate through a denser PAA network in the lower gel
according to their size difference.
When the upper gel has polymerised, the gel is put into the running chamber which is filled
with 1 × running buffer. The comb is drawn so that the slots fill with running buffer.
Every protein sample is loaded into one slot cautiously. PAGE Ruler Plus protein ladder is
loaded to one lane to estimate protein size. The gel is run for 30 min at 50 V until the colour
front reaches the separation gel and later for approx. 3 h at 70 V.
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6.12.3 Western blotting
Western blotting describes the transfer of electrophoretically separated proteins from a
polyacrylamide gel to a nitrocellulose membrane. The proteins migrate in an electric field to
the wet membrane thereby copying the original separation pattern.
After the SDS-PAGE, the blotting device is equipped with pieces of Whatman paper and
sponge pads which were soaked in 1 × transfer buffer beforehand. The gel is stapled between
sponge pad, wet Whatman paper pieces and the nitrocellulose membrane also pre-wetted in
1 × transfer buffer. To remove possible air bubbles, a pipette is rolled over the sandwich.
Finally, the sandwich is inserted into the blotting device. A cooling pack is added, everything
closed and put into the running chamber filled with 1 × transfer buffer. The blotting takes
place ON (30 V, 4 °C).
6.12.4 Immunoblotting
The next morning, the nitrocellulose membrane is washed 5 min in 1 × TBS/Tween. To saturate
any unspecific binding site, the membrane is incubated for at least 3-4 h in blocking solution
(1 × TBS/Tween + 6% skimmed milk powder). Afterwards, the primary antibody is applied ON
in 1 × TBS/Tween + 1.5% skimmed milk powder. The other day, the membrane is washed five
times in 1 × TBS/Tween. Next, the membrane is incubated in the secondary antibody solution
(1 × TBS/Tween + 1.5% skimmed milk powder) for 1 h. Again, the membrane is washed five
times in 1 × TBS/Tween. Subsequently, the immunoblot is developed for 5 min in a
chemiluminescent reaction with SuperSignal® West Pico Chemiluminescent Substrate kit. The
membrane is carefully wrapped in plastic foil, placed in a developing cassette and exposed to
Hyperfilm ECL. Densitometric analysis of the films is performed with ChemiDOC XRS analysis
software.
When β-actin is applied as loading control, the primary antibody is incubated only for 10 min.
6.13 Immunocytochemistry
For immunocytochemical analyses, cells are rinsed once with HBSS (always +Ca2+/Mg2+), fixed
in a 4% PFA solution for 10 min at RT and again washed with HBSS twice. Alternatively, cells
are fixed by adding an appropriate volume of 8% PFA solution directly to the medium to obtain
a final concentration of 4% PFA. For ChAT-staining, addition of 0.2% picric acid to the PFA
fixation solution is recommended to decrease unspecific background noise (Hu et al. 2009).
For co-localisation studies in growth cones, samples are fixed with 4% PFA/4% sucrose (37 °C)
vibration-free for 10 min at RT (Dr. Min Jeong Kye, personal communication).
In order to block any unspecific binding sites, samples are next incubated in blocking solution
for at least 1 h at RT. Samples are usually processed in a serial manner, i.e. the primary
antibody (5.9, Tab. 14) is added separately in an appropriate dilution in antibody solution
overnight at 4 °C. The next morning, specimens are washed three times with HBSS. The
corresponding secondary antibody (5.9, Tab. 15) is then administered in antibody solution for
1 h at RT (dark). Again, samples are washed three times with HBSS and nuclear staining is
performed by addition of DAPI solution for 2-3 min at RT (dark). At last, samples are washed
twice with HBSS, mounted in Mowiol 4-88 solution and covered with glass covers. Stained
samples are stored at 4 °C in the dark.
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6.14 Microscopy
Immunocytochemical stained samples are further analysed using Zeiss microscopes
(objectives 10 ×, 20 ×, 63 ×) in bright field or suitable fluorescence channels (excitation
wavelengths: 335-383 nm, DAPI; 450-490 nm, GFP; 538-562 nm, Ds Red). Pictures are taken
with Openlab, Axiovision or ZEN program and further processed by Photoshop if necessary.
For quantitative analysis, 7-10 pictures are randomly chosen. In each image section, the total
number of vital cells is ascertained by counting DAPI+ nuclei whereas the number of neurons
is determined by β III-tubulin+ cells. Then, the structures of interest (e.g. HB9+ motoneurons
or gems) are quantified and their number is computed as ratio of positive cells relative to total
cells or total neurons (day 8: HB9: 1,200-2,000 cells; ISL1: 1,400-2,400 cells in total; day 27:
HB9: 800-1,700 cells; ISL1: 300-900 neurons in total).
For gem quantification, gems are counted and their ratios calculated relative to total number
of nuclei. Fibroblasts: 150-300 cells in total; iPSCs: 950-1,300 cells in total; smNPCs: 1,200-
1,700 cells in total; MN cultures: 300-450 cells (day 8) and 200-550 cells (day 27) in total.
For neurite length measurement, outgrowth of SMI-32+ cells or β III-tubulin+ protrusions of
HB9+ or ISL1+motoneurons are manually surveyed starting from the soma until the neurite tip
by “spline curve” analysis tool. Normally, 90-160 neurites are counted for β III-tubulin+
neurons and on average 30-60 neurites for SMI-32+ neurons, respectively.
Properly shaped growth cones are sought out in three weeks old MN cultures on day 27 (see
6.8.1). In total, ten growth cones are visualised by confocal laser scanning microscopy so far
using Zeiss Meta 510 microscope in the Imaging Facility of the Cluster of Excellence in Cellular
Stress Responses in Aging-associated Diseases (CECAD, Cologne, Germany) with assistance of
Dr. Astrid Schauss and Ira Hensen. Pictures are taken with ZEN program and further analysed
by Fiji program.
6.15 Statistical methods
Statistical significance of measurements are determined by GraphPad Prism software.
Countings from immunocytochemical staining and expression rates from molecular-biological
experiments are expressed as mean values ± SEM. D’Agostino-Pearson omnibus normality test
determines non-Gaussian distribution of values. Thus, all data are analysed by Kruskal-Wallis
non-parametric ANOVA test with Dunn’s post hoc correction for multiple comparisons. Data
is compared to single healthy control r1, single healthy control r12 or pheno-grouped healthy
controls r12 and COII.2, respectively. Differences are considered significant when p <0.05.
Levels of statistical significance were pictured as asterisk and distinguished as follows:
p <0.05 = *, p <0.01 = ** and p <0.001 = ***.
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7. Results
7.1 Induction of pluripotency
The original strategy to induce somatic conversion into pluripotent stem cells involves a
retrovirally mediated transfer of the classical four Yamanaka-factors (OCT4, SOX2, KLF4,
c-MYC) by pMXs-based vectors in human adult cells (see 10.3) (Takahashi et al. 2006;
Takahashi et al. 2007).
Human fibroblast cell lines ML17 (SMA I, VPA responder), ML73 (SMA II, VPA non-responder)
and family 1 discordant siblings ML101 (asymptomatic) and ML102 (SMA III) were
reprogrammed that way at iPierian Inc. (San Francisco, USA) by Dr. John Dimos. Only one
non-validated clone per cell lines was delivered (see 5.8.3, Tab. 13). Furthermore, healthy
control cell line r1 was generated this way by retroviral transduction and validated by Matthias
Brandt at the Institute of Reconstructive Biology (RNB, University of Bonn). There, control line
r12 was generated by Dr. Michael Peitz and fully characterised by Johannes Jungverdorben
(Koch et al. 2011). In addition, control cell line COII.2 was generated and validated by Swetlana
Ritzenhofen at RNB (unpublished data).
Not only is generation of sufficient retrovirus a time-consuming elaborate process, but also
does this method not always yield an appropriate number of iPSC colonies. Numerous
attempts to reprogram human fibroblast cell lines of SMA discordant family 2 asymptomatic
members (ML11, ML13) and SMA III patients (ML12, ML14) (Fig. 10) via retroviruses did not
result in stable iPSC lines (data not shown). Moreover, random insertion of retroviruses into
the human host genome does not necessarily lead to a complete silencing of those proviral
transgenes (Takahashi et al. 2006). Thus, incomplete silencing in iPSCs may cause further
problems during subsequent differentiation processes.
To avoid the aforementioned difficulties, non-integrative reprogramming techniques
promised better results. In 2009, Fusaki and colleagues reported Sendai virus (SeV) based
vectors which are merchandised by DNAVEC Corp. (Tsukuba, Japan) (Fusaki et al. 2009). This
SeV system derives from an unsegmented (-) ssRNA virus from the Paramyxoviridae family
performing a cytoplasmatic replication cycle. So, neither a DNA-intermediate nor integration
into the host genome occurs. The SeV vectors are simply diluted over time due to cellular
division. SeV vectors are non-transmissible in cellular systems and devoid of fusion-inducing
factors (F-protein deficient) thereby possessing only little cytotoxicity (Inoue et al. 2003).
After all, SeV vectors turned out to be the most reliable reprogramming system in our hands
transforming even cell lines which proved to be reluctant to retroviral reprogramming before.
Human fibroblast cell lines from discordant family 2 (ML11, ML12, ML13 and ML14) were
reprogrammed by SeV vector system (Fig. 11; 10.4, Fig. 64). When target fibroblasts
underwent spinfection with SeV vectors containing the four Yamanaka factors (4F), some dead
cells were visible afterwards on account of mechanic or infection-conditional stress. However,
the overall viability was not massively impaired since vital fibroblasts with typical longish
spindle-like shape and undisturbed adherence behaviour were visible in two representative
cell lines (Fig. 12). In addition, the surviving fibroblasts still proliferated.
Infected fibroblasts were transferred to feeder-prepared primary plates after six days. Within
the next three to four weeks, dozens of early iPSC colonies appeared on primary 10 cm TC
dishes. Nevertheless, SeV-mediated reprogramming did not always induce transformation of
fibroblasts into pluripotent SCs successfully. Colonies disintegrated or began to transform into
immensely proliferative cell types marked by differentiated cellular morphology particularly
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in the colony’s rim area. Furthermore, a three-dimensional growth with brown or yellow cells
was apparent (Fig. 13 A). On the contrary, proper iPSC colonies were denoted by round colony
form and distinct clearly defined rims (Fig. 13 B).
Fig. 11: Schematic picture of generation of iPSCs via reprogramming human fibroblasts by SeV spinfection.
Target fibroblasts were seeded several days before infection. On day 0, fibroblasts were infected once by
spinning SeV containing medium onto target fibroblasts (spinfection). After one week further culturing in MEF
medium, 4F-fibroblasts were transferred onto feeder-plated TC dishes in iPSC medium on day 6. Since then,
cells were fed with iPSC medium. Within the next weeks, 4F-fibroblasts reprogrammed to iPSC colonies which
were picked, after all.
Fig. 10: Pedigrees of PLS3 discordant family 1 and family 2 presenting SMA III affected brothers (black
quadrats) and asymptomatic sisters (grey circles). Roman numbers defined parental and filial
generations, respectively. Age of onset in HGK27 was 13 years and in HGK22 18 years. Table below
denoted corresponding fibroblast and iPSC lines, respectively. Additionally, SMN1 and SMN2 copy
number was given as well as lifted (↑) PLS3 expression levels in blood.
62 Results
Fig. 12: Representative phase image of fibroblast cell lines three days after viral infection with four Yamanaka
factors (4F) SeV representing a male SMA III patient (A) and his asymptomatic sister (B) from PLS3 discordant
family 2. Cells sustained spinfection and exhibited viability and proliferation activity (scale bar 200 µm, valid for
all images).
Fig. 13: Representative phase images of transferred 4F fibroblasts. (A) Improper iPSC colonies from infected
fibroblast cell line 4FML11 on primary TC plates displayed irregular shape with differentiated cells at the rim and
coloured overgrowth. (B) Proper iPSCs were marked by typical ESC-like appearance including defined round
colony formation, small cell size and dense cellular package (scale bar 200 µm).
In total, 16-18 new iPSC clones per individual cell line were picked, stabilised and expanded
(see 10.1, Tab. 19). From these, two to three clones per cell line were selected to undergo
further characterisation.
HGK1, HGK4, HGK13 and HGK16 as well as healthy control lines r1 and r12 had initially been
cultivated on MEF feeder layer in iPSC medium. Later, they and all following newly generated
human iPSC lines were grown in mTeSR™1 medium by standard.
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7.2 Validation of iPSC lines
For validation of HGK1 and HGK4 see Garbes et al., 2013.
7.2.1 Morphology and expression of pluripotency surface markers
In feeder-free cultivation of human iPSCs with mTeSR™1 medium and MG-coated plates, iPSCs
formed rather irregularly shaped colonies consisting of a thin layer than a densely packed
colony as seen when propagated on MEF-feeder layers (Ludwig et al. 2006;
StemcellTechnologies Version 3.0.0).
All new iPSC lines exhibited the aforementioned hESC-like appearance including a small cell
body with high nucleus/cytoplasm ratio, flat growth and characteristic colony shape (Fig. 14).
Activity of alkaline phosphatase (AP) is a key marker of pluripotent SCs (Takahashi et al. 2007;
Smith et al. 2009). By converting a specific substrate into a chromogenic product, AP+ cells
were coloured in blue. Overt enzymatic AP activity was visualised by strong blue colour in all
human iPSC lines here (Fig. 14).
Furthermore, undifferentiated SCs expressed specific surface antigens (e.g. SSEA-3, SSEA-4,
TRA-1-60, TRA-1-81) as pluripotency markers (Smith et al. 2009). Immunocytochemical
staining of these ESC markers revealed an overall strong expression in all human iPSC lines
(Fig. 14).
7.2.2 Expression of typical pluripotency markers in human iPSC lines
Not only do pluripotent SCs express outer surface markers, but also characteristic
transcription factors and enzymes essential for the maintenance of stemness.
In reference to human ESC line I3 (Amit et al. 2002) as control, expression of those
pluripotency-related marker genes (e.g. NANOG, TERT) was determined on mRNA level by
semi-quantitative RT-PCR with human iPSC lines HGK13 and HGK16 (Fig. 15).
In the agarose gel, comparable intensity of bands regarding GAPDH expression proved equal
cDNA amounts. Despite individual differences between the three cell lines in respect of signal
intensity, human iPSC lines HGK13 and HGK16 expressed every marker gene like control ECS
line I3. As minor validation criterion, this semi-quantitative RT-PCR was not conducted for
HGK21, HGK22, HGK27 and HGK28.
64 Results
Fig. 14: Human iPSCs maintained in mTeSR™1 according to standard protocol showed a typical flat colony
appearance with dense centre in phase contrast. Note the difference between HGK13 and HGK16 (on MEF feeder
layer) and other HGK iPSCs (in feeder-free conditions) in regard to colony appearance. Blue staining of iPSC
colonies palpably evidenced stemness due to AP activity. Immunocytochemical staining visualised classical
pluripotency surface markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 were detectable on all human iPSC lines
(all red). In insets, nuclei were counterstained with DAPI (blue) (scale bar 200 µm, valid for all images).
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Fig. 15: Semi-quantitative
RT-PCR with RNA extracted
from iPCSs demonstrated the
expression of stemness-
related genes. Human
embryonic stem cell line I3
served as reference, while
GADPH was used as loading
control.
7.2.3 Human iPSCs were genomically intact
By SNP-array analysis, all new iPSC lines were scrutinised for any potential genomic aberration
which might have occurred during the gross overall cellular conversion processes of
reprogramming. Whole gDNA was isolated and amplified for subsequent SNP-array analysis.
Standard karyotyping did not suffice as validation criterion because it did not cover more
subtle genomic aberrations. High-resolution SNP-arrays revealed genomic aberrations in
established human iPSC lines initially catalogued as “genomically intact” after traditional
karyotyping (Hussein et al. 2011).
Illumina® chips were employed to verify genomic integrity of HGK21, HGK22, HGK27 and
HGK28. Fig. 16 depicted the iconographic scheme of every chromosome together with the
corresponding Log R ratio as well as B allele frequency to discover copy number variations,
aneuploidy or structural imbalances such as duplications, insertions or deletions for iPSC line
HGK21.1 as example. For data of other lines, please refer to 10.2, Fig. 61.
Chromosomes were thoroughly screened and any aberration visible in this overview picture
was marked in red circles (Fig. 16). If the mutation occurred in all clones plus the originating
fibroblast cell line, the defect was regarded as inherited intrinsic feature of this individual cell
line (Tab. 16).
Any additional obvious alteration ultimately led to the exclusion of the clone (e.g. HGK21.12,
data not shown) for a potential detrimental effect could not be ruled out later during
propagation or differentiation.
HGK13 and HGK16 were analysed by Affymetrix® Genome-Wide Human SNP Array 6.0.
Comparison of cluster signals in human iPSC lines HGK13 and HGK16 with corresponding
fibroblast donor cell lines ML102 and ML101 did not indicate any major detrimental
alterations (10.2, Fig. 62).
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Fig. 16: (A) Exemplary karyogram of human iPSC line HGK21.1 displayed every chromosome schematically
together with its corresponding B allele frequency (upper panel) and Log R ration (lower panel). Note that regular
SNPs show a Log R ratio of 0 and a B allele frequency of 0, 0.5 or 1 when homozygous. A heterozygous deletion
will result in a Log R ratio of <0 and a B allele frequency of only 0 or 1, whereas a duplication will cause a Log R
ratio of >0 and a B allele frequency of 0, ⅓, ⅔, or 1. (B) Visible genomic aberrations in this overview were encircled
in red, magnified and compared to present mutations in original fibroblast cell line ML11 (see Tab.16).
Table 16: Overview about genomic mutations prevailing in iPSC lines HGK21, HGK22, HGK27,
HGK28 and corresponding parental fibroblast cell lines. Original fibroblast lines were given
with respective iPSC progeny. For other cell lines, see 10.2, Fig. 61
Cell line Chromosomal position Type of mutation
ML11 =
→ HGK21.1
→ HGK21.8
Chr.6 p21.32
Chr.12 p11.1
Chr.19 q13.33
Chr.X q27.2
Minor duplication
Duplication
Duplication
Minor deletion
ML12 =
→ HGK27.10
→ HGK27.13
Chr.4 q28.3
Chr.6 p21.32
Chr.17 q12
Chr.19 q13.33
Duplication
Minor duplication
Minor duplication
Duplication
ML13 =
→ HGK28.9
→ HGK28.11
Chr.4 q28.3
Chr.6 p21.32
Chr.12 p11.1
Chr.19 q13.33
Chr.X q27.2
Duplication
Minor duplication
Very minor duplication
Duplication
Minor deletion
ML14 =
→ HGK22.17
→ HGK22.18
Chr.6 p21.32 Minor duplication
7.2.4 Human iPSC lines HGK13 and HGK16 largely showed inactivation of
retroviral transgenes
After having reached a pluripotent state, proviral transgenes OCT4, SOX2, KLF4 and c-MYC are
silenced in iPSCs favoured by the specific pMXs-architecture (Takahashi et al. 2006). In human
iPSC lines HGK13 and HGK16, inactivation of retroviral transgenes was examined by qRT-PCR
in which two different primer sets were used: One to detect expression of endogenous
transcripts only whereas the other recognised endogenous as well as transgene mRNA (total).
Each expression rate was normalised to GAPDH expression. A complete genetic silencing was
achieved when the overall expression rate was generated by the endogenous gene only. All
expression rates were referenced to those of respective genes in human ESC line H9 (Thomson
et al. 1998) as control.
In general, both iPSC lines showed similar expression rates of endogenous OCT4, KLF4 and
c-MYC. Just endogenous SOX2was relatively low expressed in HGK16. HGK13 showed a rather
high total KLF4 expression indicating residual transgene activity. On the contrary, the amount
of transgenic SOX2 transcripts was elevated in HGK16 hinting at an insufficient silencing here.
Yet, there was no generalised silencing defect noticeable (Fig. 17).
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7.2.5 Clones of human iPSC lines HGK21, HGK22, HGK27 and HGK28 did not
contain SeV vectors at later passages
In SeV vector transduction, no insertion of viral genes occurs into the host cell genome.
Therefore, viral transcripts are diluted over time by cell division. Between passages 5-10, new
iPSC lines lose their viral expression profile which may be enhanced by lifting the cultivation
temperature to 39 °C for a couple of days due to the thermal sensitivity of SeV vectors (Fusaki
et al. 2009).
Every clone of human iPSC lines HGK21, HGK22, HGK27 and HGK28 was checked for expression
of viral envelope protein haemagglutinin/neuraminidase (HN) by immunocytochemistry. At
early passages (<7), some parts of iPSC colonies were still HN+ pointing to a residuary
expression of SeV genes. This HN expression was also visible in differentiated cells outside
iPSC colonies (Fig. 18 A). However, at later time points no HN staining could be detected in
iPSC lines anymore (Fig. 18 B).
However, a more precise method to examine whether iPSCs were SeV-free was to assess the
expression of viral nucleocapsid protein NP via semi-qRT-PCR (Nishimura et al. 2011). Whole
RNA was isolated at different passages and examined by semi-qRT-PCR with cDNA Alpers#2
(courtesy of Swetlana Ritzenhofen) as positive control. 18S rRNA acted as loading control.
Fig. 17: Quantitative assessment
of the residual expression of the
four retroviral transgenes OCT4,
SOX2, KLF4 and c-MYC via
qRT-PCR in both iPSC lines
HGK13 and HGK16 compared to
the respective endogenous
expression of pluripotency-
associated genes OCT4, SOX2,
KLF4 and c-MYC. Complete
proviral silencing was indicated
when total expression rate
equated the endogenous
expression rate. Thus, residual
transgene expression was
detectable in HGK13 concerning
KLF4 and in HGK16 concerning
SOX2, respectively. Black bars
represented total expression
levels, grey bars represented
endogenous levels. Expression
was normalised to GAPDH level
and shown as x-fold expression
relative to human ESC line H9.
Error bars represented ± SEM of
triplicates (n=3).
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Clearly, a strong expression of SeV NP transcript was only visible in the positive control,
whereas the expression of these viral transcripts had completely disappeared in all iPSC lines
verifying the total loss of any viral vector expression activity in those iPSCs (Fig. 19).
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Fig. 19: Semi-quantitative analysis of SeV NPmRNA expression (A) in iPSCs in comparison to 18S rRNA as loading control (B).
cDNA Alpers#2 (by Swetlana Ritzenhofen) served as positive control (pos ctrl). (A) At later passages (>p7), SeV vector activity
was lost which rendered every iPSC clone virus-free. Only in the positive control a strong NP expression was detectable
proving the functionality of the PCR. (B) All samples contained functional cDNA as seen in homogenous 18S rRNA expression.
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7.2.6 Human iPSC lines developed into all three germ layers in vitro
Pluripotency is defined as the capability of unlimited differentiation into cells of all three germ
layers (i.e. endoderm, mesoderm, neuroectoderm) without extra-embryonic tissue however
(i.e. trophectoderm) whose generation is exclusively restricted to totipotent zygote and early
blastomeres (Thomson et al. 1998; Smith et al. 2009).
To test the developmental potential of pluripotent SCs in vitro, iPSC colonies were gently lifted
as whole colonies by enzymatic treatment and grown in suspension as embryoid bodies (EBs)
(see 6.6). Upon withdrawal of pluripotency-maintaining growth factors such as bFGF,
pluripotent SCs spontaneously started to differentiate into cells of all three germ layers within
those EBs (Itskovitz-Eldor et al. 2000).
When plated and immunocytochemically analysed after further growth, all iPSC lines
exhibited evident presence of tissue of endodermal (α-fetoprotein, AFP), mesodermal
(smooth muscle actin, SMA) as well as neuroectodermal origin (β III-tubulin) (Fig. 20).
7.2.7 Human iPSC lines developed into all three germ layers in vivo
Unlike in murine iPSCs, chimera formation and germ line transmission as most powerful
pluripotency quality criteria are ethically not accomplishable in this case even though
human/mouse chimeras have been generated with human ESCs (James et al. 2006). Thus, the
most stringent method for human iPSCs is teratoma formation assay (Smith et al. 2009).
All human iPSCs were injected into the testicular capsule of immuno-deficient male
SCID/Beige mice. There, the iPSCs were exposed to a varying cellular environment inducing
uncontrolled differentiation into tissues of all three germ layers (i.e. endoderm, mesoderm,
neuroectoderm). After several weeks, tumour-like transplants were excised and
immunohistochemically analysed for the presence of tissues of all three tissue lineages.
Endodermal tissue was displayed as adenoid goblet cell-like cells in an epithelial columnar
arrangement with strong purple staining (Fig. 21). As mesodermal tissue, cartilage was visible
in most cells as accumulation of huge bright cells which was clearly separated from
neighbouring tissues by a distinct seam. In HGK28.11 typical densely packed reddish muscle
cells were found as mesodermal derivative comparable to other studies (Huangfu et al. 2008;
Hayashi et al. 2010). Neural rosettes derived from ectodermal cells and appeared in nests as
dark-coloured, densely packed cells orientated in a petal-like arrangement. Instead, HGK27.13
displayed clusters of darkly stained retinal pigment epithelium as neuroectodermal tissue
similar to previous studies (Park et al. 2008; Kallos 2011; Garbes et al. 2013).
Taken together, all iPSC clones fulfilling the aforementioned validation criteria could be
regarded as fully pluripotent SCs.
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7.3 Directed differentiation of human iPSCs into mixed
motoneuronal cultures by an EB-based run-through protocol
Lacking accessibility of the actual SMA target tissue, i.e. lower α-motoneurons, has ever
impaired research in the SMA research field. Previous studies examining the role of PLS3 in
SMA or VPA responsiveness relied on patient-derived LB cell lines or fibroblasts providing
valuable data (Brichta et al. 2006; Oprea et al. 2008). Still, the actual situation in patients’ MNs
remained elusive. With iPSCs as unlimited source of cells, the major aim of this study was the
generation of such patient-derived MNs whose examination ideally ought to equip previous
studies with strong further validity.
Many different protocols exist to differentiate functional motoneurons from human
pluripotent stem cells (Wichterle et al. 2002; Ebert et al. 2009; Patani et al. 2011; Amoroso et
al. 2013). However, pioneering studies were performed by Zhang and colleagues in 2005
et seq. (Li et al. 2005; Li et al. 2008; Hu et al. 2009). Testing up to five various protocols (data
not shown), the EB-based run-through protocol of Hu and Zhang turned out as the most robust
and applicable one.
Since the original study had been carried out with human ESCs, minor modifications were
introduced to improve MN differentiation efficiency using human iPSCs (see Fig. 22): Firstly, a
shift towards neuroectodermal germ layer development in pluripotent SCs was ensured by
synergistic application of TGFβ-inhibitor SB431542 and BMP-inhibitor dorsomorphin during
EB stage. Thus, a dual SMAD-signalling inhibition was exerted which efficiently directed neural
conversion in human pluripotent SCs (Chambers et al. 2009; Kim et al. 2010). Secondly, the RA
concentration was increased from 0.1 µM to 0.75 µM to ensure full caudalisation. Thirdly, RA
administration began earlier on day 7 instead of day 10 as in the original publication. Those
changes optimised the overall MN yield for the iPSC lines used in this study when compared
to using the original run-through protocol of Hu and Zhang (see 6.4).
Fig. 22: Schematic picture of modified differentiation regimen to generate human motoneurons from iPSCs.
Proper iPSC colonies were lifted and grown in suspension as embryoid bodies (EBs). To enhance neural
development, inhibitors of BMP and TGFβ pathways – dorsomorphin and SB431542 – were administered. EB
plating resulted in formation of neural rosettes which were primed to caudal development by RA treatment.
On day 13, neural rosettes were isolated and cultivated in suspension as neurospheres. Administration of
SHH agonist purmorphamine finally ventralised neural progenitors in neurospheres leading to proper
motoneuronal precursor development. At last, neurospheres were seeded for final motoneuronal
maturation in presence of neurotrophic factors.
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7.3.1 Differentiating iPSCs according to a standard protocol resulted in low
numbers of mature MNs
The first times, human iPSC lines were differentiated into MNs according to the original
publication by Hu et al., 2009. This meant that caudalisation started on day 10 with 0.1 µM
RA. Nonetheless, dual SMAD-signalling inhibition was already carried out by administering
SB431542 and dorsomorphin from day 0 to day 6 during EB generation. However,
neuroectodermal development into pMN-regionalised cells yielded only a moderate number
of OLIG2+ progenitor cells (Fig. 23 A). After further maturation, only few neuronal cells express
typical MN-markers like ISL1, HB9 or ChAT indicating a rather poor overall efficiency (Fig. 23 B).
Fig. 23: Human control iPSC line r1 was differentiated according to the original EB-based run-through protocol
published by Hu and Zhang (Hu et al. 2009) plus administration of small compounds SB431542 and dorsomorphin
during the first seven days to favour neuroectodermal development (dual SMAD-signalling inhibition) (Chambers et al.
2009; Kim et al. 2010). Thus, regionalisation began on day 10 with application of 0.1 µM RA. (A) Before final maturation,
just few OLIG2+ progenitor cells (green) of the correct pMN domain were present on day 28 after immunocytochemical
staining. (B) Moreover, the overall yield of proper MNs was low as well marked by the sporadic presence of ISL1+
neurons (green) or HB9+ (green) cholinergic ChAT+ (red) motoneurons on day 46. Nuclei were counterstained with DAPI
(blue) (scale bar 100 µm, valid for all images).
Characteristic MN markers include the following: As cholinergic neurons, mature spinal MNs
express ChAT and vesicular acetylcholine transporter (VAChT) (Li et al. 2005). Homeobox TFs
HB9, ISL1 and LIM3 (LHX3) suffice to induce and consolidate post-mitotic MN differentiation
(Tanabe et al. 1998; Briscoe et al. 2001) and are regarded as bona fide MN-specific markers
while co-expression of ISL1, PHOX2a/2b and TBX20 bestows MNs a fate of cranial
visceromotor neurons (Arber et al. 1999; Jessell 2000). In addition, SMI-32 antibody detects a
neuronal intermediate filament in spinal MNs (Carriedo et al. 1996).
7.3.2 Motoneuronal differentiation of iPSCs according to a modified protocol
performed demonstratively better
To improve the global efficiency of MN-generation, the aforementioned modifications were
introduced to the protocol, i.e. an earlier RA administration at higher concentration (0.75 µM
RA from day 7 onwards) combined with dual SMAD-signalling inhibition.
Immunocytochemical staining showed a successful differentiation into MN-progenitor cells
(Fig. 24) indicated by strong expression of characteristic markers of the pMN domain such as
OLIG2 and NKX6.1 for ventral neural tube and upper spinal cord marker HOXB4 for
caudalisation (Li et al. 2008). Hitting the correct domain was furthermore denoted by only
rudimentary expression of markers of domains neighbouring pMN: PAX6 was expressed in
upper ventral domains (p0-pMN) (Davis-Dusenbery et al. 2014), but only sporadically in these
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MN-differentiated cells. NKX2.2 is a marker of the very ventral domain p3 (Alaynick et al.
2011), yet it was scarcely found in these MN-differentiated cells. General neural identity was
proved by overt expression of SOX2 and nestin in all cell lines. Human NSCs endogenously
express SOX2 (Kim et al. 2009b) while intermediary filament nestin is found in proliferating
NSCs of the CNS (Michalczyk et al. 2005). Taken together, a higher RA-application at an earlier
time-point demonstratively enhanced the generation of correctly regionalised pMN-like
progenitor cells in comparison to the original protocol.
Further maturation of such progenitor cells eventually led to plenty of neurons exhibiting
typical motoneuronal markers like ISL1, HB9 and ChAT (Fig. 25). The yield of double
HB9+/ChAT+bona fideMNs in this modified protocol appeared convincingly higher than in the
standard protocol. Particularly, the control line r1 as well as the representative PLS3
discordant sibling pair HGK13 (SMA III patient) and HGK16 (asymptomatic) featured more
bona fide MNs as when control line r1 is differentiated according to the standard protocol
(compare Fig. 23). Thus, in this study an optimised motoneuronal differentiation protocol has
been set up for further experiments in the actual human target tissue now. Several trials (~20)
were conducted, however, loss of usable samples and parallel attempts to increase MN yield
by additional modifications (e.g. additional administration of SHH protein for ventralisation)
prevented collection of enough data for scientifically valid comparison. Especially the
examination of quantitative differences concerning growth and long-term survival of MNs
between PLS3 discordant siblings in comparison to healthy controls and HGK1 as severely
affected SMA I patients was derogated.
Nonetheless, this new in vitro iPSC-based human MN model facilitated the detection of
additional SMA-specific disease features like the number of SMN-containing gems since
motoneuronal cultures of the representative PLS3 discordant sibling pair HGK13 (SMA III
patient) and HGK16 (asymptomatic) exhibited the typical nuclear dot-like gem localisation
(Fig. 26).
Furthermore, these iPSC-derived MNs did contain PLS3 as proven in Fig. 26 where HB9+ MNs
clearly expressed PLS3 in MNs of the PLS3 discordant sibling pair HGK13 and HGK16. This fact
will open an avenue to further elucidate how the molecular mode of action of PLS3 may exert
its protective effect in discordant siblings’ MNs.
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Fig. 26: HB9+MNs (green) in mixed motoneuronal cultures of PLS3 discordant sibling pair HGK13 (SMA III patient)
and HGK16 (asymptomatic) evidently expressed PLS3 (red). β III-tubulin+ neurons (red) in mixed motoneuronal
cultures of HGK13 (SMA III patient) and HGK16 (asymptomatic) palpably expressed SMN (green) and showed
characteristic dotted gem localisation in the nucleus (arrows) on day 41. Nuclei were counterstained with DAPI
(blue) (scale bar 20 µm, valid for all images).
7.3.3 Expression of PLS3 and SMN on RNA and protein levels in mixed
motoneuronal cultures
To determine the quantity of SMN and PLS3 on transcriptional and translational level,
respectively, total RNA and proteins were extracted from mature mixed motoneuronal
cultures.
Expression levels of SMN and PLS3 were calculated relative to expression rate of total RNA.
Analysis of mRNA expression rates in representative MN differentiation runs via qRT-PCR
revealed a low PLS3 expression rate for SMA III patient HGK13 whereas his asymptomatic
sister HGK16 showed a slightly reduced PLS3 expression rate when compared to PLS3
expression of control line r1 (Fig. 27). In contrast, the SMN expression level in both discordant
siblings was nearly equal (~30%) matching their genotype with three SMN2 copies and
significantly reduced to healthy control lines.
The amount of translated protein was valued by Western blotting and subsequent
immunoblotting (Fig. 28). Protein expression was normalised relative to β-actin expression for
quantification. The bands on the blot clearly represented the correct weight of the respective
proteins (PLS3: 72 kDa; β-actin: 50 kDa; SMN: 36 kDa) with equalised β-actin bands allowing
proper normalisation. Knock-down of PLS3 identified upper band as correct PLS3 signal (10.5,
Fig. 65). Notably, SMA III patient HGK13 exhibited evident decrease in PLS3 expression when
compared to controls. His asymptomatic sister HGK16 indicated a strong PLS3 expression in
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the immunoblot which was also reflected in the quantification but without exceeding control
values. Asymptomatic HGK16 showed rather equal PLS3 expression as healthy control r1. SMN
expression was visibly diminished in both siblings’ samples and reached just half of the amount
of control line r1 (~50%).
Fig. 27: Quantitative analysis of RNA expression levels in representative MN differentiation runs via qRT-PCR from
a mixed motoneuronal culture of healthy controls (r1 & r12) and PLS3 discordant siblings (SMA III patient HGK13
and his asymptomatic sister HGK16). PLS3 expression exhibited no significant differences between siblings yet
HGK13 showed a lower expression whereas HGK16 did not display any higher PLS3 expression in comparison to
control lines. Contrarily, the SMN expression of both siblings was similarly high at approx. 30% congruent with
their genotype of three SMN2 copies. Expression was standardised to total RNA levels (Kruskal-Wallis test).
Graphs were plotted from data of qRT-PCRs of three independent MN differentiation runs (n=3) apart from
control line r12 (n=2). Error bars represented ± SEM of biological duplicates (n=2).
Fig. 28: Quantitative analysis of protein expression
levels in a representative MN differentiation run via
immunoblot from a mixed motoneuronal culture of a
healthy control (r1) and PLS3 discordant siblings (SMA III
patient HGK13 and his asymptomatic sister HGK16).
PLS3 expression prominently differed between siblings
with almost half the expression for HGK13 and a nearly
equal expression for HGK16 relative to control r1
already discernible by weak signal intensity of correct
upper band. By contrast, the SMN expression signals of
both siblings were similarly intense reaching approx.
50% relative to control r1 after quantification which
matches their genotype of three SMN2 copies.
Expression was normalised to β-actin level
(Kruskal-Wallis test). Graph pictured data from blots of
two independent MN differentiation runs (n=2). Error
bars represented ± SEM of biological duplicates (n=2).
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7.3.4 Analysis of the composition of mixed motoneuronal cultures
Although the modified MN differentiation protocol performed better than the standard
differentiation procedure, the overall efficiency remained conspicuously below expectations.
The number of ISL1+ and HB9+ bona fide MNs ranged on average from 5%-8% of total cells,
seldom exceeding 12%. In Fig. 29 the quantification of a representative single MN
differentiation run was pictured. Both controls exhibited comparable numbers of ISL1+ cells
on low level (~6.5%). With control line r12, there was even the fewest number of HB9+ MNs
whereas MN culture of control line r1 included almost 10% HB9+MNs. In asymptomatic sibling
HGK16, the amount of HB9+ and ISL1+ cells added up to approx. 6% whereas SMA III patient
HGK13 tended to lower numbers in HB9+ MNs (~4.5%) whereas the numbers of ISL1+ MNs
even exceeded the MN numbers in the controls (~12%).
Fig. 29: Representative single quantification of HB9+ and ISL1+MNs in a mixed motoneuronal culture of PLS3
discordant sibling pair HGK13 (SMA III patient) and HGK16 (asymptomatic) as well as healthy control lines r1 and
r12. On day 48, the total number of HB9+ and ISL1+ cells was determined by immunocytochemical staining.
Cultures of control lines r1 and r12 comparably contained ISL1+ MNs whereas there were gross differences
between the lines concerning HB9+ cells. With HGK16 the MN number ranged around 6% whereas her affected
brother HGK13 showed lower HB9+ MN numbers but even more ISL1+ MNs than the controls. Graph pictured
data from quantification of one MN differentiation run (n=1).
In order to identify further neural populations within the mixed motoneuronal cultures,
samples of healthy control line r12, positive control HGK1 (SMA I patient) and the
representative PLS3 discordant sibling pair HGK22.18 (SMA III patient) and HGK28.11
(asymptomatic) were stained for different neuronal and glial markers. Cultures of cells which
had been directly differentiated towards the respective neuronal populations or glia served
as correspondent positive controls to verify antibody’s functionality.
Clearly, cultures of all cell lines predominantly consisted of non-MN cells (Fig. 30). Whereas
only very few TH+ dopaminergic neurons existed in those cultures, GABAergic neurons
(GAD65/67+) and in particular glutamatergic neurons (v-Glut 1+) strikingly prevailed. In
addition, GFAP+ glial cells were present. Yet, the longish morphology with neurite-like
extensions rather hinted at radial glia cells than at astrocytes as it was also detectable in the
corresponding positive control. Besides, iPSC-derived human astrocytes need longer
maturation periods (>90 days) (Krencik et al. 2011) and GFAP is known to label radial glia cells
as well (Campbell et al. 2002). Since the samples were stained on day 35, the presence of
astrocytes was unlikely.
After all, the high degree of non-MN cells in mixed cultures as well as the low efficiency of MN
generation raised the question if an iPSC-based differentiation protocol biased the overall
results with too high variance during such a long differentiation period. Instead, a strategy
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basing on neural stem cells (NSCs) may serve better and more reliably on account of a
standardised starting situation with a homogenous cell population.
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7.4 Motoneuronal differentiation of iPSC-derived small molecule
NPCs (smNPCs)
7.4.1 Generation of iPSC-derived small molecule NPCs (smNPCs)
Taking into account a very long differentiation period of up to seven weeks as well as a rather
low efficiency in the modified EB-based run-through protocol, the establishment of a stably
expandable fully patternable NSC population comprises several advantages. First, the already
advanced developmental state of those neuroectodermally primed precursor cells curtails the
duration of MN differentiation. Second, neural precursor cells (NPCs) form an initially more
homogenous cellular population than during the EB-based protocol, subsequently leading to
presumptively higher efficiencies. Third, by early administration of pattering morphogens
during routine cultivation NSCs can be driven more easily into the neuronal subpopulation
desired. Finally, a stable NSC population allows to monitor the entire developmental process
of in vitro MN generation: From original fibroblasts via iPSCs to NSCs and ultimately to MN
cultures, thus enabling to examine possible PLS3 mediated changes in different cell
populations of an in vitro SMA cell culture model.
A couple of human NSC lines have been previously established e.g. long-term self-renewing
neuroepithelial SCs (lt-NES®SCs) (Koch et al. 2009), primitive NSCs (Li et al. 2011) or rosette
neural cells (Elkabetz et al. 2008). Yet, every line suffers from drawbacks such as a bound
neural identity, costly growth factors for expansion or limited number of cultivable passages
(Reinhardt et al. 2013).
Recently, Reinhardt and colleagues introduced a novel type of NSCs which combines the
advantageous feature of robust cost-effective propagation and solid differentiation capability
(Reinhardt et al. 2013). These small molecule NPCs (smNPCs) are easily derived from iPSCs by
use of small compounds.
Therefore, all 13 iPSC lines were converted into corresponding smNPC lines according to a
modified fully adherent protocol as well as a modified original published protocol which
included an EB-like suspension step and dual SMAD-signalling inhibition (see Fig. 31 and 6.7).
Since the adherent protocol failed to generate proper smNPCs (data not shown), only the
smNPC lines obtained by the sphere-based original protocol were maintained and propagated.
To prove the presence of a homogenous NSC population, every smNPC line (p8-p10) was
checked for the same marker set as in the original publication by Reinhardt et al. (Fig. 32; 10.6,
Fig 65). Evidently, all smNPC lines expressed standard CNS NSC markers like SOX1, SOX2,
nestin and PAX6 in a comparable pattern compared to the original protocol. Moreover,
forebrain marker FORSE-1 which had been associated with early NSC populations
(Allendoerfer et al. 1995; Li et al. 2011) was clearly present in diffuse distribution in given
smNPC colonies. By default, smNPCs comprise an early pre-rosette NSC population. As it was
also shown in the original paper (Reinhardt et al. 2013), expression of classical rosette-markers
PLZF and ZO-1 did not reveal the typical petal-shape arrangements with centred ZO-1
accumulation (compare Fig. 38). Only when grown very densely, some smNPC (e.g. HGK21.8
or HGK27.10) lines exhibited ring-like ZO-1+ foci (Fig. 65). Thus, smNPCs fulfilled given
validation criteria additionally demonstrating neural plasticity.
Results 83
Fig. 31: Schematic picture of smNPC generation according to original protocol by Reinhardt et al., 2013. iPSC
colonies were enzymatically lifted and grown as EB-like spheres in suspension with smEB1 medium + 10 µM ROCK
inhibitor Y-7632. For four days, dual SMAD-signalling was inhibited by administration of SB431542 and LDN-93189.
After all, spheres were sown out on MG-coated dishes for further stabilisation and expansion of smNPCs.
Fig. 32: iPSC-derived smNPC lines evidently exhibited typical NSC markers PAX6 (green), SOX1 (red), SOX2
(green) and nestin (red) in four representative cell lines upon immunolabelling. Expression of anterior
marker FORSE-1 (green) was visualised as well. Since smNPCs possess an early pre-rosette NSC fate
expression of characteristic rosette-markers PLZF (green) and ZO-1 (red) did not reveal the typical petal-
like arrangement of lt-NES®SCs. Taken together, all smNPC lines were comparable to those of the original
publication according to their marker profile. Nuclei were counterstained with DAPI (blue) (scale bar
100 µm, valid for all cell lines). For other cell lines, see 10.6, Fig. 66.
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7.4.2 smNPCs differentiate into motoneurons with high efficiency
In an initial proof-of-principle experiment, an OLIG2-GFP smNPC reporter cell line (courtesy of
Lisa Neumann) was differentiated into MNs. OLIG2-GFP iPSC reporter line was a kind gift of
Ying Liu (University of California San Diego, USA).
This reporter cell line contains a knock-in of a GFP cassette into the human OLIG2 gene locus
enabling to monitor motoneuronal in vitro-differentiation (Liu et al. 2011). Upon patterning
into the pMN domain, distinct OLIG2-expression is marked by GFP fluorescence in OLIG2-GFP
reporter line.
OLIG2-GFP reporter smNPCs presented the same morphologic appearance during standard
cultivation as the smNPCs in the original publication by Reinhardt et al., 2013. One day after
splitting, OLIG2-GFP reporter smNPCs assembled in smaller colonies with a cobblestone-like
composition and flat growth (Fig. 33 A). Subsequently, those smNPCs aggregated to more
condensed colonies with distinct round edges and 3D growth similar to murine iPSCs
(Fig. 33 B).
Fig. 33: (A) OLIG2-GFP reporter smNPCs aligned to smaller flat colonies with frayed rims one day after splitting
in phase images. Single cells could still be recognised in the cobblestone-like assembly. (B) On day 4 after splitting,
smNPCs agglomerated more densely and formed tightly packed 3D colonies with sharp edges comparable to
murine iPSCs. (C) On d5 after motoneuronal induction, OLIG2-GFP reporter smNPCs considerably showed GFP
fluorescence indicating a strong OLIG2 expression. Thus, a correct regionalisation of smNPCs into the pMN
domain took widely place (scale bar 200 µm, valid for all images).
Treatment with caudalising morphogen RA (1 µM) and ventralising agents Pur (1 µM) and SAG
(1 µM) for one week evidently induced motoneuronal patterning. After five days, OLIG2-GFP
reporter gene was widely expressed in smNPCs (Fig. 33 C) notifying intense endogenousOLIG2
gene expression which hallmarked patterning of neural progenitor cells into the pMN domain.
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Indeed, immunocytochemical staining of OLIG2-GFP reporter smNPCs on day 7 revealed
strong expression of characteristic pMN-markers OLIG2, NKX6.1 and upper spinal cord marker
HOXB4. NKX2.2+ cells were also detectable denoting a strong ventralisation because NKX2.2
is a marker of the outermost ventral domain p3. Already at this early time point which is
comparable to day 28 in the iPSC-based run-through protocol, there were proper MNs
identifiable by staining HB9, ISL1 or SMI-32 (Fig. 34). Final motoneuronal maturation for
further 2-3 weeks gave rise to a considerable amount of bona fide MNs betokened by
expression of ChAT, HB9 and ISL1 (Fig. 35).
Fig. 34: Immunocytochemical staining of
motoneuronally differentiated OLIG2-GFP reporter
smNPCs on day 7 verified correct
pMN-regionalisation after one week MN-induction.
Cells broadly exhibited pMN-marker OLIG2 (green),
NKX6.1 (red) and HOXB4 (red). Robust
ventralisation was confirmed by several NKX2.2+
cells (green). First MNs were noticeable already at
this early time point because a couple of cells were
expressing SMI-32, HB9 or ISL1 (all green). Insets
showed corresponding pictures with stained nuclei.
Nuclei were counterstained with DAPI (blue) (scale
bar 100 µm, valid for all images).
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Fig. 35: Two weeks final MN maturation yielded a substantial number of ChAT+ (red)/HB9+ (green) or SMI-32+
(green) MNs in immunocytochemical staining. Strong neuronal differentiation was marked by excessive amount
of β III-tubulin+ neurons of which a sufficient portion comprised ISL1+MNs. Insets showed corresponding pictures
with stained nuclei. Nuclei were counterstained with DAPI (blue) (scale bar 100 µm, valid for all images).
7.4.3 smNPCs were convertible into another NSC subpopulation
Among the first stably expandable human NSC lines, lt-NES®SCs  were described by Koch et al.
(Koch et al. 2009). Demonstrating cellular plasticity of smNPCs and concomitantly generating
another possibly MN-differentiable NSC line, OLIG2-GFP smNPC reporter cells could be easily
converted into these lt-NES®SCs by simple medium change (Fig. 36).
With 50% confluent smNPCs medium was switched to NSC1 medium containing 20 ng/ml
bFGF for two days in total. Immediately, cells underwent obvious morphological changes
indicated by re-arrangement to the typical rosette-type shape (Fig. 37 A). Upon standard
trypsinisation regimen (Koch et al. 2009), smNPC-derived lt-NES®SCs were stably expandable
in NSC1 medium (Fig. 37 B) even when 150 nM RA and 1 µM SAG were added during expansion
to induce motoneuronal patterning (Fig. 37 C). Indeed, constant RA- and SAG-administration
shifted OLIG2-GFP lt-NES®SCs reporter cells towards a ventral-caudal pMN-like cellular fate.
OLIG2 expression in these lt-NES®SCs reporter cells was marked by GFP-fluorescence already
after one week (Fig. 37 D)
OLIG2-GFP lt-NES®SCs reporter cells showed characteristic expression of typical NSC markers
such as neural intermediate filament nestin or embryonic developmental transcription factors
SOX2, PAX6 and DACH1. Moreover, rosette markers PLZF and ZO-1 clearly visualised
characteristic blossom-like arrangement of lt-NES®SCs with a concentration of tight-junction
protein ZO-1 in the centre. Neural crest marker AP2 was only found sporadically within
lt-NES®SCs culture (Fig. 38).
For final motoneuronal differentiation, OLIG2-GFP lt-NES®SCs reporter cells were seeded in
MN1 medium. Pre-treatment with RA and SAG occurred during regular expansion culture for
either eleven days (11d+RA/SAG) or 21 days (21d+RA/SAG), respectively. As negative control
(neg ctrl) served lt-NES®SCs which were never pre-treated with RA or SAG.
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Fig. 37: (A) Changing medium converted OLIG2-GFP smNPC reporter cells immediately into lt-NES®SCs marked
by overt appearance of neural rosettes. (B) lt-NES®SCs kept this typical morphology throughout expansion (C)
even when MN patterning morphogens RA (150 nM) and SAG (1 µM) were added to regular cultivation medium
NSC1. (D) OLIG2-GFP lt-NES®SCs reporter cell line proved functional since evident GFP fluorescence was visible
in regular culture indicating OLIG2 expression upon RA- and SAG-treatment after one week (scale bar 200 µm,
valid for all images).
Fig. 36: Schematic picture of conversion of smNPCs into lt-NES®SCs and prospective motoneuronal differentiation
modified from (Koch et al. 2009). Adherent smNPCs were converted into lt-NES®SCs by simple medium change for
two days applying EGF, bFGF, B27 and GSK3 inhibitor CHIR99021. Obtained lt-NES®SCs were stably expandable and
capable of motoneuronal differentiation by RA and SAG administration and consecutive maturation.
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Immunocytochemical staining on day 1 after plating for MN maturation pictured the presence
of diverse pMN regional markers. In untreated OLIG2-GFP lt-NES®SCs reporter cells, there was
no expression of HB9, ISL1, OLIG2, NKX6.1 or HOXB4 visible. Yet, growth factor withdrawal by
medium change from NSC1 to MN1 obviously induced rapid neuronal development of lt-
NES®SCs towards β III-tubulin+ neurons even in untreated lt-NES®SCs. SMI-32 antibody
detected non-phosphorylated neurofilament-H in ventral horn motoneurons in spinal cord
slices and stained furthermore a subset of neurons in dissociated spinal cultures which
morphologically resembled motoneurons identified in vitro: large (>20 µm) cell body,
prominent neuritic arborisation and generally a single long axon (Carriedo et al. 1996). Thus,
SMI-32 was regarded as a typical motoneuronal marker (Ebert et al. 2009). However, SMI-32
antibody also recognised neurons in the PNS and CNS such as human GABAergic cortical
neurons (Campbell et al. 1989). Therefore, sporadic SMI-32+ cells apparent in negative control
rather depicted those non-motor neurons (Fig. 39 A).
Fig. 38: Immunolabelling of smNPC-derived lt-NES®SCs verified the rosette-like character by expressing typical
NSC markers PAX6 (green), SOX2 (red), nestin (red/green) and DACH1 (green). Characteristic rosette-shape was
visualised by staining PLZF (green) and ZO-1 (red) displaying a strong central ZO-1 signal with petal-like
arrangement of PLZF+ NSCs. Contamination of neural crest cells was hardly detectable by only few AP2+ cells
(red). Insets showed corresponding pictures with stained nuclei. Nuclei are counterstained with DAPI (blue) (scale
bar 100 µm, valid for all images).
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In contrast, lt-NES®SCs treated with RA and SAG beforehand for eleven days (11d+RA/SAG) or
21 days (21d+RA/SAG), respectively, clearly showed expression of characteristic pMN markers
like OLIG2, NKX6.1 and HOXB4. So, correct patterning did take place. However, OLIG2/NKX6.1
double-positive progenitor cells were noticeably rather found in lt-NES®SCs  treated for 21
days indicating that a longer patterning period led to higher number of correct MN progenitor
cells. Moreover, already one day after plating patterned lt-NES®SCs developed into MNs
expressing HB9, ISL1 and SMI-32 (Fig. 39 A).
After 16 days maturation in MN1 medium, pre-treated lt-NES®SCs exhibited distinct
expression of MN markers HB9, ISL1, ChAT and SMI-32. To evidence reliability of GFP
fluorescence as reporter signal of OLIG2 expression, cells were stained for both epitopes
simultaneously revealing a decent number of GFP/OLIG2 double-positive cells. So, there were
still MN progenitor cells present in this culture (Fig. 39 B).
However, untreated lt-NES®SCs lacked expression of HB9 and ChAT. Only very few ISL1+ and
SMI-32+ neurons were present. Since MN1 medium still contained low concentrations of RA
(50 nM) and Pur (0.5 µM), spontaneous MN differentiation might have occurred even in
untreated lt-NES®SCs.
Taken together, initial proof-of-principle experiments denoted feasibility of using stable NSC
lines for MN differentiation and advantages of RA/SAG pre-treatment.
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Fig. 39: (A) OLIG2-GFP reporter lt-NES®SCs pre-treated with RA and SAG for eleven days (11d+RA/SAG) and 21
days (21d+RA/SAG), respectively as well as untreated cells as negative control were seeded for final MN
maturation and subjected to immunocytochemistry. One day (d1) after plating, negative control did not exhibit
pMN marker gene expression but only differentiation into β III-tubulin+ neurons (red) and very few SMI-32+
neurons (green). Treated lt-NES®SCs contrarily expressed typical pMN markers OLIG2 (green), NKX6.1 (red) and
HOXB4 (red). In addition, first ISL1+ and HB9+motoneurons (green) appeared. (B) Longer maturation period for
16 days (d16) increased obvious numbers of mature motoneurons in treated lt-NES®SCs illustrated by positive
staining for ChAT (red), HB9, ISL1 and SMI-32 (all green). MN cultures still contained MN progenitors marked by
double-positive OLIG2+ (purple)/GFP+ (green) cells which were missing in negative control. Just very few ISL1+
and SMI-32+ cells were apparent in untreated lt-NES®SCs hinting at only rare spontaneous MN differentiation for
they were also devoid of mature ChAT+/HB9+mature motoneurons. Nuclei were counterstained with DAPI (blue)
(scale bar 100 µm, valid for all images).
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7.4.4 Differentiation of smNPCs from SMA patients and asymptomatic PLS3
discordant siblings into motoneuronal cultures
The preceding experiments with OLIG2-GFP smNPC reporter cell line strikingly pointed out the
advantages of this NSC line concerning feasibility, duration and differentiation efficiency.
In addition, successful application of pMN-domain inducing morphogens RA and SAG during
regular maintenance of smNPC-derived lt-NES®SCs demonstrated a visible enhancement of
efficiency in MN generation. Thus, the same approach was undertaken with the other smNPC
lines.
The regular cultivation medium NPC1 was additionally supplemented with 1 µM RA and 1 µM
SAG for at least two weeks with every cell line before the standard MN differentiation
procedure (i.e. withdrawal of GSK3 inhibitor CHIR99021 and administration of 1 µM
RA/SAG/Pur respectively for one week) was applied (Fig. 40).
In order to illustrate a correct shift into the pMN domain, representative cell lines of every
phenotype (i.e. SMA I, SMA III, asymptomatic discordant and healthy control) were
exemplarily examined for expression of standard CNS markers as well as classical
motoneuronal progenitor markers on day 8 (Fig. 41). The overt expression of pan-CNS markers
SOX2 and nestin depicted the NSC-like character of RA-treated smNPCs. Obviously, all four cell
lines exhibited a strong expression of ventral pMN markers OLIG2 and NKX6.1 and caudal
marker HOXB4 irrespective of their phenotypic background. The moderate presence of PAX6+
cells as well as the little amount of NKX2.2+ cells highlighted the exact shift of originally
anterior smNPCs into the ventral-posterior pMN domain.
Exemplary immunocytochemical staining of motoneuronally differentiated smNPC lines
representing the different phenotype classes revealed a broad expression of typical MN
markers HB9, ISL1 and SMI-32 on day 8 (Fig. 42 A). Furthermore, HB9+ MNs also expressed
PLS3 making this in vitro-disease model suitable for further studies on PLS3-specific influence
in discordant families. Remarkably, at this early time point of MN differentiation there were
Fig. 40: Schematic presentation of smNPC differentiation according to a protocol modified from
Reinhardt et al., 2013. For at least two weeks, smNPCs were primed into pMN-domain by additional application
of 1 µM RA and 1 µM SAG in standard cultivation medium NPC1 during regular maintenance. Once cells were
70% confluent, CHIR99021 was withdrawn and cells grown for one week. On day 7, patterned smNPCs were
seeded for final maturation in NPC3 medium containing growth factors. Furthermore, 0.5 mM Pur and 50 nM
RA were added from d8-d15 to warrant full motoneuronal differentiation of remaining progenitor cells.
Additionally, notch-signalling was inhibited from d8-d12 by administration of γ-secretase inhibitor DAPT to
push neuronal differentiation. At last, MN cultures were analysed after three weeks maturation.
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not fewer MNs in severely affected SMA I line HGK1. Quantification of MN number in all cell
lines highlighted this fact (Fig. 43 A, B). From three independent MN differentiation runs (n=3),
cells with these two markers were manually counted (HB9: 1,200-2,000 cells; ISL1: 1,400-
2,400 cells in total) and their ratios computed in relation to total number of cells.
With most of the cell lines, the percentage of HB9+ MNs ranged between 20-30% of all cells
(Fig. 43 A). Only HGK13, HGK16, HGK21.8 and HGK28.11 generated fewer HB9+ MNs (6-12%)
pointing out variable differentiation efficiency among individual cell lines in vitro.
Astonishingly, female control line COII.2 underperformed delivering just 2% HB9+ MNs.
Irrespective of the genetic background, there was no detectable trend in HB9 efficiency
measurable since members of all three disease-related phenotype classes (i.e. SMA I, SMA III,
asymptomatic discordant) generated a high amount of HB9+ MNs. Thus, in comparison to
control line r12 efficiency differences with statistical significance were only found for low
HB9-expressing cell line COII.2 probably reflecting more intrinsic cell line-specific features
than disease-related reasons. Therefore, no significant difference in HB9 generation was
detected when results were summarised according to the phenotype (Fig. 43 E). Note that for
comparability reasons, control line COII.2 was always excluded from phenotypic summaries
since it did not represent a proper MN culture and additionally did not give rise to sufficient
MNs until day 27 either.
Similarly, ISL1 expression on day 8 did not significantly differ amongst the cell lines (Fig. 43 B).
On average, MN cultures comprised 10-30% ISL1+ MNs independent of their corresponding
phenotypic background. Of course, grouping all values according to the phenotype did not
result in statistically significant differences (Fig. 43 F). Moreover, there was no strict
congruency between the two MN markers HB9 and ISL1 within the cell lines observable. For
example, HGK22.18 showed 23% HB9+ MN but only 11% ISL1+ MNs pinpointing the need of
examining several MN markers in parallel as carried out in this study.
Taken together, early in-vitro MN cultures exhibited rather comparable amounts of HB9+
(20-30%) or ISL1+ (~20%) cells with reasonable efficiency on day 8 when summed up according
to their phenotype. By trend, MN cultures of asymptomatic discordant women contained the
fewest HB9+ (~16%) or ISL1+ MNs (~12%).
Nonetheless, the detrimental effect of SMN loss in MN maintenance became obvious after
three weeks of further maturation (Fig. 42 B). On day 27, MN cultures were stained for MN
markers HB9, ISL1, SMI-32 and additionally mature MN marker ChAT. MN cultures of SMA I
patient line HGK1 barely contained any ISL1+ or HB9+/ChAT+ MNs anymore whereas in
discordant individuals HGK27.13 (SMA III) and HGK16 (asymptomatic) as well as healthy
control line r12 MNs expression of the aforementioned markers was demonstratively
detectable. Yet, in comparison to day 8 HGK27.13 exhibited already an apparent decline in
MN number on day 27. Notably, expression of SMI-32 did not seem to be negatively affected
in cell lines with disease-related background apparently.
Counting HB9+ and ISL1+ cells in such MN cultures evidently pointed out these trends (Fig. 43).
From three independent MN differentiation runs (n=3), cells with these markers were
manually counted (HB9: 800-1,700 cells; ISL1: 300-900 neurons in total) and their ratios
calculated relative to total number of cells (HB9) and total number of β III-tubulin+ neurons
(ISL1), respectively. Note that owing to technical reasons three trials could not be evaluated
for every cell line (see tables in Fig. 43 C, D).
Healthy control line r12 exhibited the highest percentage of HB9+ MNs (~21%) on day 27
whereas SMA I patient HGK1 suffered from a drastic drop in MN number losing almost entirely
its HB9+ cells (~0.7%) (Fig. 43 C). With varying range, SMA III cell lines and their corresponding
asymptomatic siblings’ cell lines generally revealed 3-5% HB9+ MNs after three weeks. Only
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HGK21.1, HGK27.10, HGK27.13 and HGK28.9 presented a higher HB9 number (8-13.5%).
However, for HGK21.1 there was only a single sample available depriving its validity. The other
three cell lines strongly expressed HB9 on day 8 so that their loss of HB9+ cells began from a
high level. Nevertheless, in comparison to control line r12 the decline of HB9+ MNs was only
significant with respect to SMA I HGK1. This statistically valid difference also held true in the
phenotypic overview (Fig. 43 G): While there was no significant difference detected among
healthy control, SMA III samples or asymptomatic samples on day 27, differences between
healthy control and SMA I was very significant.
Yet, in respect of number of ISL1+MNs there were no such clear differences detectable within
single cell lines (Fig. 43 D). Indeed, healthy control line r12 revealed the most ISL1+MNs (23%)
on day 27. Similarly, severely affected SMA I line HGK1 heavily lost ISL1+MNs leaving only 2.3%
from original ~20% on day 8. In cell lines from discordant family members, the amount of
remaining ISL1+ MNs ranged either between ~5-7.5% (HGK13, HGK16, HGK21.8 and
HGK22.18) or ~9-17% (HGK22.17, HGK27.10, HGK28.9). Surprisingly, SMA III patient line
HGK27.13 nearly reached the level of control line r12 (~21%). However, in comparison to day 8
HGK27.13 had to bear a loss of ~7% whereas r12 presented even a slight increase in ISL1+ cell
number (from ~21% to ~23%). Slow growing asymptomatic cell line HGK28.11 showed again
the least number of all discordant cell lines (2.8%) ranging hardly above the results of SMA I
HGK1. So, the only statistically significant difference was observed between control r12 and
SMA I HGK1 (Fig. 43 D). Understandably, those individual results were exactly reflected in the
phenotype summary (Fig. 43H). Between classified samples of SMA I, SMA III or asymptomatic
individuals, the only significant difference in ISL1 number was present between SMA III and
SMA I MN cultures on day 27. Neither was there a significant change measured when SMA III
or asymptomatic samples were likened to healthy control. Just SMA I samples showed a very
significant difference in comparison to healthy control.
In summary, matured in-vitro MN cultures on day 27 revealed only in SMA I phenotype a
significant decrease in MN survival and drastic drop of ISL1+ and HB9+ cell numbers. Even
though healthy control lost ~8% HB9+MNs, it maintained number of ISL1+MNs on nearly equal
level. MN death in SMA III or asymptomatic phenotype was insignificant concerning ISL1 and
HB9. Still, by trend the number of ISL1+ MNs was reduced almost halving when matched to
values on day 8.
In Fig. 44 the individual changes of ISL1+ and HB9+ cell numbers between day 8 and day 27
were displayed with regard to the phenotype. Basically, in all four phenotype classes the
number of HB9+MNs diminished within the three weeks of maturation (healthy control: 29.8%
↘20.8%; SMA I: 26.8% ↘0.7%; SMA III: 20.9% ↘8.9%; asymptomatic: 16.5% ↘6.3%)
(Fig. 44 A). Yet, only SMA I had to cope with such a massive loss of HB9+ MNs when day 8 was
compared to day 27. A similar steep decline in ISL1+ cell number was detected in SMA I
phenotype (19.5% ↘2.3%) (Fig. 44 B). SMA III and asymptomatic phenotype illustrated a
moderate decrease in ISL1+ cell number (SMA III: 21.5 ↘14.7%; asymptomatic: 11.8%↘7.2%)
whereas healthy control even slightly increased its ISL1+ amount (19.3% ↗23%).
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Fig. 43: Quantification of MN marker expression in smNPC-derived MN cultures of different healthy and SMA
affected or asymptomatic individuals on day 8 and after three weeks maturation on day 27. Mean number of
HB9+MNs on day 8 (A), ISL1+ MNs on day 8 (B), HB9+ MNs on day 27 (C) and ISL1+ MNs on day 27 (D) were
depicted for each individual cell line (day 8: HB9: 1,200-2,000 cells; ISL1: 1,400-2,400 cells counted in total;
day 27: HB9: 800-1,700 cells; ISL1: 300-900 neurons counted in total). Additionally, mean values were summed
up according to the phenotypic background for day 8 (E, F) and day 27 (G, H), respectively. (A) A reasonable
amount of HB9+ MNs was visible within the individual cell lines ranging between 20-30% of all cells. Fewer HB9+
MNs (6-12%) were found in cell lines HGK13, HGK16, HGK21.8 and HGK28.11, even undercut by control line
COII.2 (2%). Overt significant differences between controls r12 and COII.2 rather pointed out intrinsic features of
individual cell lines. (B) Similarly, ISL1 expression on day 8 did not significantly differ amongst the cell lines. Thus,
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no correlation between genetic background and MN number could be drawn on day 8. Nor were ISL1 and HB9
numbers congruent within a single cell line. (E, F) Grouping the data according to the four phenotypic classes did
not reveal any statistically significant difference. (C) On day 27, control line r12 showed the highest amount of
HB9+ MNs (~21%) whereas all other cell lines faced a marked drop in HB9+ number. SMA I line HGK1 almost
completely lost its HB9+ MNs (0.7%) rendering a significant difference compared to control r12. SMA III and
asymptomatic cell lines ranged from 3-13%. (G) Therefore, when those results were grouped and phenotypes
were likened to controls there was significant difference detectable. Between SMA-related phenotypes
differences were not significant. (D) Evaluation of ISL1+ cell survival did not present such a clear trend. Variances
in ISL1+ cell number were higher resulting in mostly insignificant differences. Only SMA I line HGK1 contained
significantly lower ISL1+ cell numbers. (H) Of course, these facts were reflected in the phenotype summary with
the only significant difference between controls and SMA I. Note that control COII.2 was excluded in phenotypic
MN culture overviews. Results showed the counting of three independent differentiation runs (n=3) for day 8
whose ratios were calculated in relation to total number of cells (HB9: 1,200-2,000 cells; ISL1: 1,400-2,400 cells
counted in total). For day 27, one to three independent differentiation runs (see tables in C, D) were considered
with at least half of the cell lines thrice (n=3). Mean ratios were computed relative to total number of cells (HB9)
and total number of β III-tubulin+ neurons (ISL1), respectively (HB9: 800-1,700 cells; ISL1: 300-900 neurons
counted in total; Kruskal-Wallis test, p <0.05 = *, p <0.01 = **). Note that owing to technical reasons three trials
could not be evaluated for every cell line. Error bars represented ± SEM of biological triplicates (A, B, E, F, G;
control r12, SMA I & SMA III in H) and duplicates (asymptomatic in H), respectively. Error bars in C, D (day 27)
represented ± SEM of n=MN differentiation runs as outlined in subordinated tables.
Fig. 44: Motoneuronal survival between day 8 and day 27 in smNPC-derived MN cultures of different healthy and
SMA affected or asymptomatic individuals classified in regard of their phenotypic background. (A) In all four
groups there was a loss of HB9+ MNs observable (healthy control: 29.8%↘20.8%; SMA I: 26.8% ↘0.7%; SMA III:
20.9% ↘8.9%; asymptomatic: 16.5% ↘6.3%). (B) Similarly, massive death of ISL1+ MNs was only detected in
SMA I phenotype (19.5%↘2.3%) whereas the discordant family members just exhibited a mild decline in ISL1+
cell numbers (SMA III: 21.5 ↘14.7%; asymptomatic: 11.8% ↘7.2%). Healthy controls even gained a minor
percentage of ISL1+ MNs (19.3% ↗23%). Error bars represented ± SEM of biological triplicates of three
independent differentiation runs (n=3) (A; control r12, SMA I & SMA III in B) and duplicates (n=2) (asymptomatic
on day 27 in B), respectively.
7.5 Analyses of SMN and PLS3 expression in various cell populations
of different SMA phenotypes during MN development
Although PLS3 was supposed to be solely expressed in solid tissue but not in blood (Lin et al.
1999), asymptomatic siblings from discordant families evidently over-expressed PLS3 in
blood-derived LB cell lines on RNA and protein levels (Oprea et al. 2008). However, the true
situation in patients’ MNs stayed unclear. Since data about SMN expression in MNs of patients
investigated in this study were lacking as well, respective SMN levels ought to be checked.
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To be able to follow possible changes of the expression rates during the developmental
process of MN generation in SMA affected patients, PLS3 discordant siblings and healthy
controls, the expression of PLS3 as well as SMN was examined on RNA and protein level in
different cell populations, i.e. original fibroblasts, derived iPSCs, corresponding smNPCs and
differentiated MN cultures on day 27.
7.5.1 SMN expression on RNA level in different SMA phenotypes during MN
development
As the disease cause, SMN expression was investigated first. Samples of every cell line in each
respective cell population were investigated by qRT-PCR. Data were normalised as well as
graphically plotted relative to total RNA expression.
In fibroblasts, SMN expression in control lines r12 and COII.2 was almost equal (Fig. 45 A).
SMA I patient line ML17 exhibited the least amount of SMNmRNA. Astonishingly, discordant
family members showed an inconsistent SMN expression rate: Whereas asymptomatic ML11
and ML13 as well as SMA III ML12 displayed a moderate SMN expression (~40-60% relative to
r12), the other lines asymptomatic ML101 and SMA III ML14 and ML102 nearly reached the
expression level of healthy controls (75-100% relative to r12). Grouping this data according to
the phenotypic background gave a more consistent view in which SMA I patients expressed
only ~28% SMN mRNA and SMA III and asymptomatic discordant family members ~68-74%
SMN mRNA relative to controls (Fig. 45 B). Thus, only SMA I demonstrated a very significant
difference in SMNmRNA expression.
SMN expression in iPSCs conveyed a more homogeneous impression concerning single cell
line expression (Fig. 45 C). Control lines r12 and COII.2 demonstrated the overall highest SMN
expression. Moreover, SMA I line HGK1 showed the lowest amount of SMN expression which
differed significantly from the control r12 amount. Discordant family 1 members HGK13 and
HGK16 exhibited almost half the control amount (~50% relative to r12) reflecting the genetic
background with three SMN2 copies. Since siblings of discordant family 2 possessed four
SMN2 copies, expectedly the SMN expression rate was higher (60-80% relative to r12) than in
other SMA phenotypes, however for most of the iPSC lines still distinctly lower than in control
lines. Summarising these results in respect of the phenotype represented the same picture as
in fibroblasts (Fig. 45 D). Controls expressed the highest amount of SMN whereas SMA III and
asymptomatic siblings almost equally expressed ~65% relative to controls still rendering a
significant decrease. SMA I depicted the lowest amount (27% relative to control) indicating
very significant difference.
In smNPCs, both control lines r12 and COII.2 displayed the overall strongest SMN expression
(Fig. 45 E). Again, SMA I line HGK1 showed a significantly lower amount when compared to
control r12. The discordant family members basically revealed a stronger SMN expression rate
(70-90% relative to r12) except for HGK21.8 with 46%. When the four phenotype classes were
compared, they exhibited a picture congruent with the previous phenotype summaries
(Fig. 45 F): A high SMN expression in controls, a significantly lower expression in SMA I (26%
relative to controls) and a moderate significant SMN expression diminution in SMA III and
asymptomatic groups (~65% relative to controls).
Analyses of MN culture samples revealed the highest SMN expression in control line r12
(Fig. 45 G). The least SMN expression was found in SMA I HGK1 and exceptionally in SMA III
HGK13 being significantly different relative to r12. On the other hand, the remaining SMA III
and asymptomatic individuals expressed a medium up to higher SMN amount (~43%-85%
relative to r12) which was not significant. However, the graph represented only data from a
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single MN differentiation run. Once samples of the two other runs were processed, the pooled
data might give a more conclusive picture of SMN expression in MN cultures.
Nevertheless, grouped data in the phenotypic overview (Fig. 45 H) showed a firm SMN
expression in healthy control r12 proving significantly higher than SMA I affected which
delivered just approx. 25% expression rate. In contrast, in SMA III and asymptomatic samples
SMN expression rate reached a medium level of ~56% and ~68%, respectively (relative to r12)
marking only expression in SMA III as significantly diminished.
Taken together, SMNmRNA expression differed between healthy controls, SMA I, SMA III and
asymptomatic discordant siblings according to their SMN2 copy number. Cell line-specific
variances were balanced to a conclusive phenotypic summary in which SMA I principally
expressed roughly a quarter of the control amount (~26%) resulting in a significant difference.
There was evidently a diminished SMN expression in SMA III or asymptomatic groups
detectable in comparison to healthy controls so that variance in SMN expression was often
significant, On average, in the four phenotypic classes SMA III and asymptomatic discordant
expressed ~65% and ~68%, respectively.
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Fig. 45: Quantitative analyses of SMN mRNA expression levels in different cell populations via qRT-PCR from
healthy controls, SMA I and SMA III affected and asymptomatic discordant siblings. (A) In fibroblasts, control
lines r12 and COII.2 expressed most SMNmRNA whereas SMA I ML17 the significantly least amount. Discordant
family members showed a variant expression partially lower than controls, partially almost equal. (B) Fibroblast
SMN expression in four phenotype classes exhibited no significant differences between SMA III and
asymptomatic siblings in comparison to control lines. However, SMA I expression ranged very significantly lower.
(C) In iPSCs, control line r12 displayed a significantly higher SMN expression towards SMA I line HGK1. Discordant
family members individually revealed a significantly reduced SMN expression on medium level. (D) In phenotypic
classes, the highest SMN expression was found in healthy controls whereas SMA I patient demonstrated a
significantly decreased SMN amount. SMN reduction in discordant family members was significant, yet reaching
a moderate expression level (~65%). (E) In smNPCs, SMN expression level was significantly lowered in SMA I line
HGK1 relative to control line r12 whereas in individual discordant family members SMN amount was not
significantly diminished nonetheless appeared still lower than control levels. (F) Phenotypic summary disclosed
a similar picture as in previous cell populations leaving SMA I as group with the significantly lowest SMN amount.
Still, SMN expression was significantly scaled down in SMA III and asymptomatic siblings. (G) In MN cultures
(day 27), the significantly lowest SMN amount was exceptionally detected in SMA III HGK13 although SMA I HGK1
showed diminished SMN expression as well. The SMN expression rates of other discordant family members
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ranged at an insignificant medium level mostly. (H) Consistently, phenotypic overview depicted in SMA I and
SMA III a significant reduction relative to control r12. Contrarily, the SMN expression of asymptomatic siblings
comprised a not significant medium range. Expression was normalised to total RNA levels and significance
calculated relative to r12 and healthy controls, respectively (Kruskal-Wallis test, p <0.05 = *, p <0.01 = **). Error
bars represented ± SEM of technical duplicates (n=2). MN culture displayed data of one MN differentiation run
(n=1). Note that control COII.2 was excluded in MN culture analyses.
7.5.2 PLS3 expression on RNA level in different SMA phenotypes during MN
development
Since PLS3 was evidently proven to be the causative reason of protection in asymptomatic
SMA III discordant individuals (Oprea et al. 2008), PLS3mRNA expression was also monitored
within the different cell populations of all 13 cell lines by qRT-PCR. Data were normalised
relative to total RNA expression.
In fibroblasts, cell lines showed various PLS3 expression levels irrespective of their phenotypic
background. Markedly lessened PLS3 levels were measured in SMA I line ML17, asymptomatic
ML11 and ML13 and in SMA III ML12 and ML102 with ML12 as least expressing line compared
to controls (Fig. 46 A). Subsequently, solely significant differences were detected in pooled
samples between controls and SMA III even though SMA I and asymptomatic by trend
exhibited a light decrease in PLS3 expression relative to controls (Fig. 46 B).
In iPSCs, inconsistent PLS3 expression pattern still prevailed because cell lines disclosed
diverse expression levels independent of their genetic background. In comparison to control
line r12, SMA III HGK13 expressed lower PLS3 amounts whilst most other discordant family
lines showed expression levels similar to r12. Strong increase in PLS3 expression was
determined in control COII.2, SMA I line HGK1 and asymptomatic lines HGK21.1, HGK28.9 and
HGK28.11 (Fig. 46 C). Therefore, phenotypic summary kept depicting an insignificant
expression pattern in which SMA I group was almost equal to controls, SMA III was visibly
diminished and expression in asymptomatic was slightly augmented (Fig. 46 D).
In smNPCs, individual expression rates scattered without any significant difference relative to
control r12. However, strong expressing cell lines conspicuously comprised primarily
asymptomatic cell lines beside control COII.2 and SMA I HGK1 (Fig. 46 E). Thus, phenotypic
grouping revealed no significant difference in PLS3 expression. Nonetheless, overall
expression levels were noticeably elevated in SMA I and asymptomatic (Fig. 46 F).
In MN culture, PLS3 expression in control line r12 was strikingly down-regulated giving the
lowest expression rate. So, the other cell lines presented strongly higher expression rates
relative to control with significant differences in asymptomatic HGK28.9 and HGK28.11.
Remarkably, previously high PLS3 levels in SMA I line HGK1 were attenuated. Principally, firm
PLS3 expression was observed among asymptomatic siblings with individual cell lines
exceeding expression of control r12 up to 15fold (e.g. HGK28.11) (Fig. 46 G). After phenotypic
grouping, PLS3 expression of asymptomatic was very significantly increased relative to
controls. Thereby, the previous trend was distinctly stabilised because PLS3 expression more
than doubled in asymptomatic samples compared to SMA I and SMA III (Fig. 46 H).
Taken together, PLS3 mRNA expression in fibroblasts reached comparable levels among
non-control phenotypic groups. Albeit expression rates were visibly decreased significant
difference was only revealed between controls and SMA III. Ever since, in following cell
populations expression levels in asymptomatic evidently rose in comparison to other classes
resulting in a very significant difference in MN cultures. SMA I and SMA III samples fluctuated
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in the same range. While control line r12 principally exhibited a stable expression rate in the
first three cell populations, r12 was markedly down-regulated in MN cultures.
Fig. 46: Quantitative analyses of PLS3 mRNA expression levels in different cell populations via qRT-PCR from
healthy controls, SMA I and SMA III affected as well as asymptomatic discordant siblings. (A) In fibroblasts, PLS3
expression levels fluctuated independently of the individual phenotypic background. Yet, distinctly lower
expression was determined in SMA I line ML17, asymptomatic ML11 and ML13 and in SMA III ML12 and ML102
relative to control r12. (B) Phenotypic grouping ended up with slightly reduced expression rate in non-control
classes which were nearly equal among themselves. (C) In iPSCs, control line r12 remained at PLS3 levels
previously seen in fibroblasts leaving only SMA III line HGK13 with a markedly lower PLS3 expression. Whilst the
majority of other cell lines reached control levels, other cell lines e.g. control COII.2, SMA I line HGK1 and
asymptomatic lines HGK21.1, HGK28.9 and HGK28.11 topped expression in r12. (D) Phenotypic classification
largely erased individual fluctuations so that no difference was significant relative to controls. Nevertheless,
expression in SMA I and SMA III was visibly decreased and gently raised in asymptomatic. (E) In smNPCs, a light
trend developed in noticeably higher PLS3 levels in asymptomatic cell lines. Moreover, control COII.2 and SMA I
line HGK1 expressed more PLS3 mRNA relative to control r12 whereas SMA III cell lines reached comparable
levels still with no significance at all. (F) Differences amongst phenotypic classes were not significant. Still, a
considerably higher expression rate was pointed out in SMA I and asymptomatic compared to controls whereas
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SMA III exhibited a similar expression level. (G) In MN cultures (day 27), individual cell lines presented various
expression rates. Since control line r12 strikingly disclosed lowest PLS3 expression, remaining cell lines exhibited
high elevation of PLS3 expression yet significant differences only with HGK28.9 and HGK28.11. While
asymptomatic cell lines mostly oscillated at high levels, SMA I line HGK1 and SMA III lines reached medium or
lower expression levels. (H) Phenotypic grouping revealed comparable expression levels between SMA I and
SMA III without significant differences. However, expression level in asymptomatic was very significantly
increased relative to control r12 manifesting the previous trend of strong PLS3 expression in asymptomatic
siblings. Expression was normalised to total RNA levels and significance computed relative to r12 and healthy
controls, respectively (Kruskal-Wallis test, p <0.05 = *, p <0.01 = **). Error bars represented ± SEM of technical
duplicates (n=2). MN culture displayed data of one MN differentiation run (n=1). Note that control COII.2 was
excluded in phenotypic MN culture analyses.
7.5.3 SMN and PLS3 expression on protein level in different SMA phenotypes
during MN development
To confirm SMN expression rates on protein level, whole cell extracts of all 13 cell lines in the
respective cell populations were analysed by Western blotting and subsequent
immunoblotting. Membranes were probed with antibodies against PLS3, SMN and β-actin.
Data were normalised as well as graphically plotted relative to β-actin expression.
Principally, the bands on the blots evidently represented the correct weight of the respective
proteins (PLS3: 72 kDa; β-actin: 50 kDa; SMN: 36 kDa) with equalised β-actin bands granting
proper normalisation (Fig. 47). In fibroblasts, PLS3 protein was detected as a single distinct
band, however, an overt difference in signal intensity was not visible (Fig. 47 A). If several
bands were detectable, upper band was identified as correct PLS3 band (10.5, Fig. 65).
Contrarily, SMN bands clearly exhibited diverse signal intensity with SMA I line ML17 and
SMA III line ML12 as the least expressing cell lines.
In iPSCs, PLS3 protein was visualised as two bands ranging at the assumed size of 70 kDa.
(Fig. 47 B). PLS3 in vitro knock-down in cell lines by Mohsen Hosseini identified the upper band
as correct specific PLS3 signal (10.5, Fig. 65). So, in iPSCs thick bands revealed obvious
differences in signal intensity among the present cell lines (Fig. 47 B). Control lines r12 and
COII.2 as well as SMA III lines HGK22.17, HGK22.18, HGK27.10 and HGK27.13 displayed a
rather moderate band intensity. On the contrary, asymptomatic lines HGK16, HGK21.8,
HGK28.9 and HGK28.11 and SMA I line HGK1 demonstrated a visibly elevated signal intensity.
Astonishingly, SMA III line HGK13 and asymptomatic line HGK21.1 apparently expressed the
lowest PLS3 amount. Yet, SMN protein showed a different expression pattern with SMA I line
HGK1 delivering the faintest signal. Expression in control lines r12 and COII.2 as well as
asymptomatic lines HGK16 and HGK21.8 seemed the strongest whereas the other cell lines
displayed a signal intensity in-between.
In smNPCs, PLS3 protein was detected as two distinct bands (Fig. 47 C) like in iPSCs. Signal
strength was remarkably higher in SMA I line HGK1, asymptomatic lines HGK16, HGK21.1,
HGK21.8 and HGK28.9 and control line r12. Weaker signal intensity was discernible in the
other cell lines with SMA III lines HGK13 and HGK22.17 as lowest expressing cell lines. The
SMN expression pattern expectedly reflected the differences in SMN1/SMN2 gene copies
since the band of SMA I line HGK1 was hardly observable. In control lines r12 and COII.2, the
strongest bands were detected whereas the discordant family members depicted a medium
luminance.
In MN culture samples, prominent PLS3 expression was observed in asymptomatic lines
HGK21.1, HGK21.8, HGK28.9 and HGK28.11 (Fig. 47 D). Other cell lines generated a moderate
signal intensity including SMA I line HGK1. Notably, the band of control line r12 vanished
almost completely. On the contrary, control line r12 displayed a considerable amount of SMN
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protein. The band of SMA I line HGK1 had nearly disappeared while discordant family
members disclosed rather medium intense band signals.
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Quantification of SMN protein expression
Fig. 48: Quantitative analyses of SMN protein expression levels in different cell populations via immunoblotting
from healthy controls, SMA I and SMA III affected and asymptomatic discordant siblings. (A) In fibroblasts, control
line r12 disclosed a deviant low SMN expression level. SMA I line ML17 and SMA III line ML12 showed the least
amount of SMN. Unexpectedly, other discordant family members revealed quite strong SMN expression,
however no significant difference became overt in general. (B) Subsequently, phenotype groups did not
significantly differ although SMN expression in SMA I just amounted to ~18% in comparison to healthy control.
SMA III and asymptomatic siblings even reached control expression level despite different SMN1/SMN2 copy
number. (C) In iPSCs, SMN expression levels displayed in expected manner with control r12 as high expressing
line and SMA I line HGK1 as the least. Discordant family members exhibited a slightly diminished SMN expression.
(D) Thus, phenotype groups revealed considerably less SMN expression in SMA I (~46% relative to controls) and
a marginally lessened SMN amount in SMA III and asymptomatic siblings (~89% and ~83%, respectively). (E) In
smNPCs, individual SMN expression pattern resembled the previous one, yet discordant family members
revealed an overall lesser expression rate at medium level compared to control. SMA I line HGK1 expressed the
least SMN amount. (F) Grouped phenotypes mirrored these results so that SMA I demonstrated only ~30% SMN
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expression when likened to control values. SMA III and asymptomatic siblings disclosed ~53-60% at least. (G) In
MN culture, standard control line r12 suffered an abnormal drop in SMN expression, its expression level
outnumbered by those of several discordant cell lines. Nonetheless, SMA I line HGK1 delivered the poorest SMN
amount. (H) Therefore, in phenotype classes SMA I only showed ~31% SMN expression (relative to control)
whereas SMA III and asymptomatic siblings evinced ~88% and ~126%, respectively. Expression was normalised
to β-actin protein levels and significance calculated relative to r12 and healthy controls, respectively
(Kruskal-Wallis test). In fibroblasts, error bars represented ± SEM of technical duplicates (n=2). iPSCs and smNPCs
showed data of a single immunoblotting (n=1) with error bars representing pooled samples (D, F). MN culture
(day 27) displayed data of three independent MN differentiation runs (n=3) with error bars representing ± SEM
of biological triplicates (n=3). Note that control COII.2 was excluded in phenotypic MN culture analyses.
Quantification of individual expression ratios clarified previous impressions from the
immunoblots. In fibroblasts, SMA I line ML17 showed the least expression. Despite the
presence of three SMN2 copies, SMA III line ML12 surprisingly displayed a similarly low SMN
amount. Also control line r12 exhibited an unusually low SMN expression whereas control line
COII.2 as well as further discordant family members disclosed strong SMN expression rates.
Thus, no significant difference was detected in comparison to standard control r12 (Fig. 48 A).
Phenotypic grouping of these results revealed a comparably high SMN protein expression
between controls, SMA III and asymptomatic siblings in spite of differences in SMN1/SMN2
copy number. Furthermore, SMN expression in SMA I was the least (~18% relative to controls),
yet the difference was not significant in any way (Fig. 48 B).
In iPSCs, quantified SMN expression values pictured a more consistent pattern on the other
hand: Control lines r12 and COII.2 presented high expression rates while SMA I line HGK1
expectedly expressed the least amount. On average, discordant family members displayed a
quite strong SMN expression (Fig. 48 C). In phenotypic summary, controls possessed the
strongest SMN expression. However, in discordant family members the respective SMN
expression levels almost amounted to the controls’ level (~89% and ~84%, respectively). Still,
SMA I generated the lowest amount of SMN (~46% relative to controls) in iPSCs (Fig. 48 D).
In smNPCs, quantification accorded the immunoblot signal intensity rendering control lines
COII.2 and r12 the strongest expressing lines and SMA I line HGK1 the weakest expressing line.
Expression levels of discordant family members were located at a medium range with varying
minor differences (Fig. 48 E). Such variances were flattened in the phenotypic overview so that
SMA III and asymptomatic siblings both expressed approx. 53-60% when compared to healthy
controls. The difference between controls and SMA I was even larger (~30% relative to
controls) (Fig. 48 F).
In MN cultures, control line r12 acted as outlier because it exhibited an aberrantly low SMN
expression ratio. Still, it was asymptomatic line HGK21.8 which disclosed the highest SMN
expression rate. In general, the other discordant family members presented expression levels
ranging around the control value (Fig. 48 G). Pooling these individual results according to the
phenotype classes revealed markedly decreased SMN expression in SMA I samples (~31%
relative to controls). Unexpectedly, SMA III and asymptomatic discordant samples showed an
overall SMN expression level of ~88% and ~126%, respectively, exceeding the expectable SMN
amount (Fig. 48 H).
In summary, SMN protein expression did not give such a clear distribution pattern reflecting
the SMN2 copy number as it was seen on RNA level between healthy controls, SMA I, SMA III
and asymptomatic discordant siblings. Indeed, apparent variances of individual cell lines were
flattened by phenotypic grouping. Nevertheless, in particular control line r12 often expressed
an unexpectedly low SMN amount. Still, severely affected SMA I samples constantly gave the
poorest expression SMN rate counting only approx. a third (relative to controls) on average of
all four cell populations. Yet, on average of all four cell populations SMA III and asymptomatic
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discordant reached remarkably high SMN expression levels which topped the expected SMN
protein delivery of 3-4 SMN2 copies in these cell lines.
Quantification of PLS3 protein expression
Fig. 49: Quantitative analyses of PLS3 protein expression levels in different cell populations via immunoblotting
from healthy controls, SMA I and SMA III affected and asymptomatic discordant siblings. (A) In fibroblasts,
expression equally ranged at comparable level irrespective of phenotypic background. (B) Thus, no significant
difference was observed after summarising data to phenotype groups. (C) In iPSCs, both control lines exhibited
similar expression rates. Astonishingly, SMA I line HGK1 outperformed other cell lines in expression. Still,
asymptomatic lines e.g. HGK16, HGK21.8 or HGK28.9 strongly expressed PLS3. Consistently minor expression
rates were found in SMA III lines. (D) Phenotypic grouping demonstrated nearly equal expression levels between
controls and asymptomatic. SMA III reached only half the expression rate relative to control while SMA I distinctly
showed more PLS3 expression. (E) In smNPCs, control lines and SMA I line HGK1 basically kept the previous iPSC
expression levels with minor reduction in HGK1. Additionally, asymptomatic lines demonstrated a stably high
PLS3 expression. SMA III lines HGK13 and HGK22.17 struck a visible decline in PLS3 expression and further SMA III
lines did not improve either. (F) Phenotype classes revealed SMA I and asymptomatic as top expressing groups
while SMA III occupied the last rank just delivering approx. 50% relative to controls. (G) In MN culture, control
line r12 did not up-regulate PLS3 expression rendering it the least expressing line. SMA I HGK1 also kept previous
expression rates. Contrarily, asymptomatic cell lines except for HGK16 strikingly boosted PLS3 expression. SMA III
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lines also disclosed elevated expression yet reaching medium expression levels. (H) This development was
reflected in phenotypic overview with control as least expression line. SMA I quantitatively expressed a similar
PLS3 amount as in earlier populations. Yet, SMA III and particularly asymptomatic towered above with ~335%
and ~588% PLS3 amount relative to control r12, respectively. Nonetheless, differences were solely very
significant in asymptomatic siblings relative to control. Expression was normalised to β-actin protein levels and
significance calculated relative to r12 and healthy controls, respectively (Kruskal-Wallis test, p <0.05 = *,
p <0.01 = **). In fibroblasts, error bars represented ± SEM of technical duplicates (n=2). iPSCs and smNPCs
showed data of a single immunoblotting (n=1) with error bars representing pooled samples. MN culture (day 27)
displayed data of three independent MN differentiation runs (n=3) with error bars representing ± SEM of
biological triplicates (n=3). Note that COII.2 was excluded from phenotypic overview in MN culture analyses.
Quantification of individual PLS3 expression ratios substantiated previous optic assessment of
the immunoblots. In fibroblasts, homogenous signal intensity was correctly mirrored in
individual expression rates. Cell-line specific variances did not point out any significant
differences amongst cell lines (Fig. 49 A). Hence, phenotypic grouping revealed an expression
rate on equal level (Fig. 49 B). In iPSCs, individual expression levels diversified: SMA I line HGK1
amazingly topped other cell lines in PLS3 expression. Control lines exhibited a solidly high
expression rate comparable to most asymptomatic cell lines whilst SMA III cell lines presented
a diminished PLS3 expression rate relative to control making HGK13 the least expressing line
(Fig. 49 C). Phenotypic classes reflected these facts because asymptomatic siblings expressed
equally to controls whereas SMA I demonstrated an elevated expression rate and SMA III a
minimised expression rate (Fig. 49 D). In smNPCs, visibly attenuated signal intensity in the
immunoblot with SMA III lines HGK13 and HGK22.17 perfectly transferred into the
quantification making both lines hit the bottom-line of expression. Except for HGK22.18, the
other SMA III lines expressed little PLS3 as well. While control lines disclosed a firm expression
level, SMA I line HGK1 and particularly asymptomatic lines HGK16, HGK21.1, HGK21.8 and
HGK28.9 strongly expressed PLS3 (Fig. 49 E). In phenotypic overview, SMA I demonstrated a
strongly increased PLS3 expression compared to controls. While averaged expression rate in
SMA III was almost halved compared to controls, expression level approx. equally rose in
asymptomatic (~154%) relative to controls (Fig. 49 F). In MN cultures, the overall PLS3
expression rate was noticeably increased. Comparably, control r12 expressed low PLS3
amounts as in previous cell populations. SMA I line HGK1 appeared low expressing yet it was
the globally higher expression level in the remaining cell lines which conveyed this impression.
In particular, asymptomatic sisters of family 2 exhibited a massive up-regulation in PLS3
expression as indicated by prominent immunoblot signal intensity beforehand (Fig. 47 D).
Compared to previous cell populations, SMA III lines also increased expression rates still
outplayed by asymptomatic lines (Fig. 49 G). Phenotypic classification revealed a large
significant up-regulation of PLS3 expression in asymptomatic almost sextupling the averaged
control amount (Fig. 49 H). Moreover, SMA I and SMA III disclosed higher expression levels
relative to control as well. Although differences between the latter two groups were not
significant compared to control distinct trends in expression patterns were set (Fig. 49 H).
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7.5.4 Comparative overview in SMN and PLS3 expression on RNA and protein
level in different SMA phenotypes during in vitroMN development
Plotting the data obtained from summaries of the phenotypic classes according to the four
cell populations revealed a conclusive insight into phenotype-specific changes in SMN and
PLS3 expression on RNA and protein level during in vitro development (Fig. 50).
SMN mRNA expression followed a stringent line depicting an almost parallel course in
fibroblasts, iPSCs and smNPCs. Expectedly, SMA I disclosed the least expression level and
healthy control the highest with SMA III and asymptomatic in-between. Admittedly, the
overall intervals did not appear very broad. Just in MN cultures, all cell lines befell a visible
increase in SMN expression with the smallest increment in SMA I and the strongest rise in
healthy controls (Fig. 50 A).
SMN protein expression illustrated a more oscillating course since the overall SMN protein
amount in fibroblasts was astonishingly low in controls, SMA III and asymptomatic. Although
the overall SMN amount rose in subsequent cell populations, the interval between controls
and SMA III/asymptomatic did not match the given SMN1/SMN2 copy number ratio in which
discordant family members were supposed to deliver only 40-70% of healthy controls. Here,
SMA III and discordant expressed comparable SMN amounts in fibroblasts and iPSCs. Only in
smNPCs, the expression rates fit the expected ratios. In MN cultures, SMA III reached approx.
⅔ of control expression whereas asymptomatic expressed ~87%. At least, SMA I depicted a
considerably low expression throughout development (Fig. 50 B). Remarkably, SMA III and
asymptomatic presented nearly identical SMN expression rates on both RNA and protein level.
Solely in MN cultures, there was a drastic increase detectable in asymptomatic group
unusually overtopping control amount.
PLS3 mRNA expression pictured a unique expression course. While in fibroblasts PLS3
expression barely differed among phenotype classes, asymptomatic revealed the highest
expression rate in following cell populations. Surprisingly, SMA I exhibited a continuously high
expression rate as well. From iPSCs onwards, PLS3 expression in healthy controls was
increasingly attenuated. SMA III was constantly the least expressing group apart from MN
cultures in which control r12 expressed barely any PLS3 mRNA. In principle, PLS3 expression
peaked in iPSCs and smNPSCs before expression decremented in MN cultures (Fig. 50 C).
PLS3 protein expression was equally low in fibroblasts and spread then with SMA I as highest
expressing group in iPSCs. SMA III stayed the lowest expressing class in iPSCs and smNPCs. In
smNPCs, expression levels diversified rendering SMA I and asymptomatic the high expressing
classes while healthy controls disclosed a medium expression rate. The overall PLS3
expression levels demonstrated relatively low in iPSCs and smNPCs. Finally, PLS3 levels
remarkably rose in asymptomatic MN cultures exhibiting here an almost 2fold increase
compared to SMA I and SMA III and even a 6fold increase in comparison to control. While
expression levels remained fairly unchanged in control and SMA I MN cultures compared to
those in iPSCs and smNPCs, SMA III presented a surprising augmentation overtaking the
previously mentioned two phenotype classes in PLS3 expression in MN cultures (Fig. 50 D).
Tab. 17 listed the relative expression percentage in comparison to healthy control(s) (100%)
within individual phenotypic groups in specific cell populations. Except for MN cultures (only
control r12), controls meant r12 and COII.2 (in fibroblasts, iPSCs and smNPCs).
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Table 17: SMN and PLS3 expression percentage in phenotypic classes was itemised relative to
healthy control(s) (100%) in cell populations during in vitroMN development
SMNmRNA expression SMN protein expression
Population SMA I SMA III Asymptomatic SMA I SMA III Asymptomatic
Fibroblast 27% 68% 74% 18% 98% 108%
iPSC 27% 64% 65% 46% 89% 84%
smNPC 26% 64% 65% 30% 60% 53%
MN culture 25% 56% 68% 31% 88% 126%
PLS3mRNA expression PLS3 protein expression
Population SMA I SMA III Asymptomatic SMA I SMA III Asymptomatic
Fibroblast 73% 68% 80% 99% 100% 96%
iPSC 90% 61% 110% 138% 51% 100%
smNPC 140% 99% 154% 163% 54% 154%
MN culture 382% 445% 1003% 262% 335% 588%
Fig. 50: Comparative overview in SMN and PLS3 expression during in vitro MN development. (A) On generally
lower levels, SMN mRNA expression proceeded in comparable pattern in fibroblasts, iPSCs and smNPCs with
controls at the top, SMA III and asymptomatic similarly in the middle and SMA I at the bottom-line matching the
SMN1/SMN2 copy number. In MN culture, an overall increment was detected yet leaving the previous expression
pattern unchanged except for broader intervals. (B) SMN protein expression did not exactly display mRNA
expression levels because the SMN amount in controls, SMA III and asymptomatic was basically equal denying
the absence of SMN1 copies in discordant family members. Indeed, SMA I expressed always the poorest while
controls overran SMA III/asymptomatic classes in following cell populations. Still, discordant family members
unusually expressed much SMN particularly asymptomatic in MN cultures (see Tab. 17). (C) PLS3 mRNA
expression depicted a less stringent distribution. While in fibroblasts, expression levels barely differed among
the classes, iPSCs showed a wider spreading with asymptomatic at the top, SMA I and controls following close
and SMA III at lowest expression rates. While asymptomatic prevailed as strongest expressing group which
underlined putative over-expression, controls suffered from a continuous decline in PLS3 expression leaving
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hardly any detectable in MN cultures. Also expression in SMA I dropped to equal levels as in SMA III in MN
cultures. (D) In fibroblasts, equal mRNA amounts were exactly mirrored on protein level. Subsequently, an
expression increase was observable in iPSCs with SMA I at the top, controls and asymptomatic in the middle and
SMA III at the bottom. This picture recurred in smNPCs, however, asymptomatic gradually incremented resulting
in strong expression in MN cultures after all. Also expression in SMA III augmented in MN cultures overrunning
SMA I and controls. SMN and PLS3 mRNA levels were normalised relative to total RNA levels. SMN and PLS3
protein levels were normalised relative to β-actin levels. Apart from MN cultures (control only r12), controls
meant r12 and COII.2 (in fibroblasts, iPSCs and smNPCs). Graphs were summarised from data of Fig. 45, Fig. 46,
Fig. 48 and Fig. 49.
7.5.5 Determination of gems in different SMA phenotypes during MN
development
Concomitantly to SMN loss, diminution of SMN containing foci (“gems”) in the cell nucleus is
a crucial hallmark of SMA. So, the number of gems was determined in all cell populations of
every donor fibroblast line, iPSC line and their derived smNPC lines and differentiated MN
cultures. Fig. 51 pictured immunocytochemical staining of SMN in different cell lines
representative for the four phenotypic classes (i.e. healthy control, SMA I, SMA III and
asymptomatic discordant) in varying developmental stages (i.e. original fibroblasts, derived
iPSCs, corresponding smNPCs and differentiated MN cultures on day 8 and day 27). On the
one hand, SMN was diffusely dispersed in the cytoplasm, on the other hand, there were gems
present as distinct nuclear agglomerations with obviously variable size depending on the
nucleus size.
In fibroblasts, control line JS-AF abundantly exhibited gems, every now and then even several
gems per nucleus. Already in discordant sibling pair ML13 and ML14 gems were more sparsely
distributed whereas in SMA I line ML17 there were barely found any gems (Fig. 51).
In iPSCs, gems were wide-spread in control line r12 whereas discordant sibling pair HGK21.1
and HGK22.17 contained visibly fewer gems in densely grown iPSCs. SMA I line possessed no
noticeable gems (Fig. 51).
In smNPC control line r12, gems were distributed in fewer numbers in comparison to iPSCs in
spite of a similarly growth density. Discordant family members HGK13 and HGK16 disclosed a
visible gem number comparable to previous cell populations. The same held true for SMA I
line HGK1 in which only sporadic gems could be visualised (Fig. 51).
In MN culture on day 8, a considerable number of gems was counted in control line r12. In
discordant family 2 members HGK21.1 and HGK22.18, gems were more scattered within the
mixed neuronal culture whereas SMA I line HGK1 barely displayed any gem (Fig. 51).
After three week maturation, gems were frequently recorded in mixed MN culture of control
line r12 on day 27. In discordant sibling pair HGK28.9 and HGK27.13, gems amounted to a
lower number while SMA I line HGK1 failed to present recognisable gems at all (Fig. 51).
For quantification (Fig. 52), gems were manually counted and their ratios calculated relative
to total number of nuclei. Fibroblasts: 150-300 cells in total from duplicates (n=2); iPSCs: 950-
1,300 cells in total from triplicates (n=3); smNPCs: 1,200-1,700 cells in total from triplicates
(n=3); MN cultures: 300-450 cells (day 8) and 200-550 cells (day 27) in total from three
independent MN differentiation runs (n=3).
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Fig. 52: Quantitative determination of gem number in different cell populations. (A) In fibroblasts, massive gem
reduction was overt in SMA I line ML17 while discordant family members displayed a minor decrease. Still,
diminished gem numbers were significant relative to controls. (B) Phenotypic groups indicated significant gem
decrease in SMA I and asymptomatic while gem reduction in SMA III remained insignificant as among non-control
groups. (C) In iPSCs, non-control lines exhibited very reduced gem numbers. Nonetheless, SMA I line HGK1
presented the fewest number. (D) Summarising single results to phenotypic classes pictured a very significant
diminution in SMA I, SMA III and asymptomatic relative to controls. (E) In smNPCs, SMA I line HGK1 disclosed a
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significantly low gem number whereas discordant family lines possessed overall more gems, yet compared to
control line r12 visible reduced. (F) Phenotypic grouping evidently visualised significant decline in gem number
in SMA I, SMA III and asymptomatic relative to controls. Clearly, discordant family members equally showed a
medium gem number which was significantly higher than SMA I gem number (relative to asymptomatic). (G) In
early MN culture (day 8), only SMA I line HGK1 disclosed a significant gem reduction in comparison to r12. Indeed,
discordant family lines exhibited a decreased gem number, still without significance due to an unexpectedly
lower total gem number in control r12. (H) In phenotype classes, gem number decrease was proved with strong
significance in non-control phenotypes on the other hand. SMA I kept showing the fewest gems while SMA III
and asymptomatic presented a moderate reduction. (I) In late MN culture (day 27), strongest significant decline
was observable in SMA I HGK1. Gem numbers of individual discordant family lines remained at medium high
level. (J) Phenotype classification illustrated a strong significant reduction in SMA I and asymptomatic with fewest
gem number in SMA I again. Medium expression clearly represented more SMN2 copy numbers in SMA III and
asymptomatic. Error bars represented ± SEM of duplicates in fibroblasts (n=2) and triplicates in all other cell
populations (n=3). MN cultures displayed data of three independent MN differentiation runs (n=3)
(Kruskal-Wallis test, p <0.05 = *, p <0.01 = **, p <0.001 = ***). Note that control COII.2 was excluded from
analyses in MN culture day 8 and day 27.
In fibroblasts, both controls exhibited an extraordinarily high gem number virtually furnishing
every nucleus counted with more than one gem on average. Contrarily, gem number in SMA I
line ML17 was diminished in strong significance. Gems in discordant family members
amounted to a considerable number so that corresponding reduction was insignificant relative
to control line JS-AF (Fig. 52 A). Summing up these results according to phenotypic classes
strikingly pointed out a significant decrease in gem numbers between controls and SMA I and
asymptomatic, respectively. However, the difference between SMA III and healthy controls
was insignificant as amongst non-control groups (Fig. 52 B).
In iPSCs, control lines r12 and COII.2 contained almost equal gem numbers whereas other cell
lines exhibited a remarkable decrease in gem number with SMA I HGK1 showing the fewest
gems and significant reduction. Gem number in discordant family members was found ~2-
2.5fold higher than HGK1 but still lower than in controls (Fig. 52 C). Phenotypic classification
mirrored this consistent gem number distribution with a very significant decline in gem
number relative to controls: SMA I delivered only ~13% while SMA III and asymptomatic
discordant equally exhibited ~26-27% gems (Fig. 52 D).
smNPCs control lines r12 and COII.2 comprised a reasonable gem number. Gem number in
SMA I HGK1 was very significantly lowered whereas gem numbers in discordant family
members resided at higher levels (Fig. 52 E). Grouped according to phenotypes gem number
was very significantly lessened in SMA I smNPCs (~18%) and still significantly reduced in
discordant family members compared to controls. SMA III and asymptomatic discordant
reached ~57-59% of gem number in controls rendering also a significant difference when
asymptomatic are compared to SMA I (Fig. 52 F).
In MN cultures on day 8, control line r12 revealed a relatively high gem number. Thus,
minimised gem numbers in discordant cell lines was not significant when likened to control
r12. In general, within discordant family members gem number consistently ranged between
~47-70% relative to control. SMA I HGK1 kept displaying a significant diminution in gem
number relative to r12 (Fig. 52 G). Phenotypic classification again disclosed a significant
reduction in SMA I, SMA III and asymptomatic discordant relative to control r12. SMA I
possessed only ~13% of gems in controls whereas SMA III and asymptomatic contained ~56%
and ~57%, respectively ranging significantly higher in comparison to SMA I (Fig. 52 H).
MN cultures on day 27 illustrated a similar picture as on day 8 with decreased gem number in
non-control cell lines. However, after three weeks maturation, control line r12 demonstrated
the most gems. An overall higher gem number on average in discordant family members was
observed remaining insignificant in comparison to control r12. In addition, SMA I line HGK1
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presented a highly significant drastic decrease in gem number (Fig. 52 I). The phenotypic
overview depicted an identical gem number distribution as before the maturation phase.
Relative to controls, gem number in SMA I was very significantly lowered (~11%) and markedly
decreased in SMA III and asymptomatic (~59% and ~56%, respectively). Yet, significant
difference was solely determined between asymptomatic and control. (Fig. 52 J).
Scrutinising gem number in so many cell lines of different populations enabled a thorough
insight in developmental changes (Fig. 53). Generally, in fibroblasts the highest gem number
was found in all four phenotype classes. Nevertheless, gem number in SMA I stayed on very
low level throughout further cell populations. Conversion into iPSCs led to a massive drop in
gem number in controls, SMA III and asymptomatic siblings quenching the latter ones almost
to the level of SMA I. Additionally, in smNPCs the least differences among the four classes
were visible. Motoneuronal differentiation again broadened the intervals in gem number
between the four phenotypes setting controls at top, SMA III and asymptomatic in the middle
and SMA I at the bottom line. Remarkably, discordant family groups (SMA III and
asymptomatic) presented nearly equal gem number in all cell populations.
Taken together, albeit there were overall differences in total gem numbers within single
phenotypic classes dependant on the cell population, SMN deficiency was solidly mirrored in
various cell types by gem number determination. SMA I contained just 12% of control gems
on average while in SMA III and asymptomatic averaged 52% and 51% of control gems were
observable. Percentage of gem numbers in comparison to healthy control (100%) was
itemised in Tab. 18.
Fig. 53: Overview of gem number in different cell
populations among four phenotypic classes.
Changes during developmental process to mature
MN cultures convincingly reflected phenotype in
severely affected SMA I as well as mildly affected
SMA III since gross SMN deficiency in SMA I
resulted in general poor gem formation whereas
more SMN2 copies in SMA III visibly led to a
medium gem number relative to control. Notably,
asymptomatic siblings shared almost equal gem
numbers as their SMA III affected brothers. Except
for MN cultures (control r12 only), controls meant
r12 and COII.2 (in fibroblasts, iPSCs and smNPCs).
Graph was summarised from data of Fig. 52.
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Table 18: Percentage of gem number in phenotypic classes was itemised relative to healthy
controls (100%) in cell populations during in vitroMN development
no. gems
Population SMA I SMA III Asymptomatic
Fibroblast 5% 60% 56%
iSPC 13% 26% 27%
smNPC 18% 58% 60%
MN culture d8 14% 57% 58%
MN culture d27 11% 59% 56%
7.5.6 Measurement of neurite length in MN cultures of different SMA
phenotypes
To examine whether PLS3 over-expression also impacted on the neuronal outgrowth of
differentiated smNPCs, on day 8 MN cultures of all 13 cell lines were immunocytochemically
stained for neuron-specific filament marker β III-tubulin and motoneuronal filament marker
SMI-32, respectively. The individual neurite outgrowth of HB9+, ISL1+or SMI-32+MNs was then
measured based on an assay developed by Kristina Dobrindt (personal communication) (Fig.
54).
The overall neurite length did not significantly differ between the individual cell lines neither
with β III-tubulin as general neuronal marker (Fig. 55 A) nor with SMI-32 as motoneuronal
marker (Fig. 55 C). Grouping the results into the four disease-related phenotypic classes did
not demonstrate a significant difference between the phenotypes either (Fig. 55 B, D).
Principally, the variance in neurite length was very broad.
The average length of β III-tubulin+neurites generally ranged between 70-80 µm independent
of the genetic background. Only HGK28.9 exhibited a mean neurite length of 90 µm, yet also
showing the highest variance in neurite length (Fig. 55 A). On average, the neurites in SMI-32+
MNs appeared basically longer, however, the length was also more variant (100-160 µm)
between the individual cell lines (Fig. 55 C). Indeed, summing up the latter results according
to the phenotype levelled these differences because within the four phenotypic classes the
neurite length of SMI-32+ MNs was nearly equal ranging between 117-130 µm (Fig. 55 D).
Fig. 54: Exemplary immunocytochemical staining of β III-tubulin+ (red) and SMI-32+ (green) neurites,
respectively, in MN cultures of representative control line r12 on day 8. Individual neurite outgrowth of
HB9+ or SMI-32+ MNs (both green) was assayed (purple lines) and corresponding distances (white)
registered. Nuclei were counterstained with DAPI (blue) (scale bar 100 µm, valid for all images).
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7.6 Visualisation of axonal growth cones in MN cultures
The presence of PLS3 at motoneuronal axon tips is regarded as one key feature of
PLS3-mediated protection. Differentiation of patient-derived iPSCs via smNPCs into MN
culture renders possible to examine whether PLS3 in asymptomatic siblings co-localises with
actin at putative MN growth cones. Originally, endogenous Pls3 accumulated in F-actin rich
growth cones of primary mouse MNs (Oprea et al. 2008). In PLS3 over-expressing mouse
fibroblasts, an overt strong co-localisation was visible at filopodia (Ackermann et al. 2013).
Axonal outgrowth was visualised by punctiform seeding of pMN-primed smNPCs and further
cultivation for three weeks (6.8.1). Presence of growth cones was verified by triple
immunocytochemical staining and possible co-localisation of actin and PLS3 assessed by
confocal laser scanning microscopy in nine samples. Evidently, MAPT+ axonal protrusions
ended in cones with very delicate thin branches which did contain PLS3 and actin (Fig. 56 A).
Fig. 56: (A) Visualisation of growth cones in maturing MN cultures from healthy control (r12) and PLS3 discordant
siblings (SMA III patient HGK27.13 and his asymptomatic sisters HGK21.1, HGK21.8 and HGK28.9) on day 27. MAPT+
(magenta) axons ended in delicately arborized growth cones (arrows) detectably comprising phalloidin-actin (red)
and PLS3 (green). Co-localisation appeared already in control r12 and asymptomatic HGK21.1, HGK21.8 and
HGK28.9 while such was not directly visible in SMA III HGK27.13. Following figures presented growth cones of
control r12 (B), SMA III HGK27.10 (C) and asymptomatic HGK28.9 (D) with single staining in left panels and an overlay
in the centre. Growth cones were magnified in PLS3/actin merge and collected Z-stacks analysed (right panels).
Subordinated graph pictured fluorescence intensity of given YZ plane for both PLS3 (green) and actin (red) when cut
distance [nm] was plotted against intensity. (B) Sagittal plane of control growth cone visualised PLS3 and actin nearly
equally distributed, however, frequently co-localised at the rim. Overlaid signal intensities supported this
impression. (C) In SMA III HGK27.10, presence of PLS3 and actin was visibly proved. Yet, distinct co-localisation and
congruent signal intensity patterns as in control r12 were not detected. (D) In asymptomatic HGK28.9, intense PLS3
expression was imaged particularly in the rod end and growth cone central domain whereas actin allocated
especially at the edges. Remarkably, PLS3 observably concentrated in such actin-rich areas. Z-stack analysis of such
foci pictured clear PLS3/actin co-localisation. Additionally plotted signal intensities delineated in areas of strong
actin accumulation an equally intense PLS3 concentration (scale bar 20 µm, A; 10 µm B-D).
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In control line r12, confocal laser scanning microscopy revealed an almost even distribution of
actin and PLS3 in the growth cone resulting in frequent co-localisation. Z-stack analysis
confirmed visible co-localisation of PLS3 and actin. Intensity measurements backed view of
equal PLS3 and actin allocation (Fig. 56 B).
On the other hand, SMA III patient HGK27.10 did not display such an equal distribution
(Fig. 56 C). Indeed, PLS3 and actin were also present in this growth cone, however, Z-stack
analysis failed to denote consistent co-localisation. Moreover, signal intensity graphs rather
shifted between each other.
In asymptomatic HGK28.9, intense PLS3 expression was observed in axon rod and growth cone
centre while actin accumulated especially at the rims (Fig. 56 D). Intriguingly, PLS3 allocated
in such actin-rich areas. Such co-localisation was visibly corroborated by Z-stack analyses and
signal intensity. Corresponding graphs delineating strong actin expression went along with
concomitantly high PLS3 expression yet not vice versa since areas of strong PLS3 expression
(e.g. axonal rod) were almost devoid of detectable actin. SMA I line HGK1 failed to exhibit
usable growth cones (data not shown).
7.7 Mixed motoneuronal cultures exhibited early signs of NMJ
formation when co-cultured with human myotubes
Signal transduction to target muscles is the essential feature of proper functionality in
motoneurons. Generation and maintenance of NMJs has ever since been in the focus of
elucidating the pathomechanism of SMA (Kariya et al. 2008; Kong et al. 2009; Bowerman et
al. 2012).
Even though there are miscellaneous co-culture methods published in which putative NMJ
formation is displayed, no robust standard protocol exists so far (Marchetto et al. 2008; Hu et
al. 2009; Guo et al. 2011; Son et al. 2011; Stockmann et al. 2011). Moreover, co-culturing
myotubes and motoneurons is an extremely time-consuming process for it requires a long
cultivation period until a fully stable connection between pre- and post-synaptic sites is
accomplished. Stockmann and colleagues showed in 2011 that even after 12–14 weeks
in vitro, cultivated MNs were obviously still proceeding in NMJ-development (Stockmann et
al. 2011).
In order to examine the most appropriate protocol, several different methods were tried out
varying in cell types, medium composition or addition of growth factors and small compounds
(data not shown). Initially used murine myocyte line C2C12 was replaced by healthy human
myocyte control line hMC to obtain a single-species xeno-free in vitro system. Human myocyte
line hMC was a kind gift of Prof. Hanns Lochmüller (University of Newcastle, UK). When
motoneuronal neurospheres were seeded on top of a human myotube layer, intense neuronal
outgrowth was visible contacting neighbouring myotubes (Fig. 57).
However, prolonged co-cultivation in motoneuronal maturation medium MN1 resulted only
sporadically in very early developmental signs of NMJ formation indicated by punctual
bungarotoxin positive (BTX+) AChR clustering nearby myotube nuclei accumulation.
Nonetheless, obvious AChR clustering was mostly visible in close proximity to axons (Fig. 58).
Moreover, the addition of laminin and agrin – an extracellular matrix (ECM) proteoglycan – is
regarded as beneficial for NMJ formation. Agrin is synthesised by the elongating MN axon and
secreted into the synaptic cleft. There, it essentially fosters AChR clustering on skeletal muscle
surfaces during maturation (Weston et al. 2007). Both ECM components were also part of the
enriched co-culture medium utilised by Guo and colleagues. Yet, a remarkable increase in BTX+
Results 123
AChR clusters was not observable when our MN1 medium was supplemented with laminin
and agrin (data not shown).
Fig. 57: Phase image of co-culture of human myotubes hMC with motoneuronally primed neurosphere derived
from SMA III iPSC line HGK13. Immediately after plating, strong neuronal outgrowth (arrows) took place on day 4
starting from the seeded neurosphere (right). The axonal protrusions evidently contacted vicinal thick
multi-nucleated myotubes (arrowhead) (scale bar 200 µm).
Another possibly benefiting option was presented by Peng and colleagues: In Xenopus laevis,
they demonstrated that upon neurotrophic withdrawal MNs had the propensity to induce
synaptogenesis on contact with the target muscle cell (Peng et al. 2003). During
synaptogenesis, the MN axon outgrowth had eventually to halt in order to allow the
establishment of a stable connection between the pre-synaptic and post-synaptic partners
(Sanes et al. 1999). Neurotrophic factors such as BDNF or GDNF down-regulated the
expression of agrin in MNs thereby inhibiting synaptogenesis (Peng et al. 2003). On the other
hand, Schwann cell-conditioned medium (SC-CM) was able to override the retarding effects
of neurotrophic factors concerning synapse formation in vitro (Peng et al. 2003).
Thus, mixed motoneuronal cultures were sown onto a human myotube layer and ever since
co-cultured with SC-CM for seven weeks. Murine Schwann cell line iMS32 was a kind gift of
Rebecca Conrad/Dr. Michael Karus (University of Bochum, Germany). Obviously, SC-CM
strongly enhanced clustering of BTX+ AChRs on the myotube surface (Fig.  59). Grooved
plaque-like patches were spread over large areas of the myotube surface. Many axonal
protrusions of SV2+ mature neurons extended towards the myotubes and contacted AChR
plaques. Nevertheless, a clear direct co-localisation of a presumable MN growth cone and an
AChR patch was not detectable so far.
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Fig. 59: (A) Immunocytochemical staining revealed that BTX+AChRs (red) strongly clustered on myotube surface
when co-cultured with motoneuronally differentiated iPSC line HGK16 in Schwann-cell conditioned medium
(SC-CM) for seven weeks. Note the plaque-like wide-spread AChR agglomeration on the myotube surface as in
comparison to single sparsely scattered BTX+punctae after 15 days co-culture in Fig. 58. (B) Mature SV2+ neurons
(green) did extend axonal protrusions towards these AChR clusters (arrows). (C) However, a clear NMJ-like
co-localisation was not identifiable yet. Nuclei were counterstained with DAPI (blue) (scale bar 100 µm, A, B;
20 µm, C).
Fig. 58: Immunocytochemical staining
visualized punctual bungarotoxin (BTX)
positive AChR agglomeration (red) on
hMC myotube surface in close
proximity to neurofilament (NF)
positive axons (green) of
motoneuronally differentiated control
iPSC line r1 after 15 days of co-culture.
Note several myonuclei were strung
together in the early myotube. Nuclei
were counterstained with DAPI (blue)
(scale bar 20 µm).
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7.8 Application of iPSC-derived lt-NES®SCs for examination of
cell-specific responsiveness to VPA treatment
Among potential therapeutic agents for curing SMA, histone deacetylase (HDAC) inhibitor
valproic acid (VPA) played a promising role (Brichta et al. 2006; Swoboda et al. 2011). VPA
exerted its beneficial effect by loosening chromatin structure via histone hyperacetylation,
thus amongst others stimulating transcription of remaining SMN2 copies in SMA patients
(Garbes et al. 2013). However, deeper investigations demonstrated different responses
towards VPA administration in patients’ cohorts, resulting in an ameliorative, indifferent or
damaging effect in patients. Obviously, patients reacted as positive (pos-) responders,
non-responders or negative (neg-) responders thwarting VPA application as prospective drug
(Brichta et al. 2006; Kissel et al. 2011; Piepers et al. 2011).
To elucidate the molecular reasons of this divergent responsiveness, in 2013 Garbes and
colleagues published an in-depth study in which different tissues of VPA pos-, non- and
neg-responders were treated with VPA revealing altered fatty acid uptake as underlying
rationale. In patients’ blood and fibroblasts, response to VPA treatment was measured by
changes in expression of FL-SMN2mRNA and SMN protein (Garbes et al. 2013).
Furthermore, VPA was known to interfere with neuronal GABA synthesis leading to elevated
GABA levels in GABAergic CNS neurons (Johannessen 2000). This hypothesis would mean a
stop of GABA degradation in VPA pos-responder thereby causing an increase in GABA release.
So, respective lt-NES®SC lines were derived from control ESC line HB9-GFP (Placantonakis et
al. 2009), pos-responder iPSC line HGK1 and non-responder iPSC line HGK4 according to Koch
et al., 2009, and differentiated into GABAergic neurons whose supernatant GABA release was
determined by ELISA after manufacturer’s instructions (see (Garbes et al. 2013)).
When lt-NES®SC lines were immunocytochemically stained, all three cell lines evidently
displayed pan-neuronal markers SOX2 and nestin. In addition, typical rosette-markers ZO-1
and PLZF were recognisably picturing the petal-like arrangement of rosette-like NSCs. Thus,
valid lt-NES®SC traits were proven in these cell lines (Fig. 60 A). Once lt-NES®SC lines were
subjected to directed GABAergic differentiation, immunocytochemical staining revealed
considerable presence of GABAergic neurons indicated by expression of GABAergic marker
GAD65/67 and concomitantly neuronal marker β III-tubulin (Fig. 60 B).
Subsequently, 500 µM VPA were administered to GABAergic neurons for nine days. RNA was
sampled and checked for SMN expression by qRT-PCR. Clearly, VPA exerted a boosting effect
in pos-responder HGK1, resulting in augmented SMN mRNA level. On the contrary, control
ESC and non-responder HGK4 did not illustrate a shift in SMN levels (Fig. 60 C). Finally,
supernatant of GABAergic cultures was collected and assayed for GABA content. Indeed, a
significantly increased GABA release was measured in pos-responder HGK1 whereas control
ESC remained asymptomatic by VPA application. Non-responder HGK4 even displayed a
detectable decline in GABA release (Fig. 60 D).
Taken together, VPA responsiveness was maintained in GABAergic neurons not only pointing
out the importance to verify cellular patient-specific features but also the feasibility and
reliability of iPSC-derived neuronal in vitro systems.
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Fig. 60: Assessment of VPA-mediated GABA release in lt-NES®SC-derived GABAergic neurons of VPA
pos-responder HGK1, VPA non-responder HGK4 and control ESC line HB9-GFP. (A) Immunocytochemical staining
demonstrated characteristic petal-shape arrangement of rosette-like lt-NES®SCs with PLZF+ (green) cells fanned
around the ZO-1+ (red) apical centre. Additional presence of wide-spread expression of general neuronal markers
SOX2 (red) and nestin (green) verified lt-NES®SC character. (B) Following directed GABAergic differentiation, all
three cell lines featured overt presence of true GABAergic neurons marked by GABAergic neuron marker
GAD65/67 (green) and neuronal marker β III-tubulin (red) in immunocytochemical staining. Nuclei were
counterstained with DAPI (blue) (scale bar 20 µm). GABAergic neurons were treated with 500 µM VPA for nine
days. Subsequently, expression of SMN mRNA was determined by qRT-PCR in neuronal RNA extracts. (C) VPA
treatment raised SMN levels in pos-responder HGK1 while control and non-responder HGK4 remained
unaffected. Expression was normalised to PPIB (cyclophilin B) levels. Analysis represented data from one single
GABAergic differentiation (n=1). (D) Quantifying relative GABA release in lt-NES®SC-derived GABAergic neurons
recorded a significant approx. 2.5fold elevation in GABA release in pos-responder HGK1 while non-responder
HGK4 even disclosed a significant diminution in GABA release. Mock comprised treatment with VPA solvent (i.e.
H2O dest.). Error bars represented ± SD of duplicates (n=2) (two-tailed Student's t-test, p <0.05 = *,
p <0.001 = ***). Corresponding donor fibroblast cell lines and VPA status (PR=pos-responder,
NR=non-responder) were bracketed below cell line names. Figure adapted from original publication (Garbes et
al. 2013).
Discussion 127
8. Discussion
8.1 iPSC-derived in vitro cell culture models grant more exact access
to SMA-specific features in MNs than animal models
Several well established SMA mouse models reasonably phenocopy different stages of disease
severity in humans (Hsieh-Li et al. 2000; Monani et al. 2000; Le et al. 2005; Bowerman et al.
2009). Thus, they and further animal models provide a valuable platform to investigate the
molecular and cellular pathomechanisms inhering SMA.
Examination of the effects of SMA modifying genes or drug responsiveness is of particular
interest in SMA research since they bespeak deeper evidence into SMA pathophysiology and
may grant access to possible therapeutic measures. Plastin 3 (PLS3), an actin bundling
cytoskeletal protein, was discovered as protective modifier in SMN1-deleted siblings of
discordant SMA families (Oprea et al. 2008). This finding was affirmed by further studies
(Stratigopoulos et al. 2010), yet PLS3 over-expression was not detected in blood of all
asymptomatic individuals (Bernal et al. 2011). A PLS3 over-expressing SMA mouse model
exhibited general improvements in MN-synapse architecture, function and neuromuscular
connectivity (Ackermann et al. 2013). However, the overall survival rate was not extended
whereas human PLS3 over-expressing individuals exhibit no SMA deficits and possess a regular
life expectancy.
Hence, every animal disease model can only approximate the true human state incompletely.
Since living human motoneurons cannot be sampled from SMA patients, the actual target
tissue of SMA remains inaccessible. So, the exact events of SMA pathology stay elusive. This
gap between SMA animal models and human SMA patients was bridged by the introduction
of direct reprogramming technique in which patient-derived somatic cells are converted into
induced pluripotent stem cells (iPSCs) (Takahashi et al. 2006; Takahashi et al. 2007). Those
iPSCs are capable of differentiating into cells of various lineages so that also human
motoneurons were cultivable in vitro (Dimos et al. 2008; Ebert et al. 2009). Indeed,
iPSC-derived motoneurons were successfully obtained from SMA I patients displaying the
characteristic features of SMA pathology, e.g. MN degeneration, diminished number of gems,
reduced SMN levels and phenotypic rescue by SMN increase (Ebert et al. 2009; Chang et al.
2011).
In order to circumvent the aforementioned shortcomings of a PLS3 over-expressing SMA
mouse model, the establishment of a personalised iPSC-derived in vitro cell culture model
from PLS3 discordant family members and VPA (non-)responders was the main goal of this
doctoral thesis.
8.1.1 State-of-the-art reprogramming via SeV technology reliably delivered
integration-free iPSC lines from PLS3 discordant fibroblasts
The ectopic expression of four pluripotency-related reprogramming factors (4F = OCT4, SOX2,
KLF4 and c-MYC) converts human fibroblasts into iPSCs (Takahashi et al. 2007). In total, eight
fibroblast cell lines (5.8.3, Tab. 13, 7.1, Fig. 10) were reprogrammed in this thesis. Classical
reprogramming strategy involved 4F introduction via retrovirus infection. Dr. John Dimos from
iPierian Inc. (San Francisco, USA) succeeded in reprogramming ML17 (SMA I, VPA responder),
ML73 (SMA II, VPA non-responder) and family 1 siblings ML101 (asymptomatic, PLS3
discordant) and ML102 (SMA III, PLS3 discordant) by 4F retroviruses.
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Retroviral vectors represent a suitable tool to stably introduce exogenous DNA into mitotic
mammalian host cells (Barquinero et al. 2004). The transfer of the four Yamanaka factors
during the first reprogramming studies was carried out by such retroviral transduction
rendering a reasonably moderate efficiency rate of 0.01-1% (Takahashi et al. 2006; Robinton
et al. 2012). After the transduction, multiple random insertions (1-40) of the four factors in
varying copy numbers took place into the host genome (Wernig et al. 2007; Okita et al. 2011).
Therefore, standard technology applied for reprogramming per se raised serious concerns
regarding the safe use of genetically modified cells bearing exogenous proviral transgenes
randomly integrated in their genome (Sun et al. 2010; Sancho-Martinez et al. 2011).
Furthermore, transplantation of heterogeneous iPSC populations containing cells with
incomplete reprogramming or reactivation of transgenic oncogene c-Myc had been strongly
associated with tumorigenicity in mouse models (Okita et al. 2007; Miura et al. 2009). Thus,
insufficient silencing of proviral transgenes may represent a serious problem for subsequent
applications (e.g. lineage-specific differentiation) (Sommer et al. 2012; Toivonen et al. 2013)
although the specific pMXs-plasmid backbone ought to promote transgene silencing
(Takahashi et al. 2006).
Indeed, retrovirus-mediated reprogramming failed in generating proper iPSC colonies from
human fibroblast cell lines of SMA discordant family 2 (7.1, Fig. 10) asymptomatic members
(ML11, ML13) and SMA III patients (ML12, ML14) when carried out at the Institute of
Reconstructive Neurobiology (Bonn) during this study. An inverse correlation between
reprogramming efficiency and donor age and passage number was reported (Sommer et al.
2010). Considering a relatively elevated donor age (see 5.8.3, Tab. 13) as well as a high passage
number, fibroblast cell lines ML11, ML12, ML13 and ML14 might behave reluctantly towards
retroviral reprogramming.
To overcome these pitfalls, diverse alternative reprogramming methods have been developed
within the recent years: Subsequent removal of transgenes from iPSCs by transposon-based
approaches with piggyBac (Woltjen et al. 2009) or excision of a loxP site flanked
reprogramming cassette via Cre recombinase treatment (Kaji et al. 2009); transient 4F
expression by adenoviruses (Stadtfeld et al. 2008; Zhou et al. 2009b) or episomal vectors (Yu
et al. 2009); omission of any DNA vector like zinc finger nuclease (ZFN) technology
(Ramalingam et al. 2012), application of synthetic 4F mRNAs (Warren et al. 2010), 4F proteins
(Kim et al. 2009; Zhou et al. 2009a) or miRNAs (Anokye-Danso et al. 2011; Miyoshi et al. 2011).
Despite this broad line-up of various alternative methods, unequivocal backlashes inhere in
all of them: Labour-intensive screening for excised transgene-free iPSC lines or tedious
sub-cloning, cumbersome repeated transfection cycles and an overall very poor efficiency
lessening the original efficiency rate (Robinton et al. 2012).
To avoid these overt deficits, a novel reprogramming approach by non-integrative Sendai virus
(SeV) was chosen for reprogramming human fibroblast cell lines ML11, ML12, ML13 and ML14
turning out as efficient and successful method in our hands. The non-integrative RNA SeV
replicates only in the cytoplasm. Hence, neither a DNA-intermediate nor integration into the
host genome will occur. SeV vectors simply decrease over time delivering transgene-free iPSC
lines (Fusaki et al. 2009).
Patients’ fibroblasts tolerated single spinfection with 4F SeV vectors well (7.1, Fig. 12).
Time-lapse analyses pictured the process of morphological conversion from fibroblast to iPSC
resulting in emergence of typical iPSC colonies (Araki et al. 2010). Every now and then, the
reprogramming process is not completed yet and gets stuck in intermediate states instead
(Mikkelsen et al. 2008). Therefore, accurate choice of putative iPSC colonies is essential for
further propagation and cell line integrity. Intact new iPSC colonies are characterised by
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roundish colony form, flat growth behaviour, small cell body with high nucleus/cytoplasma
ratio and prominent nucleoli and a distinct well-defined edge to the surrounding MEF-feeder
layer (Takahashi et al. 2007; Smith et al. 2009). Indeed, SeV-mediated reprogramming yielded
a high number of putative iPSC colonies on primary plates. Only colonies fulfilling the
aforementioned obvious morphological quality criteria were chosen from which scores of
clonal iPSC lines were picked from every target cell line (see 10.1, Tab. 19).
Summarised, eight fibroblast cell lines of different SMA background were successfully
reprogrammed into iPSCs.
8.1.2 Human iPSC lines are validated as fully pluripotent
Validation of iPSCs is mandatory to prove full pluripotency and to reject faulty and
inappropriate iPSC clones. Cellular conversion during reprogramming is not always complete.
Thus, cells may become trapped in intermediate states (Chan et al. 2009). These partially
reprogrammed cell lines show reactivation of a distinctive subset of SC-related genes, yet an
incomplete repression of lineage-specifying transcription factors (Mikkelsen et al. 2008).
Repeatedly, possible iPSC colonies stopped growing on primary TC dishes, collapsed or began
excessive proliferation with characteristic brown outgrowth (7.1, Fig. 13 A). Therefore, also
SeV-mediated reprogramming gave rise to such improper intermediate states.
Hence, assessment of successful reprogramming commenced with identification of compact
colonies on primary TC dishes. Such putative iPSC colonies had distinct borders with
well-defined edges and they were comprised of cells with a large nucleus, bigger nucleoli and
scant cytoplasm (Robinton et al. 2012). Exclusively, colonies fulfilling this primary morphologic
quality criterion were picked (7.1, Fig. 13 B).
However, only a combination of several criteria reliably verifies bona fide pluripotency in
human iPSCs: Pluripotent SCs are karyotypically normal (Brivanlou et al. 2003), possess a
distinctive nuclear architecture concerning lamina, nuclear speckles and heterochromatin
domains (Meshorer et al. 2006) and exhibit rapid proliferative behaviour with a shortened
G1-phase (Ghule et al. 2008). In addition, pluripotent SCs express typical surface markers
(SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81), a unique set of miRNAs, telomerase, alkaline
phosphatase and pluripotency sustaining TFs OCT4, SOX2 and NANOG whose promoters are
hypophosphorylated reflecting their transcriptionally active state (Nichols et al. 1998; Mitsui
et al. 2003; Suh et al. 2004; Wernig et al. 2007; Smith et al. 2009).
Upon further propagation, human iPSC lines HGK13, HGK16, HGK21, HGK22, HGK27 and
HGK28 stably grew and maintained typical pluripotent morphology throughout passaging
(7.2.1, Fig. 14). In addition, all iPSC lines were AP+ and expressed typical pluripotency surface
markers (7.2.1, Fig. 14). This held also true for iPSC SMA I line HGK1 and SMA II line HGK4
(Garbes et al. 2013).
Albeit standard karyotyping was frequently observed in publications to prove genomic
integrity in iPSCs, it did not suffice our quality requirements because more subtle mutations
were not covered. Moreover, established human iPSC lines initially declared as “genomically
intact” after traditional karyotyping exhibited genomic aberrations which cannot be ruled out
to interfere with subsequent applications (Hussein et al. 2011). Thorough SNP-array analyses
of iPSC lines HGK13, HGK16, HGK21, HGK22, HGK27 and HGK28 verified genomic integrity in
all respective clones (7.2.3, Fig. 16, Tab. 16). Lines HGK1 and HGK4 also passed this quality
criterion (Garbes et al. 2013).
Possible drawbacks in using retroviral reprogramming were disclosed in examining transgene
silencing in HGK1, HGK4, HGK13 and HGK16. The latter both iPSC lines still exhibited residual
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transgene activity (7.2.4, Fig. 17) as HGK1 did (Garbes et al. 2013). Even though no broad
silencing defect was detectable, leaky exogenous transgenes would perhaps yield unknown
detrimental effects in future applications, yet some studies reported no inhibition of MN
differentiation by persistent transgene expression (Boulting et al. 2011). In contrast,
generated own iPSC lines HGK21, HGK22, HGK27 and HGK28 were demonstrably
transgene-free. Neither did they express SeV surface marker protein HN (7.2.5, Fig. 18) nor
did they contain viral NP mRNA after several passages in culture (7.2.5, Fig. 19). Moreover,
this fact underlined the importance of analysing more than one clone per iPSC line to skip
problematic clones in case. Unfortunately, just one single previously unvalidated clone from
HGK1, HGK4, HGK13 and HGK16 was delivered by iPierian Inc.
To verify pluripotency in reprogrammed cells, it must be demonstrated that they are capable
of differentiating into all cell types in the developing organism. By the formation of embryoid
bodies (EBs), spontaneously formed spherical SC clusters resembling the gastrulating embryo,
the development of all three germ layers in vitro was achieved (Itskovitz-Eldor et al. 2000).
Certainly, every investigated iPSC line generated progeny of all three germ layers (7.2.6,
Fig. 20) and (Garbes et al. 2013). Nonetheless, EB-formation pictured just random
differentiation processes lacking the complex organisational interplay of embryonic
organogenesis. Hence, a stronger quality criterion represented in vivo data. Unlike with mouse
iPSCs, injection into a host blastocyst resulting in germ line competent chimeras at last (Okita
et al. 2007) was not accomplishable with human iPSCs for ethical reasons albeit human/mouse
chimeras were generated with human ESCs (James et al. 2006) which was legally not allowed
in Germany. Instead, teratoma formation assay was performed when reprogrammed cells
were injected into immuno-compromised SCID mice producing a teratoma-like neoplasia
which contained offspring of all three germ layers (Smith et al. 2009). Verifiably, all iPSC lines
developed into tissues of different embryonic lineages (7.2.7, Fig. 21) and (Garbes et al. 2013).
In conclusion, novel state of the art SeV reprogramming technique was successfully applied to
obtain integration-free fully characterised iPSC lines from PLS3 discordant SMA family
members.
8.2 Human PLS3 discordant iPSCs differentiated into mixed
motoneuronal cultures
Despite a generalised improvement concerning NMJ maintenance and function in a PLS3
over-expressing SMA mouse model, a rescue with regard to viability was not achieved in
severely affected SMA mice (Ackermann et al. 2013). Hence, amelioration on molecular and
cellular levels was not translated into enhanced long-term survival. Obviously, PLS3 exerted
its protective effect only in mildly affected SMA patients. Therefore, the establishment of an
iPSC-based MN-model of mildly affected SMA III patients and asymptomatic siblings from PLS3
discordant families was essential for future analyses of PLS3 mediated protection.
As outlined in 3.2.4, iPSC-based cell models may serve as valuable novel platform for in vitro
pathogenesis research, drug discovery and evaluation of potential therapeutics promising
“personalised” medicine. Additionally, differentiability of iPSCs into plenty of various cell
lineages circumvents the inaccessibility of diseased neurons, for example.
Among the first to profoundly recapitulate the phenotype in disease-specific iPSCs, Ebert et al.
derived iPSCs from a SMA I patient and his unaffected mother (Ebert et al. 2009).
Subsequently, the authors differentiated these human iPSC into spinal motoneurons
phenocopying the cellular deficits of SMA-affected MNs. In SMA I iPSC-derived MNs, the
authors reported fewer gems, lesser MN size, diminished SMI-32+ and ChAT+MN survival  rate
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and pre-synaptic maturation delay in vitro. Initially, SMA-iPSCs were able to produce a
comparable amount of MNs which however degenerated during time-course. The overall
amount of β III-tubulin+ neurons remained unchanged between WT and SMA I, though,
highlighting the MN-specific damage due to SMN deficiency. This MN loss obviously reflected
the prevailing view of SMA as defect in MN maintenance, not in MN generation. Furthermore,
the authors managed to lift SMN protein levels by application of TSA and VPA (see 3.1.5),
hence rescuing SMA-MNs (Ebert et al. 2009). Moreover, a SMN1 knock-down in human ESCs
modelled this disease phenotype. Neither did SMN depletion interfere with neural induction
nor with subsequent MN specification (Wang et al. 2013).
These findings were supported by following studies: SMA I iPSC-derived MN cultures disclosed
diminished MN formation ability and neurite growth impairment whereas such deficits were
relieved by ectopic SMN1 expression (Chang et al. 2011). iPSCs of two SMA I patients and
correspondent healthy controls gave rise to comparably equal amounts of SMI-32+MNs at the
start of final maturation (approx. 5%) (Sareen et al. 2012). However, during subsequent
cultivation the number of SMI-32+ MNs declined in SMA cultures. A similar observation was
made in human SMA I iPSC-derived MNs between five and eight weeks in vitro cultivation
(Corti et al. 2012).
Nevertheless, every study about iPSC-based MN-differentiation in SMA patients issued so far
dealt with congenital severe SMA I cases only. Thus, to decipher likely more subtle pathologic
changes in milder SMA cases, a suitable in vitro cell model was necessary.
8.2.1 Modifications in EB-based run-through protocol facilitated stable
differentiation of PLS3 discordant iPSCs to mixed MN cultures
Specification of different neuronal subtypes during in vitro differentiation of human
pluripotent SCs remains an elaborate challenge. Eventually, every differentiation protocol
mimics the natural principles of neurulation during human embryogenesis (see 3.3.2). In brief,
clearance of BMP and other TGFβ ligands by specific inhibitors such as chordin, noggin or
follistatin propels acquisition of neural fate in pluripotent ectodermal SCs (Weinstein et al.
1999; Muñoz-Sanjuán et al. 2002; Smukler et al. 2006). Developing neuroepithelial primitive
NSCs are subsequently further specified into manifold neuronal or glial lineages since their
cellular plasticity allows them to respond to morphogenic patterning (Seaberg et al. 2003;
Smukler et al. 2006).
If human ESCs are grown as EB aggregates in chemically defined neural medium without any
exogenous patterning morphogen, they tend to acquire an anterior identity (Pankratz et al.
2007). Therefore, neural precursor cells (NPCs) seem to adopt a rostral “forebrain-like”
positional state by default during embryogenesis. Hence, cells of caudal character (such as
midbrain, hindbrain and spinal cord) are generated by specification of rostral cells (Wilson et
al. 2001). The use of morphogens which activate or inhibit key developmental pathways
enables specifically directed neuronal differentiation (Hardingham et al. 2010).
In mammals, post-mitotic MNs derive from a narrow region in the ventral part of the neural
tube denoted as pMN domain (see 3.3.2). The joint expression of TFs, above all OLIG2, PAX6
and NKX6.1, specifies the pMN domain and is caused by morphogens SHH and RA (3.3.2,
Fig. 6). In respect of motoneuronal differentiation with human pluripotent SCs in vitro, initial
studies imitated these developmental processes (Wichterle et al. 2002; Li et al. 2005; Li et al.
2008) resulting in several protocols for differentiation of functional motoneurons from human
pluripotent stem cells (Wichterle et al. 2002; Ebert et al. 2009; Patani et al. 2011; Amoroso et
al. 2013; Li et al. 2005; Li et al. 2008; Hu et al. 2009). Many of those protocols as well as
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protocols provided by iPierian Inc. were used for MN differentiation of iPSCs. After all, an
EB-based run-through protocol proved as most reliable (Hu et al. 2009).
In Hu et al., the authors claimed to obtain 50% HB9+ MNs from original human ESC progenies.
The first study using this protocol for motoneuronal differentiation of human iPSCs did not
evaluate the amount of HB9+ MNs (Karumbayaram et al. 2009). Instead, the number of
ISL1+/β III-tubulin+neurons was given ranging between 28%-33% depending on iPSC line.
Nevertheless, the EB-based run-through protocol by Hu and Zhang was chosen as standard
MN differentiation protocol in this thesis (7.3, Fig. 22). Yet, the differentiation process was
modified at first step. In order to kick off the tendency to develop into neural tissue,
iPSC-derived EBs were subjected to dual SMAD-signalling inhibition: TGFβ-inhibitor SB431542
and BMP-inhibitor dorsomorphin synergistically promoted neural conversion of human
pluripotent SCs (Chambers et al. 2009; Kim et al. 2010a). Thus, generation of neuroepithelial
NSCs was enhanced. Moreover, dual SMAD-signalling inhibition could rescue
“under-performing” human iPSC clones in MN differentiation (Boulting et al. 2011). So,
support of neural induction apparently overcame differentiation impediments.
However, this protocol failed to yield a reasonable number of correctly patterned
pMN-progenitors or mature MNs (7.3.1, Fig. 23). Therefore, to elevate the overall amount of
MNs, further protocol modifications were introduced: The concentration of RA was lifted to
0.75 µM to ensure full caudalisation. Adequate RA signalling is required for NKX6+ cells to
progress to an OLIG2+ state as MN progenitors (Diez del Corral et al. 2003). Karumbayaram et
al. also administered 1 µM RA with human iPSCs, albeit 0.1 µM RA was titrated as sufficient
amount for motoneuronal patterning with human ESC-derived NSCs (Hu et al. 2009).
Nonetheless, alternative MN differentiation protocols applied 1 µM RA as well (Wichterle et
al. 2002; Amoroso et al. 2013).
In addition, RA administration occurred earlier (on day 7 instead of day 10). A previous study
conceptualised a specific time window in which NSCs stay responsive towards morphogenic
stimuli (Li et al. 2005). Hence, day 10 proved the optimal date for RA application in MN in vitro
differentiation (Hu et al. 2009). However, this protocol lacked boosted neurulation owing to
dual SMAD-signalling inhibition. If generation of neuroepithelial cells is sped up then, the
optimal time point would be postponed as well. Therefore, an earlier date for RA employment
seemed recommendable.
Synthetic small molecule agonists acting in the SHH signalling pathway were suitable
surrogates for purified recombinant SHH protein of original studies. The purine derivative
purmorphamine (Pur) and chlorobenzothiophene Smoothened agonist (SAG) both activated
the SHH signalling pathway (Mas et al. 2010) and were successfully used in ventralisation
during motoneuronal differentiation (Li et al. 2008; Wada et al. 2009).
8.2.2 Human iPSC lines showed a low MN efficiency when subjected to
EB-based run-through protocol
Truly, correct regionalisation of PLS3 discordant iPSC-derived neuroepithelial cells was visible
when staining for typical ventral neural tube markers OLIG2, NKX6.1 and NKX2.2 (Li et al. 2008)
(7.3.2, Fig. 24). Expression of upper spinal cord marker HOXB4 signalised posteriorisation. In
total, the amount of proper pMN-progenitor cells convincingly appeared higher than samples
differentiated according to the original run-through protocol (7.3.1, Fig. 23). However, the MN
yield did not meet expected efficacy. The number of MNs ranged between 3-10% for HB9+
neurons and 6-12% ISL1+ neurons, respectively (7.3.4, Fig. 29). Moreover, healthy control lines
often depicted the poorest MN differentiation efficiency.
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Besides, identification of the cellular composition of mixed MN cultures appeared meaningful
to exclude wrong NSC specification as reason (7.3.4, Fig. 30). Apart from scarce dopaminergic
neurons and occasional glial cells, predominantly gluatmatergic and GABAergic neurons
overbalanced. Presumably, these populations represented interneurons since GABAergic
interneurons derive from p2 domain and glutamatergic interneurons stem from p3 domain
(Alaynick et al. 2011). Both progenitor domains border the pMN domain indicating a strong
ventralisation of neuroepithelial cells. Yet, quantitative analysis of different
non-motoneuronal populations would be necessary to determine the exact constitution of
mixed cultures. As a matter of fact, a lack of MN differentiability in our iPSC lines had to be
stated. This raised the question why the efficiency had developed improperly.
A number of technical obstacles accompany iPSC-based research in neurological disorders:
Clonal variation of iPSCs influencing differentiation abilities, heterogeneity of target neurons
and glial cells and the time-consuming nature of experiments have to be subdued in order to
reproducibly detect new cellular phenotypes (Ito et al. 2012). Additionally, the lack of a
standardised motoneuron differentiation protocol complicates comparability between results
of different studies. Thus, reproducing published MN efficiencies was also hampered.
Comparable previous studies reported 10-17% SMI-32+ MNs of healthy controls after ten
weeks differentiation (Sareen et al. 2012) or 25% ChAT+/β III-tubulin+ neurons of healthy
controls after six weeks differentiation (Ebert et al. 2009). Maximum 10% HB9+ neurons of
total cells were obtained when a human control ESC line had been differentiated and even
less (1%) with a SMA I iPSC line (Chang et al. 2011). Stockmann et al. voiced
electrophysiologically functional MNs positive for MN markers HB9, ISL1, SMI-32 and vesicular
acetylcholine transporter VAChT from healthy individuals (Stockmann et al. 2011). Up to 40%
of differentiated cells were sorted as SMI-32+ MNs which formed mature synapses in vitro.
Notably, in many studies quantification was performed by determining the number of SMI-32+
cells. SMI-32 antibody binds non-phosphorylated neurofilament-H in neurons associated with
MN identity (Carriedo et al. 1996). On the other hand, SMI-32 antibody also detects neurons
in the PNS and CNS such as human GABAergic cortical neurons (Campbell et al. 1989).
Therefore, comparative quantification of unequivocal MN markers HB9 and ISL1 would have
given more valid data impact in those studies. Moreover, just one or two SMA or control cell
lines were employed and no different clones per cell line (Ebert et al. 2009; Sareen et al. 2012).
Application of different iPSC lines and several respective clones balances the inter-line
variances as outlined in 2011 by Boulting et al. (Boulting et al. 2011). Taken together,
presentation of published MN differentiation efficiencies depends on selectable parameters.
The iPSC-based run-through protocol yielded an overall low number of bona fideMNs in mixed
cultures in spite of our positive modifications. This poor outcome was either caused by
intrinsic cellular obstructions of the respective cell lines or general technical reasons.
Several different clones from different individuals and families tended to show a sub-optimal
MN number. This trend points rather to a general differentiation impediment than to a deficit
inhering in each iPSC line. Of course, it cannot be ruled out that a mutation was causative for
this low efficiency. However, genomic integrity was thoroughly scrutinised (7.2.3). The original
mutations detectable in donor fibroblasts (7.2.3, Tab. 16) were unlikely to exert any
deleterious effect because the siblings did not show any physiologic deficits apart from the
SMA III phenotype in affected individuals. On genomic level, established early human iPSC
lines presented indeed a number of genomic aberrations particularly de novo copy number
variations (CNVs) rendering mostly disadvantageous features (Hussein et al. 2011; Laurent et
al. 2011). These studies regarded such CNVs as intrinsic feature of the reprogramming process.
Expansion of human iPSCs in culture would rapidly selected against mutated cells (Hussein et
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al. 2011). However, a following study indicated such CNVs as sign of somatic mosaicism in
parental fibroblasts and their subsequent manifestation in human iPSCs owing to their clonal
origin (Abyzov et al. 2012). Since MN differentiations were undertaken with stable iPSC lines
(passage 10-25), such mutated cells should have vanished in the meantime. Furthermore, all
iPSC lines robustly fulfilled validation criteria (7.2), particularly the capability to differentiate
into all three germ layers in vitro and in vivo (7.2.6, Fig. 20; 7.2.7, Fig. 21). In summary, it thus
seems unlikely that all cell lines are affected by mutations impacting MN differentiation.
Yet, the parental epigenetic traits are obviously not absolutely obliterated during
reprogramming. Apparently, an “epigenetic memory” is retained since early passage iPSCs
exhibit residual DNA methylation signatures of the original cell rendering iPSCs more efficient
in re-differentiation to their lineage of origin (Kim et al. 2010b; Bar-Nur et al. 2011). This
phenomenon was found in iPSC lines generated in different laboratories by varying strategies
with diverse donor cells and could be partially explained by insufficient promoter methylation
of somatic genes (Ohi et al. 2011). Yet, continuous propagation largely attenuated this feature
in murine iPSCs, at least (Polo et al. 2010). Perhaps these findings contribute explanatory clues
with regard to the discrepancies seen in the developmental behaviour since some murine and
human iPSC lines differentiated less efficiently in vitro and in vivo than the ESC counterparts
(Robinton et al. 2012). Therefore, remnants of the originating fibroblast (i.e. mesodermal)
epigenetic traits might hamper neuroectodermal differentiation capability in this study. Some
authors even prefer iPSCs derived from donor cells of ectodermal origin, like keratinocytes for
instance, for they may serve better as starting population for neuronal differentiation
(Stockmann et al. 2011).
Furthermore, differentiation propensity varied also within human ESCs (Osafune et al. 2008).
In a broad panel of 16 human iPSCs and six ESCs, Boulting and colleagues evaluated their ability
to differentiate into MNs (Boulting et al. 2011). The developmental capacity between ESCs
and iPSCs was comparable, nonetheless, the differentiation efficiency between separate iPSC
lines varied (HB9+ cells: 1-6%; ILS1+ cells: 5-20% of all cells on day 32). Notwithstanding all
iPSCs in this study passed standard validation successfully, the individual propensity to
terminal MN differentiation evidently fluctuated. In particular, donor identity and donor sex
influenced the efficiency of MN differentiation (Boulting et al. 2011).
The lack of an unambiguous human spinal MN surface marker impedes MN enrichment out of
such mixed MN cultures (Wada et al. 2009). Although distinct spinal MN markers exist as
mentioned before, not all unambivalently discriminate MNs: ChAT and VAChT mark
cholinergic neurons. However, cholinergic identity is not exclusively restricted to spinal MNs
for there are cholinergic interneurons of the dorsal striatum (Witten et al. 2010). SMI-32
antibody does not only label neurons with MN morphology and location (Carriedo et al. 1996)
but also other neurons of the PNS and CNS (Campbell et al. 1989). In addition, these markers
are all intracellularly located like the motoneuronal TFs HB9, ISL1 and LIM3. Nonetheless,
enrichment of murine spinal MNs was performed by panning assays of mixed spinal cord
isolates via lectin or antibodies specifically binding neurotrophin receptor p75NTR (Wiese et al.
2010; Conrad et al. 2011). Utilising the p75NTR antibody is however an expensive approach
considering the number of cell lines in our study. Besides, these two protocols have only been
conducted with mouse spinal cord. To which extent these panning methods are feasible in
human iPSC-derived mixed MN cultures remains elusive. On the contrary, gradient
centrifugation successfully enriched human ESC- and iPSC-derived spinal MNs from in vitro
cultures (Corti et al. 2012; Wada et al. 2009). Also substrate rigidity of cultivation dishes
influenced MN differentiation yield (Sun et al. 2014).
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Regardless of any possible explanations, the low level of overall MN differentiation efficiency
hampered proper analyses in this PLS3 discordant iPSC-based MN in vitro model. Ergo, this
difficulty was tackled by a new experimental approach.
8.3 smNPC-derived motoneuronal cultures serve as beneficial
platform for disease-modelling in SMA discordant families
8.3.1 Stable NSC lines serve as standardised starting population for MN
differentiation with high efficiency
To circumnavigate the recalcitrance of individual iPSC lines towards highly efficient MN
differentiation via an EB-based run-through protocol, generation of a suitable neuroepithelial
NSC population seemed sensible. As mentioned in 7.4.1, already neurally designated
precursor populations shorten the duration of MN differentiation. Precisely, in this study the
smNPC-based MN differentiation lasted four weeks compared to eight weeks in the EB-based
run-through protocol. They are more homogenous and easily patternable. Several NPC
populations have been generated within the recent years of which all were successfully
differentiated into MNs: Directed differentiation of lt-NES®SCs yielded approx. 15%
HB9+/β III-tubulin+ neurons (Koch et al. 2009) whereas rosette neural cells delivered roughly
25% HB9+ MNs (Elkabetz et al. 2008). Flow cytometry analysis of MN-differentiated primitive
NSCs showed 53.7% neurons positive for ISL1 and microtubule-associated protein (MAP) (Li et
al. 2011). The most recent NSCs population, i.e. small molecule NPCs (smNPCs), was reported
to generate 50% HB9+/β III-tubulin+ neurons (Reinhardt et al. 2013).
Due to the cost-effective rapid generation, easy maintenance and feasibility even in functional
electrophysiological studies with smNPC-derived MNs (Naujock et al. 2014), smNPC
generation was chosen (7.4.1, Fig. 31) and successfully applied in healthy control, SMA I, SMA
III and discordant asymptomatic iPSC lines in the present study (7.4.1, Fig. 32). Although all
smNPC lines exhibited the same marker profile as given in the original publication, some lines
(e.g. HGK21.8) revealed early signs of rosette formation when grown densely indicated by
ZO-1+ ring-like centres within smNPC colonies. Therefore, present smNPC lines may constitute
a more heterogenous and plastic NSC population perhaps owing to increased Pur
concentration (1 µM) and different basal medium composition during standard cultivation
compared to Reinhardt et al., 2013.
In advance, proof-of-principle experiments with an OLIG2-GFP smNPC reporter cell line
heralded promising results concerning MN differentiation. Since SHH pathway agonist SAG
had already been successfully applied in motoneuronal differentiation of human ESCs (Wada
et al. 2009), SAG was added to the original differentiation regimen to promote additional
ventralisation. Upon motoneuronal specification via treatment with RA, SAG and Pur, effective
regionalisation was visualised by OLIG2-GFP reporter gene expression (7.4.2, Fig. 33) and
immunocytochemical staining of pMN markers (7.4.2, Fig. 34). Final MN maturation indicated
expression of ISL1, HB9, ChAT and SMI-32 and delivery of a visible amount of HB9+MNs at last
(7.4.2, Fig. 35).
Moreover, smNPCs seemed to be convertible into rosette-type cells similar to lt-NES®SCs by
simple changes in culture conditions (7.4.3, Fig. 36, Fig. 37). Already the original publication
revealed comparable convertibility upon FGF2 application (Reinhardt et al. 2013). Addition of
growth factors bFGF, EGF and B27 indeed transformed smNPCs into rosette-like lt-NES®SCs
and enabled further propagation as individual NSC population. Upon such treatment, smNPC-
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derived OLIG2-GFP reporter lt-NES®SCs expressed typical NSC markers like ESC-derived
lt-NES®SCs (Koch et al. 2009) (7.4.3, Fig. 38) and were successfully differentiated into proper
MNs (7.4.3, Fig. 39).
When OLIG2-GFP reporter lt-NES®SCs were patterned during regular cultivation with SAG
(1 µM) and rather low RA concentration (150 nM), decent GFP fluorescence indicated
expression of OLIG2 already after one week treatment (7.4.3, Fig. 37 D). Nonetheless,
patterned lt-NES®SCs retained their typical appearance and growth behaviour (7.4.3,
Fig. 37 C). When it may be possible to stably enrich the amount of OLIG2+ pMN-primed
progenitor cells in NSC lines during regular cultivation, the number of proper MNs should
increase afterwards. Forced Olig2 expression in murine ESC-derived NSCs dramatically
increased motoneuron generation in vitro from 10% to 90% HB9+/ISL1+MNs of all β III-tubulin+
neurons (Panman et al. 2011) undoubtedly corroborating the importance of the initial yield of
OLIG2+ NSCs. Successful pMN patterning with high OLIG2+ numbers may launch
correspondently efficient MN generation.
To verify whether this assumption held true, OLIG2-GFP reporter lt-NES®SCs were
simultaneously treated with 150 nM RA and 1 µM SAG for eleven days or 21 days or
maintained in standard medium without patterning morphogens. Effectiveness of
pre-patterning was visualised by evident presence of bona fide MNs expressing ChAT, HB9,
ISL1 and SMI-32 after 16 days final maturation in comparison to untreated samples (7.4.3,
Fig. 39 B). A separate patterning step without growth factors bFGF and EGF and with more RA
like in Koch et al., 2009 as outlined in Fig. 36 might even enhance the MN differentiation
efficiency.
Admittedly, for discovery of statistical significant differences concerning pre-patterning
effects several experiments must be performed and substantiated with cell counting or GFP
FACS analysis for quantification. Yet, conducting MN differentiation experiments with PLS3
discordant and SMA cell lines giving really meaningful data was prioritised.
In conclusion, smNPCs represented a homogenous stably cultivable NSC population which
responded to desired morphogenic patterning. Thus, they proved to be very suitable for
accelerated and efficient MN generation. Generation of correspondent smNPCs from healthy
control, SMA I, SMA III and discordant asymptomatic iPSC lines decisively enlivened the
continuance of our study.
8.3.2 iPSC-derived mixed motoneuronal cultures represent the first in vitro cell
model of a mild SMA phenotype and asymptomatic PLS3 over-expressing
siblings
According to their marker expression profile, smNPCs were a priori localised to the neural
plate border with moderately dorsal hindbrain character (Reinhardt et al. 2013). On the other
hand, MN differentiation implies relocating smNPCs towards a ventral-caudal fate.
Therefore, pre-patterning technique was adapted to smNPC cultivation for boosting high yield
MN differentiation. Instead of 0.5 µM Pur standard smNPC culture medium NPC1 contained
1 µM Pur (7.4.4, Fig. 40). Together with 3 µM CHIR99021, such an increase of Pur was shown
to simultaneously elevate the expression of MN progenitor markers NKX6.1 and OLIG2 on
mRNA level and in immunocytochemistry (Reinhardt et al. 2013). Thus, it was assumed that
smNPCs were even more easily shifted into the correct pMN-domain during pre-patterning.
Indeed, immunocytochemical staining of such pre-treated smNPCs distinctly depicted proper
expression of essential markers defining spinal MN progenitors such as ventral markers OLIG2
and NKX6.1 or caudal marker HOXB4 (7.4.4, Fig. 41). Parallel use of ventralising agents Pur and
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SAG during pre-patterning and regular patterning did not thrust smNPCs too ventral because
p3 marker NKX2.2 was barely expressed proving an exact hit of the desired pMN domain in
these smNPCs. However, recent data demonstrated that unlike in mice NKX2.2 encroached
into the OLIG2-expressing domain in human neural tube even resulting in MN generation
obviously (Marklund et al. 2014).
After having circumnavigated the obstacles of iPSC-based MN differentiation via application
of smNPCs, immunocytochemical staining undoubtedly identified bona fide MNs by
expression of characteristic MN markers HB9, ISL1, ChAT and SMI-32 on day 8 and day 27,
respectively (7.4.4, Fig. 42). Quantification of ISL1+ and HB9+ cells was set relative to total cell
number or β III-tubulin+ neurons as also other studies preferred calculating the ratio of
motoneurons:β III-tubulin+ neurons (Karumbayaram et al. 2009). In addition, a possible bias
of different neurogenic potential in various cell lines is lowered thereby.
Data presented valid MN numbers for most cell lines, the amount of HB9+ or ISL1+ cells ranged
between 20%-30% relative to total cell number presenting an overall meaningful yield in
comparison to MN differentiation efficiency in other NSC populations: lt-NES®SCs delivered
approx. 15% HB9+/β III-tubulin+neurons (Koch et al. 2009), rosette neural cells yielded roughly
25% HB9+ MNs (Elkabetz et al. 2008) and MN-differentiated primitive NSCs showed 53.7%
ISL1+ neurons (Li et al. 2011).
Still, number of HB9+ cells remained conspicuously below published data: ~23% in control line
r12 on day 27 compared to ~50% in healthy iPSC1-derived MN culture on day 21 (Reinhardt
et al. 2013). Unlike the original publication, DAPT was administered during final maturation in
this study. Inhibition of notch-signalling by γ-secretase inhibitor DAPT propelled neuronal
differentiation of NSCs (Borghese et al. 2010; Crawford et al. 2007). In MN cultures devoid of
DAPT treatment, differentiation of existing pMN-primed progenitors into MNs would be
deferred over time and thereby HB9+ MN pool would be constantly replenished. Contrarily,
DAPT treatment in this study irreversibly pushed neurogenesis of all pMN-primed progenitors
present at day 8 at once. Thus, total number of MN progenitor cells maturing over time may
differ between this study and the original study by Reinhardt et al., 2013. Moreover, different
propensity towards MN differentiability might explain lower total MN number since MN
numbers obviously differed between cell lines and clones of one cell line (7.4.4, Fig. 43, A-D).
Unlike in the original publication, MN maturation medium NPC3 was supplemented with low
RA (50 nM) and Pur (0.5 µM) concentrations for seven days (d8-d14) (7.4.4, Fig. 40) because
reduced concentrations of these two morphogens promoted division of OLIG2+ progenitors in
MN cultures (Hu et al. 2009; Li et al. 2008). Anyway, cross-comparison of MN differentiation
protocols between different laboratories and experimenters remain challenging unless
standardised differentiation and quantification methods are introduced.
With the majority of all single smNPC lines differentiated into MNs three times, the phenotypic
grouping validly highlighted differences in MN survival over time (7.4.4, Fig. 43 E-H).
Intriguingly, there was no significant difference in HB9+ or ISL1+ MN number detectable
between healthy controls, SMA I, SMA III and discordant asymptomatic in early MN cultures
on day 8. SMN knock-down in human ESCs did not impair subsequent MN differentiation
proving that regular SMN amounts are not mandatory for MN differentiation (Wang et al.
2013). Neither were initially lower MN numbers detected in early iPSC-derived MN cultures of
SMA I patients in previous studies corroborating present findings (Ebert et al. 2009; Sareen et
al. 2012).
Still, asymptomatic siblings denoted always the lowest MN number on day 8. However, it has
to be considered that asymptomatic comprised fewer counting data. For instance, data from
HGK21.1 was wholly missing in ISL1+ quantification thereby possibly biasing the data set (7.4.4,
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Fig. 43 D). Furthermore, cell-specific features bore detrimental effects obviously.
Asymptomatic cell line HGK28.11 disclosed the slowest growth and lowest cell number during
differentiation regimen thereby spoiling pooled data of asymptomatic additionally. Similarly,
healthy control line COII.2 absolutely underperformed during MN differentiation. Albeit COII.2
behaved normally until patterning started on day 0, neurogenesis subsequently failed
delivering more epithelial-like or glial-like cells but hardly any β III-tubulin+neurons, let alone
MNs. This explained the poor MN yield on day 8 (7.4.4, Fig. 43 A, B) and further justified the
exclusion of that cell line for quantification because COII.2 did not represent a proper MN
culture. Cortical differentiation succeeded with this line (Kristina Dobrindt, Swetlana
Ritzenhofen, personal communication), however adherent generation and cultivation into
smNPCs failed too (Bea Weykopf, personal communication). Generally, individual cell lines
behaved differently strongly advocating the use of several cell lines with several clones per
line to even this putative bias in overview panels as performed in this study.
Human ESC-derived neurons resembled foetal brain more than adult brain in terms of
molecular maturation (Patani et al. 2012). Likewise, human iPSC-derived MNs rather may
represent a pre-natal/young post-natal state. Intriguingly, severely affected SMA I exhibited
almost equally high MN numbers compared to controls on day 8. This finding underlines that
SMA is not a disorder of MN formation but MN maintenance (Sleigh et al. 2011).
Strikingly, three weeks differentiation until day 27 pictured a totally different impression of
MN survival in these in vitro MN cultures (7.4.4, Fig. 43 G, H). Relative to day 8, MN number
massively declined in SMA I (HB9+: ↘97%; ISL1+: ↘88%) (7.4.4, Fig. 44) phenocopying the
severe phenotype already seen in human SMA I foetuses where motoneuronal degeneration
already occurs in utero (Markowitz et al. 2004) and in severe SMA mouse models which
revealed normal MN number on post-natal day 1 but massive MN waste during following days
(Hsieh-Li et al. 2000; Monani et al. 2000).
Additionally, SMA III and asymptomatic siblings suffered from considerable loss in HB9+ MN
number compared to day 8 (SMA III: ↘57%; asymptomatic: ↘62%). Additionally, reduction in
ISL1+ MNs stayed insignificant yet obvious at glance (SMA III: ↘31%; asymptomatic: ↘39%).
Intermediate SMA mouse models reported significant MN loss in murine spinal cord and brain
stem as well (Bowerman et al. 2012a). Usually, SMA III manifests after the first 18 months
(Kugelberg et al. 1956). Still, clinical symptoms penetrate with delayed onset and only a mild
phenotype during childhood and early adolescence. In SMA III patients HGK22 and HGK27 the
disorder was diagnosed with 18 years and 13 years, respectively. So, the rather strong loss of
MNs in the in vitro model at this early time point in development is explainable since MN
dysfunction expresses just after many years. Thus, PLS3 over-expression in asymptomatic
siblings apparently did not result in enhanced MN survival since asymptomatic lines HGK21.8
and HGK28.9 revealed high PLS3 expression rates (7.5.3, Fig. 49 G) while MN numbers ranged
low (7.4.4, Fig. 43 C, D). This data suggested a PLS3-mediated protective effect rather in other
parts of the motor circuit than in MN maintenance itself. Hence, formation or stabilisation of
NMJs might prevent penetration of mild SMA III phenotype in asymptomatic.
Astonishingly, HB9 number also diminished (↘30%) in controls during three weeks maturation
questioning whether cultivation conditions might interfere with MN survival. In contrast,
number of ISL1+ MNs even slightly increased (↗19%) in controls during MN maturation
rebutting the assumption that external and not cell-autonomous effects elicit MN death.
Murine Hb9 expression persists in most adult post-mitotic MNs owing to its requirement for
the maintenance of Isl1 expression in post-mitotic MNs (Arber et al. 1999). However, HB9
expression is down-regulated for assignation of specific motor column identities in the
developing spinal cord (William et al. 2003). Moreover, in maturing ESC-derived MN cultures,
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number of HB9 expressing cells decreased after three weeks concomitantly with
proportionally increasing ChAT expression (Hu et al. 2009; Li et al. 2005). Likewise, this finding
was observed in MN cultures of ESC line HB9-GFP (Placantonakis et al. 2009) and was
additionally outlined in an overview of stem cell-based in vitro MN differentiation (Davis-
Dusenbery et al. 2014). Such processes may be causal for general disappearance of HB9 signal.
On the other hand, ISL1 function is obligatory for all spinal MNs (Pfaff et al. 1996) therefore
serving as more meaningful tool for MN survival determination. ISL1+ and HB9+ MNs are not
absolutely identical and respective expression does not always overlap in vivo or in vitro.
Instead, separate staining only marks MN subsets (Amoroso et al. 2013). This fact points out
the importance of employing several MN markers for quantification as it was conducted in
this study whereas previous studies mostly relied on a single MN marker.
When the presented in vitro system resembled an early post-natal stage of human
development, deleterious effect of SMN loss was already visible in SMA I at this early
time-point. Instead, milder SMA III phenotype and discordant asymptomatic showed tendency
to delayed MN loss being congruent with the patients’ disease progress. In most studies with
severe early-onset SMA I patients, total MN differentiation time amounted to 6-10 weeks
(Corti et al. 2012; Sareen et al. 2012). Since human neurons developed ten times slower than
in murine systems (Stockmann et al. 2011), a longer differentiation period might be
recommendable to carve out more subtle changes in ISL1+ MN survival among SMA III and
asymptomatic MN cultures.
SMA III MNs may require additional exposition to biological, chemical or environmental
stressors to accelerate disease progression and to reveal pathological phenotypes as it was
carried out in a stem cell model of Parkinson’s Disease (Nguyen et al. 2011). Undeniably,
oxidative stress had been associated with SMA pathology in respect of MN degeneration
(Hayashi et al. 2002; Wang et al. 2013) or disturbed SMN complex formation (Wan et al. 2008).
So, employment of stressors like hydrogen peroxide (H2O2) in the SMA III in vitromodel might
sensitise MNs for expressing a more pronounced disease phenotype.
In summary, an in vitro SMA model of mild SMA III and PLS3 discordant asymptomatic
individuals based on iPSC-differentiation was introduced in this doctoral thesis for the first
time. The present in vitro cell model feasibly sufficed then as platform for further studies in
PLS3 discordant families.
8.3.3 MN neurite length did not differ among healthy controls, SMA I, SMA III
and asymptomatic in MN in vitromodel
Since MN loss in SMA was associated with a dying-back axonopathy (Cifuentes-Diaz et al.
2002; Fallini et al. 2012), maintenance of neuronal protrusions such as axons was always
focussed on in SMA research. Furthermore, PLS3 over-expression was capable of rescuing
axonal growth defects in smn depleted zebrafish or mice (Oprea et al. 2008; Hao le et al. 2012,
Ackermann et al. 2013). Therefore, measurement of neurite length in PLS3 discordant MN
cultures seemed reasonable.
Neurites are regarded as transient protrusions of early in vitro neurons which develop further
into axons or dendrites (Alberts et al. 2002). The former can be selectively discriminated by
staining for Tau proteins (axons), the latter by microtubule-associated protein 2 (MAP2)
(dendrites), for instance (Rossoll et al. 2003) as late structures of mature neurons.
On day 8, there was no significant length difference observed in healthy controls, SMA I,
SMA III and asymptomatic MN cultures regarding β III-tubulin+ or SMI-32+ neurites (7.5.6,
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Fig. 55). A previous study reported a significantly delayed neurite outgrowth in iPSC-derived
MN cultures (Chang et al. 2011) which our data apparently contradict.
The authors referred to earlier publications: After five days cultivation, primary MNs from a
severe SMA mouse model indeed revealed significantly shorter axons (Rossoll et al. 2003). In
zebrafish, SMN deficiency caused reduced axonal length but exerted no negative effect on
dendrites (McWhorter et al. 2003). Isolated primary murine MNs of control, heterozygous and
SMA I mice showed short axons and disturbed neurite network in SMA I samples (Ting et al.
2007). Notably, these studies always explicitly measured axonal length and not neurite length.
Although defects in neurite networks of SMA I primary mouse MNs were observed, neurite
length measurement was not presented (Ting et al. 2007). Thus, careful discrimination has to
occur between axons and neurites.
Moreover, different experimental approaches have to be considered: Between two
time-points (day 2 and day 5), Chang and colleagues monitored β III-tubulin+ neurite growth
from seeded neurospheres in SMA I MN cultures and ESC healthy control. Contrarily, our
measurement comprised only a single time-point yet distinctly in HB9+, ISL1+or SMI-32+ MNs.
Otherwise, cellular clustering in maturing MN cultures would have prevented unequivocal
identification of MNs and appending neurites.
In our very young MN cultures (day 8), the detrimental effect of SMN loss in neurite outgrowth
might not have been displayed. Murine studies investigated primary spinal cord MNs, i.e. fully
matured MNs (Rossoll et al. 2003; Ting et al. 2007). Therefore, singularisation of older MN
cultures (day 27 et seq.) may enable to measure axons and neurites in our human in vitro
system. However, poor recovery rate of singularised MN cultures thwarted such attempts
hitherto (data not shown).
Averaged neurite length amounted to ~220 µm (ESC control) and ~100 µm (SMA I) on day 2
but were not proved significant (Chang et al. 2011). Significant differences became just
observable after prolonged cultivation (5 days) and SMN rescue (Chang et al. 2011). Still, in
their study β III-tubulin+ neurites grew longer in comparison to our study (~75 µm, control and
~80 µm, SMA I) (7.5.6, Fig. 55 B). However, measurements were performed directly one day
after seeding and not after two days as in Chang et al., 2011. Of course, increasing the
numbers of neurites counted particularly in SMI-32+ MNs will solidify our data.
8.4 Examination of SMN and PLS3 expression in different cell
populations mirrors SMA phenotypes
Genetic expression rates were monitored in parental fibroblasts, derived iPSCs, corresponding
smNPCs and differentiated MN cultures on day 27 comprising the entire in vitro MN
differentiation process of the four phenotype classes (healthy controls, SMA I, SMA III and
asymptomatic). RNA and protein extractions from all these conditions suited well for
downstream analyses of SMN and PLS3 expression rates, respectively.
8.4.1 SMN expression levels mimic effects of SMN1/SMN2 copy number in
phenotype classes during in vitroMN development
Deletion or conversion of SMN1 gene in SMA patients inevitably leads to MN death and
consequently SMA phenotype (Burghes 1997; Lefebvre et al. 1995). Yet, remaining SMN2
genes still provide approx. 10% FL-SMN mRNA/protein per copy thereby easing disease
severity with increasing number (Brahe 2000; Helmken et al. 2003; Wirth et al. 2006b). As
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outlined in 5.8.3, Tab. 13, SMN1-deleted lines SMA I HGK1 possesses 2 SMN2 copies,
discordant family 1 members HGK13 and HGK16 comprise 3 SMN2 copies and discordant
family 2 members HGK21, HGK22, HGK27 and HGK28 present 4 SMN2 copies. Accordingly, the
amount of FL-SMN mRNA/protein ought to range between 20-40% in comparison to healthy
controls with 2 SMN1 copies delivering 100% FL-SMN mRNA/protein. Previous studies already
proved diminished SMN expression rates in iPSC-derived SMA I models (Corti et al. 2012; Ebert
et al. 2009).
Indeed, concerning mRNA levels significantly decreased SMN expression levels could be
recapitulated in SMA I affected relative to controls (7.5.1, Fig. 45; 7.5.4 Fig. 50 A). SMA I
reached approx. a quarter of control expression levels in all cell populations (7.5.4, Tab. 17)
fitting the low SMN2 copy number. However, in SMA III and asymptomatic significant
differences were detected in iPSCs, smNPCs and SMA III MN cultures compared to controls
albeit a visible decrement in SMN mRNA expression emerged also in other cell populations
(7.5.1, Fig. 45). Still, the decline in SMN amount disclosed at a higher level (mostly 60-75%
relative to control) than 3-4 SMN2 copies expectedly should deliver (7.5.4, Tab. 17). Anyway,
this distribution pattern typically recurred throughout MN development in all cell populations
very consistently (7.5.1, Fig. 45). Of course, inclusion of more controls and SMA I or SMA II
might enhance the validity of this data.
Preliminary results from SMN protein analyses did not resemble the expected distribution
pattern with respect to SMN1/SMN2 copy number (7.5.3, Fig. 48, 7.5.4 Fig. 50 B). Grouped
according to their phenotypes, controls, SMA III and asymptomatic fibroblasts presented
similar SMN protein amounts while SMA I showed a considerable diminution in expression
(7.5.3, Fig. 48 B). Previous determination of SMN expression in family 2 fibroblasts
(ML11-ML14) revealed no significant difference between SMA III and asymptomatic either
(Helmken et al. 2003). Similar results were obtained in iPSCs with an overall higher protein
expression rate in all phenotypes resulting in nearly equal SMN amounts in controls, SMA III
and asymptomatic (7.5.3, Fig. 48 D). Surprisingly, SMA I iPSCs delivered almost half the SMN
amount relative to control topping the expectable quantity from 2 SMN2 copies. Despite
higher total SMN protein amounts in WT iPSCs any significant differences in SMN protein
between WT control and SMA I iPSCs were not reported in previous studies (Ebert et al. 2009).
Not until the start of in vitro MN differentiation via smNPCs into early MN cultures, the
distribution pattern shaped the way better suiting SMN1/SMN2 copy numbers in phenotype
classes (7.5.3, Fig. 48 F, H): While SMA I delivered roughly ~30% SMN protein compared to
controls, SMA III and asymptomatic positioned at a medium expression level (53-60% relative
to controls) in smNPCs (7.5.4, Tab. 17). However, ~88% SMN protein expression in SMA IIII
and ~126% SMN expression in asymptomatic MN cultures acted as outlier. Relying on a single
control line (r12) in MN cultures might bias these results in case r12 samples exhibited
unforeseen variance in SMN expression as indicated by large error bar (7.5.3, Fig. 48 H).
Naturally, preliminary SMN protein results have to be confirmed by consecutive
immunoblotting or inclusion of other controls to obtain scientifically valid numbers
particularly in iPSCs and fibroblasts which might clarify unusual SMN expression levels.
Significant differences with regard to SMN RNA/protein expression rates were evidently
demonstrated in humans between healthy controls and SMA patients of various severities and
in mouse models (Coovert et al. 1997; Hsieh-Li et al. 2000; Lefebvre et al. 1995; Monani et al.
2000). SMN protein levels ranged higher in foetal tissue than in post-natal (Burlet et al. 1998).
More precisely, SMN is low expressed in adult fibroblasts and blood (lymphocytes), medium
expressed in muscle and highly in brain, kidney, liver and spinal cord but a 100fold reduction
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was observed in SMA I spinal cord (Coovert et al. 1997) illustrating the obvious link between
SMA pathology, MN death and locally insufficient SMN expression.
Evidently, our study provided comparable findings since somatic differentiated foetal-like MN
cultures exhibited an overall higher SMN expression rate in all phenotype classes (7.5.1,
Fig. 45 H) whereas total SMN expression rate was detectably lower in adult fibroblasts, iPSCs
and smNPCs (7.5.1, Fig. 45 B, D, F). Additionally, global SMN protein levels in adult fibroblasts
ranged conspicuously below those in iPSCs or foetal-like MN cultures matching results of
former studies (7.5.3, Fig. 48 B, D, H).
Of course, fibroblasts depicted varying growth behaviour and proliferation speed due to
passage-related senescence (data not shown). Thus, stem cell populations such as iPSCs and
smNPCs may prove more homogeneous. Wang and colleagues determined FL-SMN expression
at different steps of human ESC-based MN run-through differentiation protocol (Wang et al.
2013). Like in iPSCs and smNPCs of our study, healthy ESCs and early neuroepithelial
progenitors expressed almost equal SMN amounts, yet upon differentiation into proper MNs
SMN rate considerably rose comparable to the course in this study (7.5.4, Fig. 50 A). SMN
levels were up-regulated in differentiating PC12-derived NSCs (Navascues et al. 2004; Oprea
et al. 2008) and increased in human neuroblastoma cell line SH-SY5Y upon MN differentiation
(Clelland et al. 2009). Comparably, SMN expression rose on RNA and protein levels after MN
induction compared to smNPCs (7.5.4, Fig. 50 A, B).
Besides, SMN2 copies were declared as not fully equal due to conversion or fusion events
causing hybrid copies (Hahnen et al. 1996; Chen et al. 2011): Gem number and SMN
expression levels differed among SMA I and SMA II patients despite nominally sharing the
same SMN2 copy number (Coovert et al. 1997; Wirth 2000). In addition, percentage of FL-SMN
RNA and protein obtained from SMN2 copies varied between 10-30% according to several
studies (Coovert et al. 1997; Lefebvre et al. 1997; Helmken et al. 2003; Sendtner 2010). Thus,
mildly affected SMA III and asymptomatic siblings might also express more than 10% SMN
RNA per SMN2 copy resulting in fluctuating expression rates.
Already in MN cultures derived by the EB-based run-through protocol overt differences in
SMN expression were observable. SMA III HGK13 and asymptomatic HGK16 delivered
comparably significantly lower SMN amounts (~30%, mRNA; ~50%, protein) relative to
controls (7.3.3, Fig. 27, Fig. 28). Expectedly, scarce amount of MNs in such cultures did not
influence the overall SMN expression in a neuronal system. Hence, previous results from
smNPC-derived cultures were demonstratively backed.
In conclusion, from SMN expression rates of different phenotype classes throughout in vitro
MN differentiation it can be deduced that the present iPSC-based cell system is definitely
suitable to mimic SMN deficiency during development lending support to further SMA-related
studies.
8.4.2 Gem number reliably depicts SMN deficiency in different phenotype
classes throughout development
While cytoplasmatic SMN protein is diffusely spread, nuclear SMN agglomerates into distinct
~0.1–1 µm sized structures termed “gems” nearby Cajal bodies (Liu et al. 1996). Loss of gems
correlates with low SMN expression in SMA patients as a sign of SMA pathology (Coovert et
al. 1997).
Previously, presence of gems was quantitatively assessed in fibroblasts, iPSCs (control
~50 gems/100 nuclei, SMA I ~8 gems/100 nuclei) and iPSC-derived neurons and astrocytes
(Ebert et al. 2009), again in iPSCs (control ~60 gems/100 nuclei, SMA I ~8 gems/100 nuclei)
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(Corti et al. 2012) and in fibroblasts (control ~2 gems/nucleus, SMA I ~0 gems/nucleus) (Chang
et al. 2011). Similarly, gems were quantified in this study, however, more cell lines comprising
different SMA phenotypes were examined to improve data validity. Moreover, gem number
assessment was performed at important stations of in vitroMN developmental course, i.e. in
original fibroblasts, derived iPSCs, corresponding smNPCs and differentiated MN cultures on
day 8 and on day 27 thereby deepening the insight in SMN-specific changes during
development and exceeding the data base provided in previous studies.
Although absolute gem number per 100 nuclei differed among cell populations, a recurrent
distribution pattern was detectable between the phenotype groups within a single cell
population (7.5.5, Fig. 52). Healthy controls abundantly exhibited highest gem number per 100
nuclei (fibroblasts: ~117; iPSCs: ~15; smNPCs: ~9; MN culture d8: ~27; MN culture d27: ~21)
mirroring sufficient SMN1 expression. However, SMN1-deleted individuals held gem numbers
equivalent to their SMN2 copy number. SMA I line HGK1 (2 SMN2 copies) betokened the
significantly lowest gem number in all cell populations (fibroblasts: ~5; iPSCs: ~2; smNPCs:
~1.5; MN culture d8: ~2; MN culture d27: ~3.5) in comparison to controls. Partially, SMA I gem
numbers even ranged significantly lower when compared to mildly affected SMA III and
discordant asymptomatic. Furthermore, SMA III and asymptomatic revealed nearly always the
same gem numbers which were significantly lessened compared to controls however
reflecting the medium SMN2 (3-4) copy number (fibroblasts: ~66-71; iPSCs: ~4; smNPCs: ~5-6;
MN culture d8: ~15; MN culture d27: ~12-13). Consequently, the first time ever individual gem
numbers were continuously strung together through several different cell populations even
reflecting phenotypic differences during developmental processes in solid significance (7.5.5,
Fig. 53).
Total gem numbers in fibroblasts matched previous results of controls and SMA patients with
various severity in which also a direct correlation between SMN1/SMN2 copies, gem numbers
and disease severity was found (Coovert et al. 1997). Roughly simplified, SMA III and
asymptomatic exhibited ~55-60% relative to control gem number mirroring the medium
FL-SMN protein delivery from 3-4 SMN2 copies. In iPSCs, exceptionally only a quarter of gems
(~25%) were visualised.
SMN protein complexes appear as independent sub-nuclear structures during embryonic
development and like other RNA-processing nuclear compartments e.g. Cajal bodies, gems
are subjected to temporo-spatial regulation during developmental processes (Young et al.
2001). Diverse human foetal tissue samples all presented gems (Young et al. 2001), yet in
rapidly proliferating undifferentiated cells, gems were only detected in a small proportion
(Carvalho et al. 1999). Additionally, SMN-containing gems were barely detectable in
undifferentiated PC12-derived neural precursor cells until neuronal differentiation was
induced (Navascues et al. 2004). Taken together, these findings give explanatory clues to
overall lower gem numbers in highly proliferative iPSCs and smNPCs.
The number of RNA-processing compartments like Cajal bodies linked to SMN via coilin
correlates with neuronal soma size (Pena et al. 2001). While some authors reported fewer
gem numbers in adult neuronal tissues or explanted adult neurons (Pena et al. 2001; Young
et al. 2001), other studies claimed an abundance of gems in differentiated PC12-derived
neurons (Navascues et al. 2004) whereas the former in vitro systems rather approach the true
in vivo state. Thus, early smaller neurons are expected to contain fewer gems than mature
neurons. Congruent with this common view of increasing gem number upon neuronal
differentiation, smNPC-derived MN cultures in this study globally exhibited higher gem
numbers with regard to control, SMA III and asymptomatic when compared to precedent cell
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populations. Only in SMA I gem number stagnated throughout development at very low
number (7.5.5, Fig. 53).
Although the gem distribution pattern pictured the different SMN copy numbers of phenotype
classes more precisely and consistently than corresponding SMN protein data particularly
concerning SMA III and asymptomatic (7.5.4, Fig. 50 B), admittedly, the present gem
percentage of SMA III and asymptomatic (~55-60% relative to control gem number) beat the
expected rate because 3-4 SMN2 copies were supposed to generate just 10% FL-SMN/copy,
hence totally 30-40% FL-SMN protein (Brahe 2000; Wirth et al. 2006b). As already outlined in
the previous section (8.4.1), SMN2 copies are not absolutely identical on account of preceding
conversion events influencing regulatory sequences (Coovert et al. 1997; Feldkötter et al.
2002; Mailman et al. 2002). Thus, SMN protein with different capabilities of accumulation in
gems was generated which may explain relatively high gem number in SMA III and
asymptomatic.
Taking into account the absolute SMN expression levels of all phenotype groups (8.4.1), gem
numbers were not directly reflected. Much SMN protein did not automatically correspond to
high gem number since in iPSCs, gem numbers were low (7.5.5, Fig. 53) while SMN protein
levels were high (7.5.4, Fig. 50 B). Indeed, absolute SMN amount does not necessarily transfer
into respective gem number because additional nuclear assembly factors are required and
gems also serve as nuclear SMN storage (Young et al. 2000).
Really, gems were prior detected in iPSC-derived MN cultures, yet no quantification was
performed (Corti et al. 2012; Ebert et al. 2009). Minimum counted iPSC or fibroblast cell
number amounted to 100 cells (Corti et al. 2012; Ebert et al. 2009) or sometimes even less
(35-60 cells) (Chang et al. 2011).
In contrast, this study coherently reveals for the first time phenotype-specific changes in SMN
expression and subsequent gem formation during in vitro MN differentiation. The large
number of cell lines plus additional sub-clones as well as high number of cells assessed firmly
fortifies present results and extends data of previous studies.
8.4.3 PLS3 expression notifies cell type-specific as well as phenotype-related
differences amongst phenotypic classes during in vitroMN development
Inaccessibility of neural tissue samples from PLS3 discordant family members impeded
elucidation of PLS3-mediated amelioration in mild SMA phenotype. Actin-bundling protein
PLS3 is expressed in all solid tissues including spinal cord (Lin et al. 1999). PLS3 expression on
RNA and protein level in LB cell lines of rare discordant family individuals distinctly differed
among discordant siblings revealing a strong PLS3 over-expression in blood of asymptomatic
individuals which eventually led to the discovery of PLS3 as protective modifier in SMA III
(Oprea et al. 2008).
In fibroblasts, PLS3 protein is visualised as distinct single band, however, no difference
between SMA III and asymptomatic siblings was detected on RNA or protein levels (Bernal et
al. 2011; Oprea et al. 2008). Similarly, PLS3/PLS3 expression in fibroblasts of healthy controls,
SMA I, SMA III and asymptomatic did not significantly differ (7.5.4, Fig. 50 C, D) strengthening
results of previous studies. Considering absolute expression values, PLS3/PLS3 expression in
fibroblasts was generally quite low compared to other cell populations (7.5.4, Fig. 50 C, D).
From iPSCs onwards, asymptomatic cell lines commenced to gradually augment PLS3/PLS3
expression levels individually and grouped, particularly once subjected to neural development
into smNPCs and MN cultures (7.5.2, Fig. 46; 7.5.3, Fig. 49). In contrast, SMA III patients
displayed the lowest PLS3 protein amount within the four phenotype groups despite rising
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PLS3 mRNA rates (7.5.4, Fig. 50 C, D). Remarkably, SMA I line HGK1 presented throughout
strong PLS3/PLS3 expression until MN cultures (7.5.4, Fig. 50 C, D). PLS3 expression rate was
not determined in this patient’s blood why an over-expression state cannot be defined. Any
possible existing PLS3 over-expression did not rescue this severe SMA phenotype with only
two SMN2 copies anyway. Amazingly, healthy control line r12 maintained absolute PLS3
expression level until MN differentiation when PLS3 expression was massively down-regulated
(7.5.2, Fig. 46 G). Comparably, PLS3 protein amount did not rise during development unlike in
other cell lines (7.5.3, Fig. 49 G). Since control line COII.2 did not represent a proper MN
culture, its data were only included when presenting as flawless population (i.e. fibroblast,
iPSC, smNPC). Of course, results included very preliminary data from iPSCs and smNPCs which
had to be confirmed by repetition, yet by trend results would fit the overall view.
Since iPSCs and smNPCs represent transient structures during human neural development,
fibroblasts and MN cultures with mature post-mitotic cells reflect more the in vivo state. Of
course, MN cultures as target tissue displayed the most interesting cell population.
Already in MN cultures derived by the EB-based run-through protocol obvious differences in
PLS3 expression were detected. SMA III HGK13 denoted a conspicuous reduction in PLS3/PLS3
expression compared to controls whereas asymptomatic HGK16 delivered comparable PLS3
amounts relative to controls exhibiting no over-expression on RNA or protein level however
(7.3.3, Fig. 27, Fig. 28). In smNPC-derived MN cultures of these two lines, similar results were
obtained for PLS3mRNA levels (7.5.2, Fig. 46 G). However, on protein level HGK13 and HGK16
almost expressed the same PLS3 amount (7.5.3, Fig. 49 G). Concerning individual absolute
expression strength, such inconsistency in PLS3 expression was sometimes seen between
SMA III affected and asymptomatic siblings as well as among discordant asymptomatic
individuals themselves (Bernal et al. 2011; Oprea et al. 2008) most probably reflecting
individuals’ intrinsic features and familial differences. Still, asymptomatic siblings verifiably
expressed more PLS3 in blood than their SMA III siblings (Bernal et al. 2011; Oprea et al. 2008).
More importantly, this fact points out the necessity to employ several cell lines to validly
discover a specific phenotype as it was done in this study.
Similar to a recently introduced mouse model in which PLS3 rescued just mildly affected SMA
mice (Ackermann et al. 2013), PLS3 over-expression only improved MN survival in SMN1
depleted individuals comprising ≥3 SMN2 copies (i.e. SMA III and asymptomatic) but not in
SMA I affected (2 SMN2 copies). Unlike in zebrafish where decreasing Pls3 protein amounts
accompanied declining Smn protein amounts (Hao le et al. 2012), data from our in vitro MN
system did not suggest a direct dependency between both proteins since SMA I line HGK1
frequently exhibited high PLS3 expression rates despite overt SMN deficiency (7.5.4, Fig. 50).
Relation to age and sex were examined in PLS3 expression. Pre-pubertal females and younger
males (<11 years) exhibited an almost 2fold increase in PLS3 expression in blood relative to
older males and post-pubertal women (Stratigopoulos et al. 2010). Moreover, PLS3 levels of
post-pubertal female SMA III patients ranged higher than in more severely affected
post-pubertal female patients alluding to a gender-specific feature since PLS3 gene maps to
Xq23 (Stratigopoulos et al. 2010). Intriguingly, healthy infant controls (≤3 years) principally
denoted higher PLS3 expression levels in blood in comparison to older healthy children
insinuating an age-dependent down-regulation during development (Yanyan et al. 2014).
Since healthy, SMA III and asymptomatic fibroblast cell lines were sampled from older
individuals (18-61 years, see 5.8.3, Tab. 13) thereby reflecting the person’s true age, the
comparably low overall and within almost equal PLS3 expression would be explainable (7.5.3,
Fig. 49 B).
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The reprogramming process is assumed to erase any somatic trait and reset a juvenile state in
iPSCs (Jaenisch et al. 2008). Thus, any previous age-related influence on PLS3/PLS3 expression
should be eradicated in iPSCs and derived cell lines. Nonetheless, a basically higher PLS3
expression rate in infant SMA patients (≤3 years) relative to controls was reported as
compensatory effect in such patients (Yanyan et al. 2014). This may explain the up-regulated
PLS3/PLS3 expression in SMA I, SMA III and asymptomatic siblings in MN cultures while healthy
control r12 did not increase PLS3/PLS3 expression (7.5.4, Fig. 50 C, D). Admittedly, the present
MN cultures are far away from the border age (3 years) after which differences were seen in
Yanyan et al. Still, it cannot be ruled out that such transcriptional regulatory processes begin
earlier in neural lineages than in blood.
Additionally, there was no significantly different PLS3 expression rate in blood between
healthy controls, SMA I, SMA II and SMA III patients below three years of age (Yanyan et al.
2014). Comparably, PLS3 expression in our developmentally young MN cultures is expected to
present equal amounts of PLS3 among SMA I and SMA III patients which holds true indeed
(7.5.3, Fig. 49 H). Yet, control lines ranged even lower. Besides, over-expression in
asymptomatic siblings strikingly outlined a persisting PLS3 over-expression obviously
counteracting deleterious effects of SMN deficiency which already struck their symptomatic
SMA III siblings.
As known, PLS3 was vastly expressed in actively dividing cells (Rao et al. 2003) perfectly going
in line with increasing PLS3 expression rates in iPSCs and smNPCs of all phenotype classes
(7.5.4, Fig. 50 C, D). Since PLS3 is highly expressed in spinal cord (Oprea et al. 2008), evident
presence of PLS3 in HB9+ MNs (7.4.4, Fig. 42 A) would reflect respective expression rates in
mixed MN cultures addressing the decisive question if PLS3 over-expression in blood is
mirrored in MN cultures thereby corroborating current hypothesis that PLS3 mediates
protection specifically in spinal cord.
MN content in smNPC-derived MN cultures did not obviously correlate with PLS3 expression.
While SMA III lines HGK22.17, HGK27.10 or HGK27.13 still exhibit relatively high numbers of
HB9+ and ISL1+ MNs (7.4.4, Fig. 43 C, D), PLS3 expression was fairly low (7.5.3, Fig. 49 G). In
contrast, asymptomatic lines HGK21.8 and HGK28.9 depicted globally lower MN numbers
(7.4.4, Fig. 43 C, D) while PLS3 expression demonstrably exceeded all others (7.5.3, Fig. 49 G).
Furthermore, SMA I line HGK1 still expressed PLS3 reasonably although SMA I MN cultures
were virtually devoid of MNs.
Of course, in a mixed in vitro MN culture it was impossible to figure out whether remaining
MNs or other CNS populations in asymptomatic siblings were responsible for this striking PLS3
over-expression. To address that question MNs have either to be enriched (Corti et al. 2012)
or differentiated into specific CNS populations e.g. astrocytes and GABAergic or glutamatergic
interneurons and subsequently checked for PLS3 expression. Since smNPCs already reveal a
visible PLS3 over-expression in asymptomatic, it might be speculated that neural lineages and
especially MN-specific differentiation indeed exposed or even triggered PLS3 over-expression
in those asymptomatic. Future analyses of pMN-primed smNPCs or other NSC populations will
provide quick proof. Of course, inclusion of more SMA I patients and healthy control will fortify
this data since data of single SMA I line HGK1 puts common validity on narrow grounding.
Bernal et al. uttered doubts whether small positive variances in LB lines of asymptomatic
individuals indicating a PLS3 over-expression reflect the real state in individuals’ spinal cord
(Bernal et al. 2011). Present results of this study contrarily advocated a transfer of elevated
PLS3 levels in blood into the CNS and impressively emphasised the apparent importance of
increased PLS3 expression in MN cultures exerting its protective effect specifically in spinal
cord.
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8.5 PLS3 and actin apparently co-localise in neuronal growth cones of
MN cultures
The morphology of growth cones is described as the outer axon tip where a rod of stable
microtubule in the axon shaft terminates in a cone-shaped structure with highly dynamic
actin-containing finger-like protrusions (Lowery et al. 2009) as it was demonstrated in isolated
murine MNs (Jablonka et al. 2013). Co-localisation of Pls3 was demonstrated in primary
murine MNs (Oprea et al. 2008) as well as in filopodia of PLS3 over-expressing MEFs
(Ackermann et al. 2013).
Evident motor growth cone identification necessitates skilful experimental setting: Additional
specific axon staining by microtubule associated protein τ (MAPT) or acetylated tubulin is
mandatory to unambiguously discriminate the axon tip between dendrites. Furthermore,
motor axons have to be identified by MN markers like ISL1, ChAT or SMI-32. A quadruple
staining of PLS3, actin plus a MN-marker (e.g. ChAT) and an axonal marker (e.g. MAPT) was
not feasible. Thus, (motor)neuronal identification markers (i.e. ChAT, ISL1, neurofilament)
were verified in parallel with cytoskeletal markers (i.e. PLS3, actin, MAPT) in
immunocytochemical staining. Calculation of MN amount per sample will proportionally
depict number of putative motor growth cones.
Indeed, present growth cones of controls, SMA III and asymptomatic siblings were shaped
accordingly and did display presence of PLS3 and actin in such growth cones (7.6, Fig. 56 A).
MAPT+ axons evidently denoted axons ending in such growth cones. In line with common
knowledge (Lowery et al. 2009), actin allocated primarily in the peripheral zone and
filopodia-like protrusions (7.6, Fig. 56). In all three phenotype groups examined, PLS3 and actin
often overlaid. In SMA I line HGK1, no usable growth cone were detected (data not shown). In
control r12, equal PLS3/actin distribution pattern met expected regular PLS3 function to
bundle F-actin despite globally lower PLS3 expression rates (7.5.3, Fig. 49 G) indicating that
present PLS3 amount sufficed to fulfil its function.
Unlike in SMA III, asymptomatic strikingly revealed that strong actin accumulation was always
accompanied by PLS3 co-localisation. Contrarily, SMA III HGK27.10 evidently displayed an
incongruent trend in both intensity graphs since high peaks of actin signals were not covered
by respective PLS3 signals. In short, actin-rich areas entailed visible PLS3 amounts but not vice
versa implying that high actin amounts may attract PLS3. Of course, too few growth cones
were analysed to state any valid explanation. Speculating, this process might lead to retention
of already fewer actin filaments and extended stabilisation in asymptomatic nonetheless.
SMN depletion was evidently linked to disturbed axonal mRNA-transport and local β-actin
mRNA translation (Rossoll et al. 2003; Hubers et al. 2010; Akten et al. 2011; Fallini et al. 2013;
Yoo et al. 2013) as well as impaired NMJ maintenance which derived from growth cones
(Akten et al. 2011). Thus, SMA III growth cones may suffer from F-actin diminution whose
detrimental effects could not be compensated by overall surplus PLS3 expression rates in
asymptomatic MN cultures.
Nevertheless, any meaningful conclusion cannot be drawn until now since too few growth
cones were analysed. Data yield ranged very low for only nine growth cones were examined
so far. After prolonged MN cultivation and subsequent immunocytochemical staining
procedure, sensitive growth cones might have shrunk or collapsed. Anyway, detecting usable
growth cones turned out as challenging task. Besides, Ackermann et al. were able to utilise
V5-tagged PLS3 for strong immunocytochemical staining whereas in this model only
endogenous PLS3 was stainable which may give weaker signals.
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Motor growth cone identity was not defined either due to a lack of suitable staining
combination. Parallel ISL1/HB9 quantification (7.4.4, Fig. 43 C, D) delivered just an
approximate benchmark. Furthermore, without a proper method to quantify the exact
amount of F-actin and PLS3 it will remain elusive whether overt PLS3 over-expression really
leads to more local growth cone PLS3 in asymptomatic. Therefore, examining pivotal
PLS3/actin co-localisation in NMJs would give more insight into PLS3-mediated protection as
in a plain MN culture. Additionally, the problem of MN identity in growth cones was removed
since only MNs generate NMJs (Manuel et al. 2011).
Still, the present system may deliver useful data concerning growth cone stability. Growth
cones could be categorised with respect to their shape, for example dystrophic or regular.
8.6 Establishment of a co-culture model of mixed motoneuronal
cultures and human myotubes decisively broadened the possibility
in studying SMA-conditioned NMJ pathology
Maintenance defects in neuromuscular junctions (NMJs) have always been suspected as one
principal reason for pathogenic effects in SMA. Upon SMN-depletion, lower α-motoneurons
suffer from foetal developmental maturation anomalies which consequently lead to a
postnatal retrograde axonal dying-back mechanism ending in motor axon disruption and
eventually entire MN degeneration (Fidzianska et al. 2002; Ito et al. 2011; Fallini et al. 2012).
Therefore, a reliable cellular in vitro model phenocopying synaptogenesis between MN and
muscle and formation of NMJs is crucial for elucidating SMA pathology. In particular, PLS3 did
exert its protective effect in a mouse model putatively in motor axon growth cones by actin
stabilisation. Thus, synaptic function and neuromuscular connectivity were maintained and
NMJ decay was countervailed (Ackermann et al. 2013). Therefore, establishment of a human
co-culture model comprising iPSC-derived patient-specific motoneurons and human
myotubes will come in handy to examine the exact working mechanism of PLS3 in SMA
discordant motoneurons.
Indeed, the basic experimental set-up for such an in vitro model has successfully been
established in this doctoral thesis. On the pre-synaptic site, human motoneurons were
differentiated from iPSCs. On the post-synaptic site, human myotube formation was induced
in vitro. During myogenesis, several post-mitotic myoblasts align and fuse to primitive primary
myotubes, large syncytial multinucleated cells (Slater 2009). These relatively few primary
myotubes were clearly on hand in this co-culture model. Moreover, neurons did contact these
myotubes (7.7, Fig. 57) and long-term co-culture (up to seven weeks) succeeded.
A manifest sign of NMJ formation is a clustering of AChRs on the muscular surface (Slater
2009). During murine embryogenesis, MN-mediated agrin secretion induces cytoskeletal
re-distribution of membrane-linked AChRs on the sarcolemma surface. Originally evenly
dispersed AChRs coalesce to plaque-like patches in the centre of myotubes in late
embryogenesis. During postnatal development, these patches form riffled shapes and
perforate later to the characteristic pretzel-structure owing to massive sarcolemma folding
when the motor axon tip bulges into this developing motoric end-plate (Sanes et al. 2001; Wu
et al. 2010). In humans, comparable developmental processes are assumed.
Truly, these early developmental changes concerning size, shape and topography on the
post-synaptic muscle site were mimicked in the present co-culture model. The early AChR
clustering was rather punctiform and occurred in close proximity to a queue of myonuclei in
the syncytial myotube (7.7, Fig. 58). In mammals, there is often an early postnatal
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accumulation of such sub-synaptic myoneuclei (Slater 2009). Later, AChRs clearly arranged in
a plaque-like furrowed shape indicating an early sign of NMJ formation (7.7, Fig. 59 A). These
morphological differences visible between MN1 fed co-cultures (7.7, Fig. 58) and SC-CM fed
co-cultures (7.7, Fig. 59 A) also reflected varying culture periods (15 days vs. 49 days), ergo
the natural developmental process.
Even though motoneurons require neurotrophic factors in vitro and in vivo (Hughes et al.
1993), it is obviously not necessary to supplement a MN-myotube co-culture with further
neurotrophic factors (e.g. NT3, BDNF, GDNF) since they are secreted by skeletal muscle cells.
Then, these factors convey rather a local effect in developing NMJs than a general MN survival
stimulus (Peng et al. 2003). Administration of additional neurotrophic factors even impeded
synaptogenesis and NMJ formation on account of inhibition of agrin synthesis in pre-synaptic
MNs (Peng et al. 2003). This might also explain the poor yield of NMJ-like structures in MN1
fed co-cultures because MN1 is supplemented with BDNF, GDNF and IGF-1.
Evidently, SC-CM gave the best results in respect to visual morphological changes in
MN-myotube co-culture. SC-CM exerted its stimulatory synaptogenic effect most probably via
a combination of mostly unknown factors. Although Schwann cells secrete agrin, SC-CM by
itself did not increase AChR clustering on muscle (Yang et al. 2001). More likely, SC-CM factors
directly act on MN gene expression thereby promoting proper synapse formation. In rat
SC-CM, TGF-β1 signalling boosted motoneuronal agrin expression in a co-culture system (Feng
et al. 2008).
Yet, no bona fide NMJs were found in the present co-cultures. Of course, the overall low
number of MNs upon iPSC differentiation reduced the probability of MN-myotube contact.
Moreover, the time of co-cultivation might have been too short. When data from different
studies were compared, it became obvious that human neurons developed about ten times
slower than cells from other well characterised murine model systems, for example
(Stockmann et al. 2011). Even after 12–14 weeks MN-myotube co-culture, NMJ formation has
not completed in vitro yet (Stockmann et al. 2011).
Still, this experimental set-up with SC-CM may serve as valuable platform for further studies
in SMA pathogenesis and effects of modifiers when a higher MN number will be available with
NSC-based MN differentiation. Nonetheless, in comparison to other publications (Hu et al.
2009; Guo et al. 2011; Stockmann et al. 2011) the SC-CM mediated co-culture system
presented in this thesis showed a more distinct BTX+ AChR clustering on the post-synaptic
muscle site – the first hallmark of proper NMJ formation.
8.7 iPSC-derived GABAergic neuronal cultures evidently reflected
molecular cause of diverging VPA responsiveness in SMA patients
Before the recent introduction of SMN2 splicing compounds as highly potent drug in
treatment of severe Δ7 mice (Naryshkin et al. 2014), histone deacetylase (HDAC) inhibitors
such as valproic acid (VPA) were regarded as potentially promising therapeutic (Brichta et al.
2006; Swoboda et al. 2011). Notwithstanding, deeper analyses delineated a differing
responsiveness towards VPA administration amongst SMA patients counteracting VPA
application as cure (Brichta et al. 2006; Piepers et al. 2011). A recent study depicted altered
fatty acid metabolism, precisely the fatty acid uptake by membrane translocase CD36 as
causative (Garbes et al. 2013).
In addition, VPA is known to inhibit an enzymatic compound of GABA synthesis resulting in
elevated GABA levels (Johannessen 2000). Thus, GABAergic neurons of VPA responders are
supposed to respond particularly intensely upon VPA application. Indeed, lt-NES®SC-derived
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GABAergic neuron cultures of VPA responder/non-responder iPSC lines notably reflected the
according VPA response previously observed in fibroblasts and blood cell lines (Garbes et al.
2013). Supernatant of VPA responder culture contained measurably more GABA than control
ESC line or VPA non-responder who even exhibited a significant lower GABA release (7.8,
Fig. 60 D). Thus, an in vitro system representing the CNS strongly aided the discovery of CD36
as cause for different VPA responsiveness in SMA patients.
Of course, examining more than one VPA responder/non-responder each would have backed
these findings with more validity. Additionally, differentiation into MN cultures will deliver the
final proof of VPA response in patients’ target tissue.
8.8 Summarised findings pinpoint advantages of an iPSC-based MN
culture system and reliable validity in modelling SMA phenotype
in vitro
Taken together, this study successfully applied iPSC technology in setting up patient-derived
neuronal in vitro cell models for the first time with VPA (non-)responders and PLS3 discordant
mildly SMA III affected or asymptomatic individuals in comparison to healthy controls and
severe SMA I cases.
Firstly, a broad range of SMA patients’ samples of different disease severity and PLS3
discordant siblings were converted into bona fide iPSC lines via retroviral or state-of-the-art
SeV reprogramming. Secondly, generation of stably expandable and pMN-patternable NSC
population (smNPCs) enabled robust MN differentiation with sufficient yield. Thirdly,
accessibility of different cell populations, i.e. original fibroblasts, derived iPSCs, corresponding
smNPCs and differentiated MN cultures facilitated monitoring of SMA-specific changes during
the developmental process of human MN generation. Fourthly, not only was a significant
decline in MN number observed in SMA I cultures but also gradually decremented MN
numbers in SMA III and asymptomatic cultures. Fifthly, SMN expression on RNA and protein
level revealed lowest expression rate in SMA I cultures and moderate reduction in SMA III and
asymptomatic cultures recapitulating SMN2 copy number effects and generally known SMN
expression changes in adult versus foetal tissue and cell types. Sixthly, PLS3 expression on RNA
and protein level indicated strong trend in over-expression of asymptomatic samples in iPSCs
and neural lineages possibly pinpointing the protective effect of PLS3. Finally, differences in
gem number perfectly matched respective diminished SMN expression rates in SMA I, SMA III
and asymptomatic samples.
Moreover, successful set-up of a human MN-myotube co-culture model paved the way for
future studies of NMJ formation in PLS3 discordant individuals. Furthermore, VPA-dependent
changes of GABA release in GABAergic neuron cultures clearly corroborated molecular causes
of altered fatty acid metabolism which underlay VPA responsiveness in SMA patients. In
addition, this finding provided evidence that VPA responsiveness found in blood and
fibroblasts similarly mirrored in a neuronal cell system.
In summary, data of this study profoundly displayed the advantageous applicability of
iPSC-derived patient-specific SMA in vitro cell models – an indispensable benefit for further
research mapping crucial mechanisms underlying modifier-mediated protection in SMA.
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After having established the fundamental experimental settings for a PLS3 discordant
iPSC-based in vitro model mimicking evidently mild SMA progression in SMA III patients and
PLS3 over-expression in asymptomatic siblings, following steps ought to be envisaged:
Previous studies dealing with iPSC-based SMA models as well as PLS3 discordant mouse
models demonstrated changes in axonal outgrowth, growth cone architecture or G-/F-actin
ratio (Oprea et al. 2008; Ebert et al. 2009; Ackermann et al. 2013). Thus, such findings should
be confirmed. Including SMA II line HGK4 would comprise all degrees of severity in this study.
Additional examination of unrelated SMA III patients from non-discordant families may back
present data. Shorter intervals of analysis and more samples throughout the in vitro
differentiation would give more coherent insight in cell-specific PLS3 and SMN expression
changes.
Moreover, insight is gained how the mode of action of PLS3 exerts its protective effect on
molecular level in the context of the SMA pathomechanism. For instance, calcium binding was
discovered as essential for PLS3 function in Smn-deficient MNs in zebrafish (Lyon et al. 2013)
so that investigation of Ca2+ homeostasis in human MNs would be worth checking.
Interestingly, PLS3 lacking its actin-binding domains was still able to rescue motor axons in
smn morphants leading to the speculative assumption that PLS3 might exert its ameliorative
function independent of the cytoskeleton (Lyon et al. 2013). Earlier studies uttered
perturbations in neurotransmitter release and synaptic vesicle cycle (Torres-Benito et al.
2011) predestining endocytosis as future research topic in discordant MN cultures.
Additionally, our group identified further modifying genes in SMA discordant families
prefiguring involvement of these SMA modifiers in endocytotic processes (Dr. Markus
Rießland, publication in preparation).
Correct mRNA localisation and on-site protein synthesis are essential processes required for
synaptic development, function and activity (Wiersma-Meems et al. 2005; Liu-Yesucevitz et
al. 2011). This aspect is emphasised by the connection between mRBPs such as FMRP and
SMN and neurological diseases like fragile-X syndrome and SMA (Bassell et al. 2008; Piazzon
et al. 2008). Particularly in SMA, this link provides a plausible insight into neuromuscular
pathology since the entire process of endocytosis, neurotransmitter release and the SV cycle
in the motor axon depends on proper actin dynamics, alluding to the pivotal role of SMN in
NMJ maintenance. Hence, analysing the variability of endocytotic properties in iPSC-derived
PLS3 discordant MN tips may unclose access to PLS3-mediated protection.
Even comparison between healthy control and diseased cell lines is just able to roughly
approximate the true in vivo state because individual cell line-specific features of every cell
line are benevolently left aside when drawing conclusions. Generation of age/gender-
matched isogenic gene-corrected control cell lines carrying the same genetic variants apart
from the disease-causing gene would find a remedy (Hargus et al. 2013; Sandoe et al. 2013).
As key feature of SMA pathogenesis, NMJ maintenance capability represents an important
aspect in SMA research and was already assessed in SMA mouse models (Ackermann et al.
2013; Bowerman et al. 2012a). Highly efficient generation of iPSC-derived myocytes (Darabi
et al. 2012; Salani et al. 2012) would enable the generation of a doubly patient-derived in vitro
co-culture model dodging any putative biasing allogenic effect between MNs and myotubes.
Transplanted iPSC-derived human MNs successfully formed functional connections with rat
muscles (Su et al. 2013). In addition, rapid progress in biomaterial research even resulted in a
murine 3D neuron-muscle construct displaying NMJ formation (Morimoto et al. 2013).
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Rescue experiments always grant great significance to scientific studies. Therefore,
monitoring effects of exogenous PLS3 over-expression in smNPCs/MNs of SMA III discordant
patients and reciprocal of PLS3 knock-down in smNPCs/MNs of healthy control individuals or
asymptomatic siblings might deliver valuable data about SMA pathology. Genome editing
strategies like transcription activator-like effector nuclease (TALEN) or clustered regularly
interspaced short palindromic repeats/Cas9 RNA-guided nucleases (CRISPR/Cas9) system also
evolve very fast in context of SC research (Ding et al. 2013; Horii et al. 2013) thereby
simplifying the feasibility. Additionally, generation of isogenic cell lines is manageable by such
techniques. Variability of human pluripotent SCs in modelling disease phenotypes originates
from genetic background and derivation method (Sandoe et al. 2013). To attenuate such
experimental “noise” large patients’ cohorts and many cell lines are necessary. However,
isogenic cell lines better fulfil this purpose since fewer SC lines are needed to grant
generalisibilty of results. Possibly more subtle differences between patients and controls
could be carved out as well (Sandoe et al. 2013). Evidently, isogenic ESC lines demonstrated a
more similar whole-genome expression profile compared to unrelated ESC lines (Soldner et
al. 2011).
Since VPA-responsiveness was examined in a GABAergic neuronal system, generation of
corresponding smNPC lines and subsequent MN differentiation may finalise research in this
area by checking SMN expression levels in smNPCs/MNs upon VPA treatment in
(non-)responders.
Direct transdifferentiation between somatic lineages elegantly circumvents reprogramming
difficulties, time-consuming iPSC validation and subsequent differentiation. Inarguably,
scientific groups succeeded in directly converting fibroblast into induced neurons (iNs) and
even motoneurons (iMNs) (Vierbuchen et al. 2010; Son et al. 2011). Besides, iN technology
successfully displayed familial Alzheimer’s Disease phenotype on cellular level (Qiang et al.
2011). Notwithstanding, the efficiency remained very low and ectopic over-expression of
several lineage-specific TFs required good technical practice. Still, improved techniques may
facilitate iN application (Daniela Eckert, personal communication).
Stem cell research unavoidably fuels hopes to generate personalised cells or tissues and to
employ these in cellular engraftment strategies as potential custom-made therapy. However,
replacement of fully functional MNs seems an insurmountable obstacle because motor axon
guidance through limbs and subsequent synapse formation via NMJs remains virtually
impossible in post-natal humans. Hence, diseased MNs in SMA patients cannot be replaced.
Still, the idea was seized in impressive publications in which primary mouse NSCs, later murine
ESC-derived NSCs or human iPSC-derived genetically corrected SMA MNs were injected in
cerebrospinal fluid of post-natal SMA mice (Corti et al. 2008; Corti et al. 2010; Corti et al.
2012). Implanted cells differentiated primarily into neuronal cells or partially into glial cells,
yet also retained NSC or MN states, respectively. Ameliorative effects were exerted via
secretion of neuroprotective growth factors thus stabilising endogenous SMA MNs or
establishment of new NMJs by donor MNs. Therefore, a promising trail to follow in humans
might focus on supportive cell types in the motor circuit. SMN depletion evidently affected
also murine Schwann cells (Hunter et al. 2014) and human iPSC-derived astrocytes (McGivern
et al. 2013) intrinsically. Hence, such cell populations may prove more feasible for
transplantation in older humans. Nevertheless, potential benefits must be carefully pondered
with respect to risks of tumorigenicity or unknown long-term effects after engraftment of
exogenous cells.
Indeed, Nobel prize-awarded iPSC technology opened an avenue to spectacular new insights
into manifold disease pathomechanisms.
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Original Publications
“VPA response in SMA is suppressed by the fatty acid translocase CD36”
Lutz Garbes, Ludwig Heesen, Irmgard Hölker, Tim Bauer, Julia Schreml, Katharina
Zimmermann,Michaela Thoenes, Michael Walter, John Dimos, Michael Peitz, Oliver Brüstle,
Raoul Heller and Brunhilde Wirth, Hum Mol Genet. 2013 Jan; Vol. 22, No. 2, p.398-407
“Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and
Italian familial breast cancer cases”
Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, Wappenschmidt
B, Dick M, Arnold N, Bugert P, Niederacher D, Meindl A, Schmutzler RK, Bartram CC, Ficarazzi
F, Tizzoni L, Zaffaroni D, Manoukian S, Barile M, Pierotti MA, Radice P, Burwinkel B,
Peterlongo P, Hum Mutat. 2010 Jan;31(1):E1052-7
Conferences
23rd May 2014 Annual Human Genetics meeting, Universität zu Köln, Cologne, Germany
(poster presentation)
Title: Differentiating patient-derived iPS cells into motoneurons for
tissue-specific analysis of SMN-specific changes in SMA patients
Ludwig Heesen, Michael Peitz, Lutz Garbes, Irmgard Hölker, Kristina
Hupperich, John Dimos, Oliver Brüstle, Brunhilde Wirth
13th-14th
February 2014
5th International Symposium “Crossroads in Biology” (CIB), Universität zu
Köln, Cologne, Germany (member of organisational board)
Website: http://crossroads.uni-koeln.de/
23rd-24th
April 2013
7th International Stem Cell Network Meeting, Cologne, Germany
25th-27th
January 2013
Neuromics Kick-off Meeting, Sitges, Spain (poster presentation)
Title: Differentiating patient-derived iPS cells into motoneurons for
tissue-specific analysis of SMN-specific changes in SMA patients
Ludwig Heesen, Michael Peitz, John Dimos, Oliver Brüstle, Brunhilde
Wirth
29th November
2012
Annual Human Genetics meeting, Universität zu Köln, Cologne, Germany
(oral presentation)
Title: Generation of human iPSCs of PLS3 discordant families &
re-differentiation to SMA motoneurons (MNs)
Ludwig Heesen, Michael Peitz, John Dimos, Oliver Brüstle, Brunhilde
Wirth
154 Publications, oral & poster presentations
21st-24th
June 2012
16th International Families of SMA Meeting, Bloomington, USA
(conference report for the Initiative SMA e.V.)
Website: http://www.initiative-sma.de
Header: 16. Kongress der Families of SMA
13th May 2011 Annual Human Genetics meeting, Universität zu Köln, Cologne, Germany
(poster presentation)
Title: Differentiating patient-derived iPS cells into motoneurons for
tissue-specific analysis of SMN-specific changes in SMA patients
Ludwig Heesen, Michael Peitz, John Dimos, Oliver Brüstle, Brunhilde
Wirth
5th-6th
April 2011
6th Internationales Stammzellnetzwerk Meeting, Essen, Deutschland
22nd-24th
March 2010
9th Transgenic Technology Meeting, Berlin, Germany
(poster presentation)
Title: Generating patient-derived iPS cells & motoneurons for
tissue-specific analysis of SMN-specific changes in SMA patients
Ludwig Heesen, Michael Peitz, John Dimos, Oliver Brüstle, Brunhilde
Wirth
9th October
2009
Annual Human Genetics meeting, Universität zu Köln, Cologne, Germany
(poster presentation)
Title: Generation and application of iPS cells & motoneurons for tissue-
specific analysis of SMN-specific changes in SMA patients
Ludwig Heesen, Brunhilde Wirth, Michael Peitz, Oliver Brüstle
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11. Appendix
11.1 List of all iPSC clones picked
Cell line Cell line
HGK21 (= ML11) HGK27 (= ML12)
Clone # % confluence % differentiated cells Clone # % confluence % differentiated cells
1 90 0 1
2 95 5 2 80 20
3 90 5 3 90 15
4 60 30 4 70 15
5 90 15 5 85 20
6 70 15 6 90 50
7 80 20 7 100 50
8 80 15 8 80 10
9 65 10 9 80 30
10 80 10 10 90 5
11 80 5 11 90 50
12 75 5 12 95 30
13 75 15 13 95 15
14 85 5 14
15 90 10 15 90 50
16 90 5 16 90 50
17 80 60
18 90 60
Cell line Cell line
HGK22 (= ML14) HGK28 (= ML13)
Clone # % confluence % differentiated cells Clone # % confluence % differentiated cells
1 90 15 1 75 30
2 100 40 2 90 15
3 100 40 3 90 20
4 75 5 4 90 35
5 70 20 5 85 5
6 70 20 6 70 25
7 70 20 7 80 5
8 8 85 10
9 80 45 9 75 5
10 70 50 10 80 15
11 85 10 11 80 5
12 90 15 12 90 10
13 70 15 13 90 10
14 80 15 14 90 15
15 15 90 10
16 75 20 16 95 15
17 45 0
18 50 0
Tab. 19: Overview of all new iPSC clones with percentage of confluence and degree of
contamination by differentiating cells before first split. Highlighted in red are clones not having
grown properly after picking. Highlighted in yellow are clones which failed SNP-array analysis.
Highlighted in turquoise are clones matching all validation criteria so far.
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11.2 SNP-array data
Fig. 61: Schematic karyograms of new iPSC lines and corresponding parental fibroblasts. gDNA
is extracted and amplified for whole-genome SNP-array. Each chromosome is depicted
together with its corresponding B allele frequency (upper panel) and Log R ration (lower
panel). Note that regular SNPs show a Log R ratio of 0 and a B allele frequency of 0, 0.5 or 1
when homozygous. A heterozygous deletion will result in a Log R ratio of <0 and a B allele
frequency of only 0 or 1, whereas a duplication will cause a Log R ratio of >0 and a B allele
frequency of 0, visible here is an original pre-existing
mutation as already seen in the parental fibroblast cell lines (7.2.3, Tab. 16).
Fibroblast ML11
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iPSC HGK21.8
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Fibroblast ML14
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iPSC HGK22.17
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iPSC HGK22.18
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Fibroblast ML12
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iPSC HGK27.10
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iPSC HGK27.13
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Fibroblast ML13
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iPSC HGK28.9
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iPSC HGK28.11
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Fig. 62: Cluster signals plotted in human iPSC lines HGK13 and HGK16 (red dots) with
corresponding fibroblast donor cell lines ML102 and ML101 (blue dots). Physical intactness of
the genome is demonstrated by SNP-array analysis in iPSC lines HGK13 versus parental
fibroblast line ML102 and HGK16 versus parental fibroblast line ML101.
iPSC line HGK13 versus fibroblast line ML102
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iPSC line HGK16 versus fibroblast line ML101
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11.3 pMXs vector maps
Fig. 63: Vector maps of retro-DNA plasmids pMXs-hOCT4, pMXs-hSOX2, pMXs-hKLF4,
pMXs-hc-Myc (© Addgene Inc., USA).
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11.4 SeV plasmid
A
B
Fig. 64: Schematic illustration of SeV plasmids. (A) The plasmid pSeV18+b(+) (~15,000 nt)
carries original full-length SeV cDNA. (B) In F-protein deficient SeV vector, genes of
reprogramming factors are inserted at 18+, PM, MHN, HNL and L, respectively. The polar
effect controls the expression rate of inserted genes according to their position (T7, T7 phage
promoter; Rbz, hepatitis deltavirus ribozyme sequence) (modified from (Hirata et al. 2002;
Fusaki et al. 2009)).
11.5 Identification of PLS3 bands on immunoblots
Fig. 65: Immunoblot revealed identity of correct PLS3 band in duplicate. Human glioblastoma
cell line U-373 was treated with 50 ng/ml small interfering RNA (siRNA) directed against PLS3
and AllStars Negative Control siRNA. Proteins were isolated 48 h after knock-down. Evidently,
strong expression intensity of upper PLS3 band was dimmed in comparison to AllStars
Negative Control defining this band as correct PLS3 band. Thus, this specific upper band was
subsequently analysed in all immunoblots (see Fig. 47). Results were successfully repeated in
HEK cells too (Mohsen Hosseini, personal communication). All data and supportive
information were kindly provided by Mohsen Hosseini.
3' 5'
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11.6 Validation of smNPCs
Fig. 66: Further iPSC-derived smNPC lines clearly presented typical NSC markers PAX6 (green), SOX1 (red),
SOX2 (green), nestin (red) as well as anterior marker FORSE-1 (green). Since smNPCs possess an early pre-
rosette NSC fate expression of characteristic rosette-markers PLZF (green) and ZO-1 (red) did not show the
typical petal-like arrangement of lt-NES®SCs unless some lines (e.g. HGK21.8 and HGK27.10) grew densely.
Then, ZO-1+ rings emerged. In summay, the marker profile of all smNPC lines was comparable to data in the
original publication. Nuclei were counterstained with DAPI (blue) (scale bar 100 µm, valid for all images).
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